A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03158285

Enrollment

741

Registered

2017-05-18

Start date

2017-07-12

Completion date

2020-11-10

Last updated

2026-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthritis, Psoriatic

Brief summary

The primary purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.

Detailed description

This is a study of guselkumab in participants with active PsA who are biologically naive and have had inadequate response to standard therapies. It will evaluate the clinical efficacy of guselkumab in the reduction of signs and symptoms, structural damage inhibition and the safety profile of guselkumab in the treatment of PsA. The study will consist of a screening phase (up to 6 weeks), a blinded treatment phase (approximately 100 weeks) including a placebo controlled period from Week 0 to Week 24 and an active treatment period from Week 24 to Week 100 and a safety follow-up phase of 12 weeks after the last administration of study agent. Efficacy, health economics, safety, pharmacokinetics, immunogenicity, biomarker and pharmacogenomics evaluations will be performed in the study at defined schedule.

Interventions

DRUGGuselkumab

Participants will receive 100 mg of guselkumab as a sterile liquid for SC injection.

DRUGPlacebo

Participants will receive matching placebo as SC injection.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Have a diagnosis of Psoriatic Arthritis (PsA) for at least 6 months before the first administration of study agent and meet Classification criteria for Psoriatic Arthritis (CASPAR) at screening * Have active PsA as defined by: at least 5 swollen joints and at least 5 tender joints at screening and at baseline, and CRP greater than or equal to (\>=) 0.6 milligram per deciLitre (mg/dL) at screening from the central laboratory * Have at least 1 of the PsA subsets: distal interphalangeal joint involvement, polyarticular arthritis with absence of rheumatoid nodules, arthritis mutilans, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis (confirmation of sacroiliitis should be performed at the screening visit by a locally performed pelvic x-ray \[single anterior-posterior view\] unless a pelvic or SI joint x-ray or pelvic magnetic resonance imaging (MRI) has been previously performed. Results must be documented) * Have active plaque psoriasis, with at least one psoriatic plaque of \>= 2 centimeter (cm) diameter or nail changes consistent with psoriasis or documented history of plaque psoriasis * Have active PsA despite previous non-biologic disease-modifying antirheumatic drug (DMARD), apremilast, and/or nonsteroidal anti-inflammatory drug (NSAID) therapy

Exclusion criteria

* Has other inflammatory diseases that might confound the evaluations or benefit of guselkumab therapy, including but not limited to rheumatoid arthritis (RA), axial spondyloarthritis (this does not include a primary diagnosis of PsA with spondylitis), systemic lupus erythematosus, or Lyme disease * Has previously received any biologic treatment * Has ever received tofacitinib, baricitinib, filgotinib, peficitinib (ASP015K), decernotinib (VX-509), or any other Janus kinase (JAK) inhibitor * Has received any systemic immunosuppressants (eg, azathioprine, cyclosporine, 6 thioguanine, mercaptopurine, mycophenolate mofetil, hydroxyurea, tacrolimus) within 4 weeks of the first administration of study agent * Is currently receiving 2 or more non-biologic DMARDs (other than methotrexate \[MTX\], sulfasalazine \[SSZ\], Hydroxychloroquine \[HCQ\], leflunomide \[LEF\]) including, but not limited to chloroquine, gold preparations, and penicillamine within 4 weeks before the first administration of study agent * Has received apremilast within 4 weeks prior to the first administration of study agent

Design outcomes

Primary

Measure	Time frame	Description
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24	Week 24	ACR 20 response: \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP. Treatment Failure (TF) criteria- discontinued study drug, initiated/increased dose of non-biologic disease-modifying antirheumatic drugs (DMARDs) or oral corticosteroids, initiated prohibited psoriatic arthritis treatment.

Secondary

Measure	Time frame	Description
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24	Baseline and Week 24	HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.
Percentage of Participants Who Achieved an ACR 50 Response at Week 24	Week 24	ACR 50 response was defined as greater than or equal to (\>=)50 percent (%) improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and C-Reactive Protein (CRP).
Percentage of Participants Who Achieved Psoriasis Response With IGA Score of 0 (Cleared) or 1 (Minimal) and >=2 Grade Reduction From Baseline at Week 24 Among Participants With >=3% BSA Psoriatic Involvement and IGA Score of >=2 (Mild) at Baseline	Week 24	A psoriasis Investigator's Global Assessment (IGA) response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>=2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 16	Week 16	ACR 20 response was defined as \>= 20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.
Change From Baseline in Modified Van Der Heijde-Sharp (vdH-S) Score at Week 24	Baseline and Week 24	Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
Percentage of Participants With Resolution of Enthesitis at Week 24 Among the Participants With Enthesitis at Baseline	Week 24	Enthesitis was assessed using the Leeds Enthesitis Index (LEI), a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI\>0. The outcome measure was planned to be reported for pooled population from CNTO1959PSA3001 and CNTO1959PSA3002 studies.
Percentage of Participants With Resolution of Dactylitis at Week 24 Among the Participants With Dactylitis at Baseline	Week 24	The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \>0. The outcome measure was planned to be reported for pooled population from CNTO1959PSA3001 and CNTO1959PSA3002 studies.
Change From Baseline in Enthesitis Score (Based on LEI) at Week 24 Among the Participants With Enthesitis at Baseline	Baseline and Week 24	Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicate improvement of enthesitis. The outcome measure was planned to be reported for pooled population from CNTO1959PSA3001 and CNTO1959PSA3002 studies.
Change From Baseline in Dactylitis Scores at Week 24 Among the Participants With Dactylitis at Baseline	Baseline and Week 24	The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Negative changes from baseline indicate improvement of dactylitis. The outcome measure was planned to be reported for pooled population from CNTO1959PSA3001 and CNTO1959PSA3002 studies.
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24	Baseline and Week 24	SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Change From Baseline in Disease Activity Score (DAS28) (C-reactive Protein [CRP]) Score at Week 24	Baseline and Week 24	The Disease Activity Index Score (DAS28) based on C-Reactive Protein (CRP) is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative changes from baseline indicate improvement of arthritis.
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Mental Component Summary (MCS) at Week 24	Baseline and Week 24	SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 50 Response at Week 16	Week 16	ACR 50 response was defined as \>= 50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 70 Response at Week 24	Week 24	ACR 70 response was defined as \>= 70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.
Percentage of Participants Who Achieved ACR 20 Response Through Week 24	Weeks 2, 4, 8, 12, 16, 20 and 24	ACR 20 response was defined as \>= 20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.
Percentage of Participants Who Achieved ACR 50 Response Through Week 24	Weeks 2, 4, 8, 12, 16, 20 and 24	ACR 50 response was defined as \>= 50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.
Percentage of Participants Who Achieved ACR 70 Response Through Week 24	Weeks 2, 4, 8, 12, 16, 20 and 24	ACR 70 response was defined as \>= 70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.
Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24	ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment (PtGA) of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment (PGA) of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (milligram/deciliter \[mg/dL\]).
Change From Baseline in HAQ-DI Score at Weeks 2, 4, 8, 12, 16, 20 and 24	Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24	HAQ-DI score assess functional status of participant. It is a 20 question instrument that assess the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative changes from baseline indicate improvement of physical function.
Percentage of Participants Who Achieved >=0.35 Improvement From Baseline in HAQ-DI Score Through Week 24 Among Participants With HAQ-DI Score >=0.35 at Baseline	Weeks 2, 4, 8, 12, 16, 20 and 24	HAQ-DI score assess functional status of participant. It is a 20 question instrument that assess the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3, where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.
Percentage of Participants Who Achieved a DAS28 (CRP) Response Through Week 24	Weeks 2, 4, 8, 12, 16, 20 and 24	DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. DAS 28 (CRP) response criteria was defined as follows: Good response: \<=3.2 at visit and \>1.2 improvement; Moderate response: \>3.2 at visit and \>1.2 improvement or \<=5.1 at visit and \>0.6-1.2 improvement; No response: \<=0.6 improvement, or \>5.1 at visit and \<=1.2 improvement. The values are 0=best to 10=worst. A DAS28 (CRP) responder is defined as achieving a good or moderate DAS28 response at a specific visit.
Percentage of Participants Who Achieved a DAS28 (CRP) Remission Through Week 24	Weeks 2, 4, 8, 12, 16, 20 and 24	DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. DAS 28 (CRP) remission was defined as DAS 28 (CRP) value \<2.6 at the analysis visit.
Change From Baseline in DAS28 (CRP) at Weeks 2, 4, 8, 12, 16, 20 and 24	Baseline, Weeks 2, 4, 8, 12, 16, 20 and 24	DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative changes from baseline indicate improvement of arthritis.
Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) Through Week 24	Weeks 2, 4, 8, 12, 16, 20 and 24	The modified PsARC response was defined as improvement in at least 2 of the four criteria: \>=30% decrease in swollen joint count, \>=30% decrease in tender joint count, \>=20% improvement in patient's Global Assessment of Disease Activity (arthritis) on a VAS (0-100 mm, 0=excellent and 100= poor), \>=20% improvement in physician's Global Assessment of Disease Activity using VAS (VAS: 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), and at least one of the 2 joint criteria with no deterioration in the other criteria.
Percentage of Participants With Resolution of Enthesitis Through Week 24 Among the Participants With Enthesitis at Baseline	Weeks 2, 4, 8, 16 and 24	Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI\>0.
Percentage of Participants With Resolution of Dactylitis Through Week 24 Among the Participants With Dactylitis at Baseline	Weeks 2, 4, 8, 16 and 24	The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \>0.
Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 2, 4, 8, 16, and 24 Among the Participants With Enthesitis at Baseline	Baseline, Weeks 2, 4, 8, 16 and 24	Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicate improvement of enthesitis.
Change From Baseline in Dactylitis Scores at Weeks 2, 4, 8, 16 and 24 Among the Participants With Dactylitis at Baseline	Baseline, Weeks 2, 4, 8, 16 and 24	The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Negative changes from baseline indicate improvement of dactylitis.
Change From Baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 8, 16 and 24	Baseline, Weeks 8, 16 and 24	PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a composite score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0= 0 sites with tenderness to 6= worst possible score; 6 sites with tenderness), tender dactylitis count (scoring each digit from 0-3 \[where 0= no tenderness and 3= extreme tenderness\] and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score with score range 0-100 (higher score-better quality of life) of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.
Change From Baseline in Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Composite Score (GRACE) at Weeks 16 and 24	Baseline, Weeks 16 and 24	GRACE index is a composite PsA disease activity score converted from Arithmetic Mean of Desirability Function (AMDF), derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), patient's global assessment of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100=poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), patient's global assessment of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL=25.355 + \[2.367\HAQ-DI\]-\[0.234\SF-PCS\]-\[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score ranges from 0-100, higher scores= better quality of life) and SF-MCS (score ranges from 0-100, higher scores= better quality of life). Total score is from 0-10, lower score=better response. Higher score indicates more active disease activity. Negative change from baseline indicates improvement of PsA disease activity.
Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Work Time Missed) at Weeks 16 and 24	Baseline, Weeks 16 and 24	Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.
Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Impairment While Working) at Weeks 16 and 24	Baseline, Weeks 16 and 24	Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.
Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Overall Work Impairment) at Weeks 16 and 24	Baseline, Weeks 16 and 24	Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAi-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.
Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Activity Impairment Outside of Work ) at Weeks 16 and 24	Baseline, Weeks 16 and 24	Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.
Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Week 16 and 24	Baseline, Weeks 16 and 24	The mCPDAI assessed 4 domains (joints, skin, entheses, and dactylitis). The mCPDAI scores were calculated using the following assessments: joints (66 swollen and 68 tender joint counts), HAQ-DI score, PASI, dactylitis, and enthesitis. Within each domain a score (range 0-3) was assigned, where 0= Not involved, 1= Mild, 2= Moderate and 3= Severe. The scores for each domain were then added together to give a final score range of 0 to 12. A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity.
Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Weeks 2, 4, 8, 12, 16, 20 and 24	Baseline, Weeks 2, 4, 8, 12, 16, 20 and 24	DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL, value \<lower limit of quantification \[LLOQ\] is considered equal to half of the value of LLOQ for numerical calculations), patient assessment of pain (0-10cm VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. The assessment does not have a score range with an upper or lower bound.
Percentage of Participants Who Achieved Minimal Disease Activity (MDA) Criteria Through Week 24	Weeks 16 and 24	MDA is a measure that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved the PsA MDA at a visit if the participant has fulfilled at least 5 of the following 7 criteria at that visit: Tender joint count (68 joints)\<=1, Swollen joint count (66 joints) \<=1, Psoriasis activity and severity index \<=1, Patient's Assessment of Pain \<=15 on a 100-unit VAS, Patient's Global Assessment of Disease Activity (arthritis and psoriasis) \<=20 on a 100-unit VAS, HAQ-DI score \<=0.5, and Tender entheseal points \<= 1 (LEI index score \<= 1).
Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Weeks 8, 16 and 24	Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis and peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.
Percentage of Participants Who Achieved PASI 75 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Weeks 16 and 24	PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 75 response: \>=75% improvement in PASI score from baseline.
Percentage of Participants Who Achieved PASI 90 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Weeks 16 and 24	PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 90 response: \>=90% improvement in PASI score from baseline.
Percentage of Participants Who Achieved PASI 100 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline	Weeks 16 and 24	PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 100 response: 100% improvement in PASI score from baseline.
Percentage of Participants With an IGA Score of 0 (Cleared) Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Weeks 16 and 24	A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>=2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Change From Baseline in PASI Score at Weeks 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Baseline, Weeks 16 and 24	PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. Negative change from baseline indicates improvement of psoriasis.
Percentage of Participants Who Achieved a DLQI Score of 0 or 1 Through Week 24 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Weeks 8, 16, 24	Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. A DLQI score of 0 or 1 indicates psoriasis had no effect at all on patient's life.
Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score Through Week 24 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Weeks 8, 16, 24	Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. An improvement of 5 points was considered clinically meaningful.
Change From Baseline in DLQI Score at Weeks 8, 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Baseline, Weeks 8, 16 and 24	Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. Negative changes from baseline indicate improvement of life quality impacted by psoriasis.
Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Weeks 16 and 24	In PASI, each area (head, trunk, upper and lower extremities) was assessed for % of area involved and translated to numeric score from 0 (no involvement) to 6 (90-100% involvement) and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI produces numeric score from 0 to 72. Higher scores=more severe disease. PASI 75: \>=75% improvement in PASI score from baseline. ACR 20: \>=20% improvement in swollen joint count (SJC) (66 joints) + tender joint count (TJC) (68 joints) and \>=20% improvement in 3 of 5: patient's assessment of pain (VAS; 0-100 mm, 0=no pain to 100=worst possible pain), PtGA of disease activity (VAS; 0-100 mm, 0=excellent to 100=poor), PGA of disease activity (VAS; 0-100 mm, 0=no arthritis to 100=extremely active arthritis), patient's assessment of physical function (HAQ-DI -20-question instrument; range- 0=no difficulty to 3=inability to perform task) and CRP.
Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Weeks 16 and 24	In PASI, each area (head, trunk, upper and lower extremities) was assessed separately for % of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90-100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI produces numeric score range from 0 to 72. Higher scores=more severe disease. PASI 75 response: \>=75% improvement in PASI score from baseline. Modified PsARC response: improvement in at least 2 of 4 criteria: \>=30% decrease in SJC and TJC, \>=20% improvement in PtGA of Disease Activity (arthritis) on VAS (0-100 mm, 0=excellent and 100=poor), \>=20% improvement in PGA of Disease Activity on VAS (VAS: 0-100 mm, 0=no arthritis and 100=extremely active arthritis), and at least 1 of 2 joint criteria with no deterioration in other criteria.
Change From Baseline in Modified vdH-S Erosion Score at Week 24	Baseline and Week 24	Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
Change From Baseline in Modified vdH-S Joint Space Narrowing (JSN) Score at Week 24	Baseline and Week 24	The modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). The JSN score is the total JSN score in 40 joints of the two hands and 12 joints of the 2 feet. Each joint is scored from 0 to 4 with 0 indicating no JSN, and 4 indicating a complete loss of joint space, bony ankylosis, or complete luxation, for a maximum JSN score of 208. Higher score indicates more severe joint space narrowing. A positive change from baseline in the modified vdH-S JSN score indicates progression of joint space narrowing.
Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 24	Baseline and Week 24	Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand (Hand erosion score) scored according to 0 (no erosion) to 5 (complete collapse of bone) for a maximum hand erosion score of 200, and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum foot erosion score of 120. Higher scores indicate more joint damage. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum Hand JSN score of 160 and maximum Foot JSN score of 48. Higher scores indicate more joint damage. Hand Score (sum of Hand Erosion Score and Hand JSN Score) scored as 0-360 and Foot score (sum of foot erosion score and foot JSN score) scored as 0-168. Higher scores indicate more joint damage.
Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Score at Week 24	Week 24	Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
Percentage of Participants With a Change of <=0 From Baseline and <=0.5 From Baseline in Modified vdH-S Erosion Score at Week 24	Week 24	Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
Percentage of Participants With a Change of <=0 From Baseline and <=0.5 From Baseline in Modified vdH-S JSN Score at Week 24	Week 24	The modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). The JSN score is the sum of JSN score in 40 joints of the two hands and 12 joints of the 2 feet. Each joint is scored from 0 - 4 with 0 indicating no JSN, and 4 indicating a complete loss of joint space, bony ankylosis, or complete luxation, for a maximum JSN score of 208. Higher score indicates more severe joint space narrowing. Change from baseline in the modified vdH-S JSN score \<=0 (assessed by both readers) or \<=0.5 (assessed by at least one reader) was considered as no progression of JSN.
Percentage of Participants Without Radiographic Progression (Based on the Smallest Detectable Change [SDC]) From Baseline at Week 24	Week 24	Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic progression was defined as change from baseline in the modified vdH-S score \<=SDC of 2.18.
Percentage of Participants Without Radiographic Joint Erosion Progression (Based on SDC) From Baseline at Week 24	Week 24	Modified vdH-S score is sum of erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC defined as the cut-off above which changes can be detected beyond measurement error. Without radiographic joint erosion progression was defined as change from baseline in modified vdH-S erosion score \<=SDC of 1.83.
Percentage of Participants Without Radiographic JSN Progression (Based on the SDC) From Baseline at Week 24	Week 24	The modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). The JSN score is the sum of JSN score in 40 joints of the two hands and 12 joints of the 2 feet. Each joint is scored from 0 - 4 with 0 indicating no JSN, and 4 indicating a complete loss of joint space, bony ankylosis, or complete luxation, for a maximum JSN score of 208. Higher score indicates more severe joint space narrowing. The smallest detectable change (SDC) was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic JSN progression was defined as change from baseline in the modified vdH-S JSN score \<=SDC of 1.11.
Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline and Week 24	Baseline and Week 24	Pencil in Cup or Gross Osteolytis Deformities are radiographic features specific for psoriatic arthritis.
Change From Baseline in SF-36 PCS Score at Weeks 8, 16 and 24	Baseline, Weeks 8, 16 and 24	SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Change From Baseline in SF-36 MCS Score at Weeks 8, 16 and 24	Baseline, Weeks 8, 16 and 24	SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Baseline and Weeks 8, 16 and 24	SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales: physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health. The scores 0-100 (where higher scores indicated a better quality of life) from each subscale of SF-36 were normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better health status. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score Through Week 24	Week 8, 16 and 24	SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.
Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score Through Week 24	Week 8, 16 and 24	SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 8, 16, and 24	Baseline, Weeks 8, 16 and 24	The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.
Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score Improvement Through Week 24	Weeks 8, 16 and 24	The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.
Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) at Weeks 16 and 24: EQ-VAS	Baseline, Weeks 16 and 24	EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a vertical line VAS with scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). A higher score indicates better health and positive changes from baseline indicate improvement of health status
Change From Baseline in EQ-5D-5L at Weeks 16 and 24: EQ-5D Index	Baseline, Weeks 16 and 24	EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a weighted summary index (EQ-5D index), which ranges from 0 (dead) to 1.00 (full health). A higher score indicates better health and positive changes from baseline indicate improvement of health.
Percentage of Participants Who Achieved ACR 20 Response at Weeks 24, 28, 36, 44 and 52	Weeks 24, 28, 36, 44 and 52	ACR 20 response was defined as \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
Percentage of Participants Who Achieved ACR 50 Response at Weeks 24, 28, 36, 44 and 52	Weeks 24, 28, 36, 44 and 52	ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
Percentage of Participants Who Achieved ACR 70 Response at Weeks 24, 28, 36, 44 and 52	Weeks 24, 28, 36, 44 and 52	ACR 70 response was defined as \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
ACR Components at Weeks 24, 28, 36, 44 and 52	Weeks 24, 28, 36, 44 and 52	ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).
Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Baseline, Weeks 24, 28, 36, 44 and 52	ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).
Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Baseline, Weeks 24, 28, 36, 44 and 52	ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).
Percentage of Participants Who Maintained an ACR 20 Response at Week 52 Among Participants Who Achieved an ACR 20 Response at Week 24	Week 52	ACR 20 response was defined as \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
Percentage of Participants Who Maintained an ACR 50 Response at Week 52 Among Participants Who Achieved an ACR 50 Response at Week 24	Week 52	ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
Percentage of Participants Who Maintained an ACR 70 Response at Week 52 Among Participants Who Achieved an ACR 70 Response at Week 24	Week 52	ACR 70 response was defined as \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 millimeters \[mm\], 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
Change From Baseline in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52	Baseline, Weeks 24, 28, 36, 44 and 52	HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.
Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52 Among Participants With HAQ-DI Score >=0.35 at Baseline	Weeks 24, 28, 36, 44 and 52	HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.
Percentage of Participants Who Maintained a HAQ-DI Response (>=0.35 Improvement From Baseline in HAQ-DI Score) at Week 52 Among Participants Who Achieved a HAQ-DI Response at Week 24	Week 52	HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.
Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 24, 28, 36, 44 and 52	Weeks 24, 28, 36, 44 and 52	DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. DAS28 (CRP) response criteria was defined as follows: Good response: \<=3.2 at visit and \>1.2 improvement; Moderate response: \>3.2 at visit and \>1.2 improvement or \<=5.1 at visit and \>0.6-1.2 improvement; No response: \<=0.6 improvement, or \>5.1 at visit and \<=1.2 improvement. The values are 0=best to 10=worst. A DAS28 (CRP) responder was defined as achieving a good or moderate DAS28 response at a specific visit.
Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 24, 28, 36, 44 and 52	Weeks 24, 28, 36, 44 and 52	DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. DAS28 (CRP) remission was defined as DAS28 (CRP) value \<2.6 at the analysis visit.
Change From Baseline in DAS28 (CRP) Score at Weeks 24, 28, 36, 44 and 52	Baseline, Weeks 24, 28, 36, 44 and 52	DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative changes from baseline indicate improvement of arthritis.
Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 24, 28, 36, 44 and 52	Weeks 24, 28, 36, 44 and 52	The modified PsARC response was defined as improvement in at least 2 of the four criteria: \>=30% decrease in swollen joint count, \>=30% decrease in tender joint count, \>=20% improvement in patient's Global Assessment of Disease Activity (arthritis) on a VAS (0-100 mm, 0=excellent and 100= poor), \>=20% improvement in physician's Global Assessment of Disease Activity using VAS (VAS: 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), and at least one of the 2 joint criteria with no deterioration in the other criteria.
Percentage of Participants With Resolution of Enthesitis at Weeks 24 and 52 Among the Participants With Enthesitis at Baseline	Weeks 24 and 52	Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI\>0.
Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 24 and 52 Among the Participants With Enthesitis at Baseline	Baseline, Weeks 24 and 52	Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicate improvement of enthesitis.
Percentage of Participants With Resolution of Dactylitis at Weeks 24 and 52 Among Participants With Dactylitis at Baseline	Weeks 24 and 52	The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \>0.
Change From Baseline in Dactylitis Score at Weeks 24 and 52 Among the Participants With Dactylitis at Baseline	Baseline, Weeks 24 and 52	The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. A higher score indicates more severe dactylitis. Negative changes from baseline indicate improvement in dactylitis.
Change From Baseline in Psoriatic Arthritis Disease Activity (PASDAS) Score at Weeks 24 and 52	Baseline, Weeks 24 and 52	PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a composite score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0= 0 sites with tenderness to 6= worst possible score; 6 sites with tenderness), tender dactylitis count (scoring each digit from 0-3 \[where 0= no tenderness and 3= extreme tenderness\] and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score with score range 0-100 (higher score-better quality of life) of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.
Percentage of Participants With Low or Very Low Disease Activity Based on Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 24 and 52	Weeks 24 and 52	PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a composite score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0= 0 sites with tenderness to 6= worst possible score; 6 sites with tenderness), tender dactylitis count (scoring each digit from 0-3 \[where 0= no tenderness and 3= extreme tenderness\] and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score with score range 0-100 (higher score-better quality of life) of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.
Change From Baseline in Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 24 and 52	Baseline, Weeks 24 and 52	GRACE index is a composite PsA disease activity score converted from AMDF, which was derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), patient's global assessment of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100= poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), patient's global assessment of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL =25.355 + \[2.367\HAQ-DI\] - \[0.234\SF-PCS\] - \[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score ranges from 0 to 100, higher scores= better quality of life) and SF-MCS (score ranges from 0 to 100, higher scores= better quality of life). The total score is from 0-10, where lower score indicates better response. Higher score indicates more active disease activity. Negative change from baseline indicates improvement of PsA disease activity.
Percentage of Participants With Low Disease Activity Based on Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 24 and 52	Weeks 24 and 52	GRACE index is a composite PsA disease activity score converted from Arithmetic Mean of Desirability Function (AMDF), derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), PtGA of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100=poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), PtGA of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL=25.355 + \[2.367\HAQ-DI\]-\[0.234\SF-PCS\]-\[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score range= 0-100, higher scores= better quality of life) and SF-MCS (score range=0-100, higher scores= better quality of life). Total score is 0-10, lower score=better response. Higher score= more active disease activity. Negative change from baseline indicates improvement of PsA disease activity. GRACE low disease activity is GRACE score \<=2.3 at the analysis visit.
Change From Baseline in the Disease Activity Index for Psoriatic Arthritis (DAPSA) Score at Weeks 24, 28, 36, 44 and 52	Baseline, Weeks 24, 28, 36, 44 and 52	DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL), patient assessment of pain (0-10cm VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. The assessment does not have a score range with an upper or lower bound.
Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Weeks 24 and 52	Baseline, Weeks 24 and 52	The mCPDAI assessed 4 domains (joints, skin, entheses, and dactylitis). The mCPDAI scores were calculated using the following assessments: joints (66 swollen and 68 tender joint counts), HAQ-DI score, PASI, dactylitis, and enthesitis. Within each domain a score (range 0-3) was assigned, where 0= Not involved, 1= Mild, 2= Moderate and 3= Severe. The scores for each domain were then added together to give a final score range of 0 to 12. A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity.
Percentage of Participants With Low Disease Activity Based on Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Weeks 24 and 52	Weeks 24 and 52	The mCPDAI assessed 4 domains (joints, skin, entheses, and dactylitis). The mCPDAI scores were calculated using the following assessments: joints (66 swollen and 68 tender joint counts), HAQ-DI score, PASI, dactylitis, and enthesitis. Within each domain a score (range 0-3) was assigned, where 0= Not involved, 1= Mild, 2= Moderate and 3= Severe. The scores for each domain were then added together to give a final score range of 0 to 12. A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. mCPDAI low disease activity is defined as mCPDAI score \<=3.2 at the analysis visit.
Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 24 and 52	Weeks 24 and 52	MDA is a measure that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved the PsA MDA at a visit if the participant has fulfilled at least 5 of the following 7 criteria at that visit: Tender joint count (68 joints)\<=1, Swollen joint count (66 joints) \<=1, Psoriasis activity and severity index \<=1, Patient's Assessment of Pain \<=15 on a 100-unit VAS, Patient's Global Assessment of Disease Activity (arthritis and psoriasis) \<=20 on a 100-unit VAS, HAQ-DI score \<=0.5, and Tender entheseal points \<= 1 (LEI index score \<= 1).
Percentage of Participants With Very Low Disease Activity (VLDA) at Weeks 24 and 52	Weeks 24 and 52	A measurement that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved VLDA at a visit if the participant fulfilled all 7 criteria (tender joint count \<=1; swollen joint count \<=1; PASI \<=1; patient pain VAS score of \<=15; patient global disease activity VAS \[arthritis and psoriasis\] score of \<=20; Health Assessment Questionnaire (HAQ) score \<=0.5; and tender entheseal points \<=1) at that visit.
Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score at Weeks 24 and 52 Among Participants With Spondylitis and Peripheral Arthritis at Baseline	Baseline, Weeks 24 and 52	Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis and peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.
Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 24 and 52 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Weeks 24 and 52	Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis and peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.
Change From Baseline in PASI Score at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Baseline, Weeks 24 and 52	PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. Negative change from baseline indicates improvement of psoriasis.
Percentage of Participants Who Achieved PASI 50 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Weeks 24 and 52	PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 50 response: \>=50% improvement in PASI score from baseline.
Percentage of Participants Who Achieved PASI 75 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Weeks 24 and 52	PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 75 response: \>=75% improvement in PASI score from baseline.
Percentage of Participants Who Achieved PASI 90 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Weeks 24 and 52	PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 90 response: \>=90% improvement in PASI score from baseline.
Percentage of Participants Who Achieved PASI 100 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Weeks 24 and 52	PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 100 response: 100% improvement in PASI score from baseline.
Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Weeks 24 and 52	In PASI, each area (head, trunk, upper and lower extremities) was assessed for % of area involved and translated to numeric score from 0 (no involvement) to 6 (90-100% involvement) and for erythema, induration, and scaling, each rated on scale of 0 to 4. PASI produces numeric score from 0 to 72. Higher scores=more severe disease. PASI 75: \>=75% improvement in PASI score from baseline. ACR 20: \>=20% improvement in SJC (66 joints)+TJC (68 joints) and \>=20% improvement in 3 of 5: patient's assessment of pain (VAS; 0-100 mm, 0=no pain to 100=worst possible pain), PtGA of disease activity (VAS; 0-100 mm, 0=excellent to 100=poor), PGA of disease activity (VAS; 0-100 mm, 0=no arthritis to 100=extremely active arthritis), patient's assessment of physical function (HAQ-DI -20-question instrument; range- 0=no difficulty to 3=inability to perform task) and CRP.
Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Weeks 24 and 52	In PASI, each area (head, trunk, upper and lower extremities) was assessed separately for % of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90-100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4. PASI produces numeric score range from 0 to 72. Higher scores=more severe disease. PASI75 response: \>=75% improvement in PASI score from baseline. Modified PsARC response: improvement in at least 2 of 4 criteria: \>=30% decrease in SJC and TJC, \>=20% improvement in PtGA of Disease Activity (arthritis) on VAS (0-100 mm, 0=excellent and 100=poor), \>=20% improvement in PGA of Disease Activity on VAS (VAS: 0-100 mm, 0=no arthritis and 100=extremely active arthritis), and at least 1 of 2 joint criteria with no deterioration in other criteria.
Percentage of Participants Who Achieved an IGA Response at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Weeks 24 and 52	A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>= 2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Percentage of Participants Who Achieved an IGA Score of 0 (Cleared) at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Weeks 24 and 52	A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>= 2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Percentage of Participants Who Achieved a DLQI Score of 0 or 1 at Weeks 24 and 52 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Weeks 24 and 52	Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. A DLQI score of 0 or 1 indicates psoriasis had no effect at all on patient's life.
Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score at Weeks 24 and 52 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Weeks 24 and 52	Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. An improvement of 5 points was considered clinically meaningful.
Change From Baseline in DLQI Score at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Baseline, Weeks 24 and 52	Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. Negative changes from baseline indicate improvement of life quality impacted by psoriasis.
Change From Baseline in Modified vdH-S Score at Week 52	Baseline and Week 52	Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
Change in Total Modified vdH-S Score From Week 24 to Week 52	From Week 24 to Week 52	Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage.
Change From Baseline in Modified vdH-S Erosion Score at Week 52	Baseline and Week 52	Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
Change in Modified vdH-S Erosion Score From Week 24 to Week 52	From Week 24 to Week 52	Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage.
Change From Baseline in Modified vdH-S JSN Score at Week 52	Baseline and Week 52	Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
Change in Modified vdH-S JSN Score From Week 24 to Week 52	From Week 24 to Week 52	Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage.
Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 52	Baseline and Week 52	Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand (Hand erosion score) scored according to 0 (no erosion) to 5 (complete collapse of bone) for a maximum hand erosion score of 200, and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum foot erosion score of 120. Higher scores indicate more joint damage. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum Hand JSN score of 160 and maximum Foot JSN score of 48. Higher scores indicate more joint damage. Hand Score (sum of Hand Erosion Score and Hand JSN Score) scored as 0-360 and Foot score (sum of foot erosion score and foot JSN score) scored as 0-168. Higher scores indicate more joint damage.
Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Score at Week 52	Week 52	Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Erosion Score at Week 52	Week 52	Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S JSN Score at Week 52	Week 52	Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
Percentage of Participants Without Radiographic Progression Based on the (SDC) From Baseline at Week 52	Week 52	Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic progression was defined as change from baseline in the modified vdH-S score \<=SDC of 2.39.
Percentage of Participants Without Radiographic Joint Erosion Progression Based on (SDC) From Baseline at Week 52	Week 52	Modified vdH-S score is sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is summary of erosion severity in 40 joints of hand scored according to surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is total JSN score in same 52 joints as above, each joint scored according to subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic joint erosion progression was defined as change from baseline in modified vdH-S erosion score \<=SDC of 2.22.
Percentage of Participants Without Radiographic JSN Progression Based on (SDC) From Baseline at Week 52	Week 52	Modified vdH-S score is sum of erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is summary of erosion severity in 40 joints of hand scored according to surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is total JSN score in same 52 joints as above, each joint scored according to subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as cut-off above which changes can be detected beyond measurement error. Without radiographic JSN progression was defined as change from baseline in modified vdH-S JSN score \<=SDC of 1.02.
Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline and Week 52	Baseline and Week 52	Percentage of Participants with Pencil in cup or Gross Osteolysis Deformities were reported. Pencil in Cup or Gross Osteolytis Deformities are radiographic features specific for psoriatic arthritis.
Change From Baseline in SF-36 PCS Score at Weeks 24 and 52	Baseline, Weeks 24 and 52	SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Change From Baseline in SF-36 MCS Score at Weeks 24 and 52	Baseline, Weeks 24 and 52	SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Baseline, Weeks 24 and 52	SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales: physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health. The scores 0-100 (where higher scores indicated a better quality of life) from each subscale of SF-36 were normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better health status. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score at Weeks 24 and 52	Weeks 24 and 52	SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.
Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score at Weeks 24 and 52	Weeks 24 and 52	SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.
Change From Baseline in FACIT-Fatigue Score at Weeks 24 and 52	Baseline, Weeks 24 and 52	The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.
Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score Improvement at Weeks 24 and 52	Weeks 24 and 52	The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.
Change From Baseline in EQ-5D-5L at Weeks 24 and 52: EQ-VAS	Baseline, Weeks 24 and 52	EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a vertical line VAS with scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). A higher score indicates better health and positive changes from baseline indicate improvement of health status.
Change From Baseline in EQ-5D-5L at Weeks 24 and 52: EQ-5D Index	Baseline, Weeks 24 and 52	EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a weighted summary index (EQ-5D index), which ranges from 0 (dead) to 1.00 (full health). A higher score indicates better health and positive changes from baseline indicate improvement of health.
Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire Scores (Percent Work Time Missed) at Weeks 24 and 52	Baseline, Weeks 24 and 52	Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.
Change From Baseline in WPAI Scores (Percent Impairment While Working) at Weeks 24 and 52	Baseline, Weeks 24 and 52	Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.
Change From Baseline in WPAI Scores (Percent Overall Work Impairment) at Weeks 24 and 52	Baseline, Weeks 24 and 52	Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.
Change From Baseline in WPAI Scores (Percent Activity Impairment Outside of Work) at Weeks 24 and 52	Baseline, Weeks 24 and 52	Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.
Percentage of Participants Who Achieved ACR 20 Response at Weeks 52, 68, 76, 84 and 100	Weeks 52, 68, 76, 84 and 100	ACR 20 response was defined as \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
Percentage of Participants Who Achieved ACR 50 Response at Weeks 52, 68, 76, 84 and 100	Weeks 52, 68, 76, 84 and 100	ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
Percentage of Participants Who Achieved ACR 70 Response at Weeks 52, 68, 76, 84 and 100	Weeks 52, 68, 76, 84 and 100	ACR 70 response was defined as \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
ACR Components at Weeks 52, 68, 76, 84 and 100	Weeks 52, 68, 76, 84 and 100	ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).
Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Baseline, Weeks 52, 68, 76, 84 and 100	ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).
Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Baseline, Weeks 52, 68, 76, 84 and 100	ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).
Percentage of Participants Who Maintained an ACR 20 Response at Week 100 Among Participants Who Achieved an ACR 20 Response at Week 52	Week 100	ACR 20 response was defined as \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
Percentage of Participants Who Maintained an ACR 50 Response at Week 100 Among Participants Who Achieved an ACR 50 Response at Week 52	Week 100	ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
Percentage of Participants Who Maintained an ACR 70 Response at Week 100 Among Participants Who Achieved an ACR 70 Response at Week 52	Week 100	ACR 70 response was defined as \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 millimeters \[mm\], 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
Change From Baseline in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100	Baseline, Weeks 52, 68, 76, 84 and 100	HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3, where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.
Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100 Among Participants With HAQ-DI Score >=0.35 at Baseline	Weeks 52, 68, 76, 84 and 100	HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3, where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.
Percentage of Participants Who Maintained a HAQ-DI Response (>=0.35 Improvement From Baseline in HAQ-DI Score) at Week 100 Among Participants Who Achieved a HAQ-DI Response at Week 52	Week 100	HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3, where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.
Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 52, 68, 76, 84 and 100	Weeks 52, 68, 76, 84 and 100	DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. DAS28 (CRP) response criteria was defined as follows: Good response: \<=3.2 at visit and \>1.2 improvement; Moderate response: \>3.2 at visit and \>1.2 improvement or \<=5.1 at visit and \>0.6-1.2 improvement; No response: \<=0.6 improvement, or \>5.1 at visit and \<=1.2 improvement. The values are 0=best to 10=worst. A DAS28 (CRP) responder was defined as achieving a good or moderate DAS28 response at a specific visit.
Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 52, 68, 76, 84 and 100	Weeks 52, 68, 76, 84 and 100	DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. DAS28 (CRP) remission was defined as DAS28 (CRP) value \<2.6 at the analysis visit.
Change From Baseline in DAS28 (CRP) Score at Weeks 52, 68, 76, 84 and 100	Baseline, Weeks 52, 68, 76, 84 and 100	DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative changes from baseline indicate improvement of arthritis.
Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 52, 68, 76, 84 and 100	Weeks 52, 68, 76, 84 and 100	The modified PsARC response was defined as improvement in at least 2 of the four criteria: \>=30% decrease in swollen joint count, \>=30% decrease in tender joint count, \>=20% improvement in patient's Global Assessment of Disease Activity (arthritis) on a VAS (0-100 mm, 0=excellent and 100= poor), \>=20% improvement in physician's Global Assessment of Disease Activity using VAS (VAS: 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), and at least one of the 2 joint criteria with no deterioration in the other criteria.
Percentage of Participants With Resolution of Enthesitis (LEI) at Weeks 52, 76 and 100 Among the Participants With Enthesitis (LEI) at Baseline	Weeks 52, 76, and 100	Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI\>0.
Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 52, 76 and 100 Among the Participants With Enthesitis at Baseline	Baseline, Weeks 52, 76 and 100	Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicate improvement of enthesitis.
Percentage of Participants With Resolution of Dactylitis at Weeks 52, 76 and 100 Among Participants With Dactylitis at Baseline	Weeks 52, 76 and 100	The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \>0.
Change From Baseline in Dactylitis Scores at Weeks 52, 76 and 100 Among the Participants With Dactylitis at Baseline	Baseline, Weeks 52, 76 and 100	The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Negative changes from baseline indicate improvement of dactylitis.
Change From Baseline in PASDAS Score at Weeks 52, 76 and 100	Baseline, Weeks 52, 76 and 100	PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a composite score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0= 0 sites with tenderness to 6= worst possible score; 6 sites with tenderness), tender dactylitis count (scoring each digit from 0-3 \[where 0= no tenderness and 3= extreme tenderness\] and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score with score range 0-100 (higher score-better quality of life) of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.
Percentage of Participants With Low or Very Low Disease Activity Based on PASDAS at Weeks 52, 76 and 100	Weeks 52, 76 and 100	PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a composite score of overall disease activity combining PtGA of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), PGA of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0= 0 sites with tenderness to 6= worst possible score; 6 sites with tenderness), tender dactylitis count (scoring each digit from 0-3 \[where 0= no tenderness and 3= extreme tenderness\] and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score with score range 0-100 (higher score-better quality of life) of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity. Low: PASDAS \<= 3.2; Very low: PASDAS \<= 1.9.
Change From Baseline in GRAPPA Composite Score (GRACE) at Weeks 52, 76 and 100	Baseline, Weeks 52, 76 and 100	GRACE index is a composite PsA disease activity score converted from Arithmetic Mean of Desirability Function (AMDF), derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), patient's global assessment of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100=poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), patient's global assessment of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL=25.355 + \[2.367\HAQ-DI\]-\[0.234\SF-PCS\]-\[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score ranges from 0-100, higher scores= better quality of life) and SF-MCS (score ranges from 0-100, higher scores= better quality of life). Total score is from 0-10, lower score=better response. Higher score indicates more active disease activity. Negative change from baseline indicates improvement of PsA disease activity.
Percentage of Participants With Low Disease Activity Based on Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 52, 76 and 100	Weeks 52, 76 and 100	GRACE index is a composite PsA disease activity score converted from Arithmetic Mean of Desirability Function (AMDF), derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), PtGA of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100=poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), PtGA of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL=25.355 + \[2.367\HAQ-DI\]-\[0.234\SF-PCS\]-\[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score range= 0-100, higher scores= better quality of life) and SF-MCS (score range=0-100, higher scores= better quality of life). Total score is 0-10, lower score=better response. Higher score= more active disease activity. Negative change from baseline indicates improvement of PsA disease activity. GRACE low disease activity is GRACE score \<=2.3 at the analysis visit.
Change From Baseline in DAPSA at Weeks 52, 68, 76, 84 and 100	Baseline, Weeks 52, 68, 76, 84 and 100	DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL, value \<lower limit of quantification \[LLOQ\] is considered equal to half of the value of LLOQ for numerical calculations), patient assessment of pain (0-10cm VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. The assessment does not have a score range with an upper or lower bound.
Percentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100	Weeks 52, 68, 76, 84 and 100	DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL), patient assessment of pain (0-10 cm VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10 cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. The assessment does not have a score range with an upper or lower bound. Low: DAPSA\<=14; Remission: DAPSA\<=4.
Change From Baseline in mCPDAI Score at Weeks 52, 76 and 100	Baseline, Weeks 52, 76 and 100	The mCPDAI assessed 4 domains (joints, skin, entheses, and dactylitis). The mCPDAI scores were calculated using the following assessments: joints (66 swollen and 68 tender joint counts), HAQ-DI score, PASI, dactylitis, and enthesitis. Within each domain a score (range 0-3) was assigned, where 0= Not involved, 1= Mild, 2= Moderate and 3= Severe. The scores for each domain were then added together to give a final score range of 0 to 12. A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity.
Percentage of Participants With Low Disease Activity Based on mCPDAI at Weeks 52, 76 and 100	Weeks 52, 76 and 100	The mCPDAI assessed 4 domains (joints, skin, entheses, and dactylitis). The mCPDAI scores were calculated using the following assessments: joints (66 swollen and 68 tender joint counts), HAQ-DI score, PASI, dactylitis, and enthesitis. Within each domain a score (range 0-3) was assigned, where 0= Not involved, 1= Mild, 2= Moderate and 3= Severe. The scores for each domain were then added together to give a final score range of 0 to 12. A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. mCPDAI low disease activity is defined as mCPDAI score \<=3.2 at the analysis visit.
Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 52, 76 and 100	Weeks 52, 76 and 100	MDA is a measure that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved the PsA MDA at a visit if the participant has fulfilled at least 5 of the following 7 criteria at that visit: Tender joint count (68 joints)\<=1, Swollen joint count (66 joints) \<=1, Psoriasis activity and severity index \<=1, Patient's Assessment of Pain \<=15 on a 100-unit VAS, Patient's Global Assessment of Disease Activity (arthritis and psoriasis) \<=20 on a 100-unit VAS, HAQ-DI score \<=0.5, and Tender entheseal points \<= 1 (LEI index score \<= 1).
Percentage of Participants With VLDA at Weeks 52, 76 and 100	Weeks 52, 76 and 100	A measurement that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved VLDA at a visit if the participant fulfilled all 7 criteria (tender joint count \<=1; swollen joint count \<=1; PASI \<=1; patient pain VAS score of \<=15; patient global disease activity VAS \[arthritis and psoriasis\] score of \<=20; Health Assessment Questionnaire (HAQ) score \<=0.5; and tender entheseal points \<=1) at that visit.
Change From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among Participants With Spondylitis and Peripheral Arthritis and BASDAI Score>0 at Baseline	Baseline, Weeks 52, 76 and 100	Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis and peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.
Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Weeks 52, 76 and 100	Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis and peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.
Change From Baseline in PASI Score at Weeks 52, 76 and 100 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Baseline, Weeks 52, 76 and 100	PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. Negative change from baseline indicates improvement of psoriasis.
Percentage of Participants Who Achieved PASI 50 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Weeks 52, 76 and 100	PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 50 response: \>=50% improvement in PASI score from baseline.
Percentage of Participants Who Achieved PASI 75 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Weeks 52, 76 and 100	PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 75 response: \>=75% improvement in PASI score from baseline.
Percentage of Participants Who Achieved PASI 90 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Weeks 52, 76 and 100	PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 90 response: \>=90% improvement in PASI score from baseline.
Percentage of Participants Who Achieved PASI 100 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Weeks 52, 76 and 100	PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 100 response: 100% improvement in PASI score from baseline.
Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Weeks 52, 76 and 100	In PASI, each area (head, trunk, upper and lower extremities) was assessed for % of area involved and translated to numeric score from 0 (no involvement) to 6 (90-100% involvement) and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI produces numeric score from 0 to 72. Higher scores=more severe disease. PASI 75: \>=75% improvement in PASI score from baseline. ACR 20: \>=20% improvement in swollen joint count (SJC) (66 joints) + tender joint count (TJC) (68 joints) and \>=20% improvement in 3 of 5: patient's assessment of pain (VAS; 0-100 mm, 0=no pain to 100=worst possible pain), PtGA of disease activity (VAS; 0-100 mm, 0=excellent to 100=poor), PGA of disease activity (VAS; 0-100 mm, 0=no arthritis to 100=extremely active arthritis), patient's assessment of physical function (HAQ-DI -20-question instrument; range- 0=no difficulty to 3=inability to perform task) and CRP.
Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response at Weeks 52, 76, and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Weeks 52, 76 and 100	In PASI, each area (head, trunk, upper and lower extremities) was assessed separately for % of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90-100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI produces numeric score range from 0 to 72. Higher scores=more severe disease. PASI 75 response: \>=75% improvement in PASI score from baseline. Modified PsARC response: improvement in at least 2 of 4 criteria: \>=30% decrease in SJC and TJC, \>=20% improvement in PtGA of Disease Activity (arthritis) on VAS (0-100 mm, 0=excellent and 100=poor), \>=20% improvement in PGA of Disease Activity on VAS (VAS: 0-100 mm, 0=no arthritis and 100=extremely active arthritis), and at least 1 of 2 joint criteria with no deterioration in other criteria.
Percentage of Participants With an IGA Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Weeks 52, 76 and 100	A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>= 2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4). IGA Response is defined as achieving IGA score of 0 or 1, and \>=2 grade reduction from baseline.
Percentage of Participants With an IGA Score of 0 (Cleared) at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Weeks 52, 76 and 100	A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>= 2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Percentage of Participants Who Achieved a DLQI Score of 0 or 1 at Weeks 52, 76 and 100 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Weeks 52, 76 and 100	Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. A DLQI score of 0 or 1 indicates psoriasis had no effect at all on patient's life.
Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score at Weeks 52, 76 and 100 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Weeks 52, 76 and 100	Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. An improvement of 5 points was considered clinically meaningful.
Change From Baseline in DLQI Score at Weeks 52, 76 and 100 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Baseline, Weeks 52, 76 and 100	Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. Negative changes from baseline indicate improvement of life quality impacted by psoriasis.
Change in Modified vdH-S Score From Baseline to Week 100	Baseline to Week 100	Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
Change in Total Modified vdH-S Score From Week 52 to Week 100	From Week 52 to Week 100	Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage.
Change in Modified vdH-s Erosion Score From Baseline to Week 100	Baseline to Week 100	Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
Change in Modified vdH-s Erosion Score From Week 52 to Week 100	From Week 52 to Week 100	Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
Change in Modified vdH-s JSN Score From Baseline to Week 100	Baseline to Week 100	Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
Change in Modified vdH-s JSN Score From Week 52 to Week 100	From Week 52 to Week 100	Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
Change From Baseline to Week 100 in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores)	Baseline to Week 100	Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand (Hand erosion score) scored according to 0 (no erosion) to 5 (complete collapse of bone) for a maximum hand erosion score of 200, and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum foot erosion score of 120. Higher scores indicate more joint damage. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum Hand JSN score of 160 and maximum Foot JSN score of 48. Higher scores indicate more joint damage. Hand Score (sum of Hand Erosion Score and Hand JSN Score) scored as 0-360 and Foot score (sum of foot erosion score and foot JSN score) scored as 0-168. Higher scores indicate more joint damage.
Percentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S Score	Baseline to Week 100	Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
Percentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S Erosion Score	Baseline to Week 100	Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
Percentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S JSN Score	Baseline to Week 100	Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.
Percentage of Participants Without Radiographic Modified vdH-S Progression Based on (SDC) From Baseline to Week 100	Baseline to Week 100	Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic progression was defined as change from baseline in the modified vdH-S score \<=SDC of 3.46.
Percentage of Participants Without Radiographic Erosion Progression (Based on SDC) From Baseline to Week 100	Baseline to Week 100	Modified vdH-S score is sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is summary of erosion severity in 40 joints of hand scored according to surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic erosion progression was defined as change from baseline in the modified vdH-S erosion score \<=SDC of 2.66.
Percentage of Participants Without Radiographic JSN Progression (Based on SDC) From Baseline to Week 100	Baseline to Week 100	Modified vdH-S score is sum of erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is summary of erosion severity in 40 joints of hand scored according to surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic JSN progression was defined as change from baseline in the modified vdH-S JSN score \<=SDC of 1.66.
Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline, Weeks 24, 52, and 100	Baseline, Weeks 24, 52, and 100	Pencil in Cup or Gross Osteolytis Deformities are radiographic features specific for psoriatic arthritis.
Change From Baseline in SF-36 PCS Score at Weeks 52, 76 and 100	Baseline, Weeks 52, 76 and 100	SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Change From Baseline in SF-36 MCS Score at Weeks 52, 76 and 100	Baseline, Weeks 52, 76 and 100	SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Baseline, Weeks 52, 76 and 100	SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales: physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health. The scores 0-100 (where higher scores indicated a better quality of life) from each subscale of SF-36 were normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better health status. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score at Weeks 52, 76 and 100	Weeks 52, 76 and 100	SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.
Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score at Weeks 52, 76 and 100	Weeks 52, 76 and 100	SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 52, 76 and 100	Baseline, Weeks 52, 76 and 100	The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.
Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score at Weeks 52, 76 and 100	Weeks 52, 76 and 100	The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.
Change From Baseline in EQ-5D-5L at Weeks 52, 76 and 100: EQ-VAS	Baseline, Weeks 52, 76 and 100	EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a vertical line VAS with scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). A higher score indicates better health and positive changes from baseline indicate improvement of health status.
Change From Baseline in EQ-5D-5L at Weeks 52, 76 and 100: EQ-5D Index	Baseline, Weeks 52, 76 and 100	EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a weighted summary index (EQ-5D index), which ranges from 0 (dead) to 1.00 (full health). A higher score indicates better health and positive changes from baseline indicate improvement of health.
Change From Baseline in WPAI Scores (Percent Work Time Missed) at Weeks 52, 76 and 100	Baseline, Weeks 52, 76 and 100	Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.
Change From Baseline in WPAI Scores (Percent Impairment While Working) at Weeks 52, 76 and 100	Baseline, Weeks 52, 76 and 100	Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.
Change From Baseline in WPAI Scores (Percent Overall Work Impairment) at Weeks 52, 76 and 100	Baseline, Weeks 52, 76 and 100	Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.
Change From Baseline in WPAI Scores (Percent Activity Impairment Outside of Work) Weeks 52, 76 and 100	Baseline, Weeks 52, 76 and 100	Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.

Countries

Bulgaria, Czechia, Estonia, Latvia, Lithuania, Malaysia, Poland, Russia, Spain, Taiwan, Turkey (Türkiye), Ukraine, United States

Contacts

STUDY_DIRECTORJanssen Research & Development, LLC Clinical Trial

Janssen Research & Development, LLC

Participant flow

Pre-assignment details

A total of 741 participants were randomized and 739 participants received at least one dose of study drug: 246 in placebo group, 248 in guselkumab 100 mg q8w group, and 245 in guselkumab 100 mg q4w group. Two participants were randomized in error and were never treated. Disposition is presented till active treatment period (Week100).

Participants by arm

Arm	Count
Placebo to Guselkumab 100 mg q4w Participants were randomized to receive placebo matched to guselkumab subcutaneous injections every 4 weeks through Week 20 in the placebo controlled period (PCP), then to receive guselkumab 100 milligrams (mg) subcutaneous injection from Week 24 every 4 weeks through Week 100 in the active treatment period.	246
Guselkumab 100 mg q8w Participants were randomized to receive guselkumab 100 mg subcutaneous injections at Weeks 0 and 4, then every 8 weeks (q8w) through Week 100 and placebo matched to guselkumab injections at Week 8 then q8w through Week 100.	248
Guselkumab 100 mg q4w Participants were randomized to receive guselkumab 100 mg subcutaneous injections every 4 weeks (q4w) through Week 100.	245
Total	739

Baseline characteristics

Characteristic	Placebo to Guselkumab 100 mg q4w	Guselkumab 100 mg q8w	Guselkumab 100 mg q4w	Total
Age, Continuous	46.3 years STANDARD_DEVIATION 11.68	44.9 years STANDARD_DEVIATION 11.89	45.9 years STANDARD_DEVIATION 11.47	45.7 years STANDARD_DEVIATION 11.68
Ethnicity (NIH/OMB) Hispanic or Latino	1 Participants	1 Participants	0 Participants	2 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	245 Participants	247 Participants	245 Participants	737 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Asian	4 Participants	8 Participants	3 Participants	15 Participants
Race (NIH/OMB) Black or African American	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) More than one race	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) White	242 Participants	240 Participants	242 Participants	724 Participants
Region of Enrollment BULGARIA	14 participants	9 participants	6 participants	29 participants
Region of Enrollment CZECH REPUBLIC	13 participants	5 participants	15 participants	33 participants
Region of Enrollment ESTONIA	5 participants	8 participants	5 participants	18 participants
Region of Enrollment LATVIA	3 participants	3 participants	0 participants	6 participants
Region of Enrollment LITHUANIA	8 participants	8 participants	4 participants	20 participants
Region of Enrollment MALAYSIA	3 participants	6 participants	3 participants	12 participants
Region of Enrollment POLAND	35 participants	27 participants	23 participants	85 participants
Region of Enrollment RUSSIAN FEDERATION	92 participants	77 participants	104 participants	273 participants
Region of Enrollment SPAIN	3 participants	12 participants	4 participants	19 participants
Region of Enrollment TAIWAN	0 participants	1 participants	0 participants	1 participants
Region of Enrollment TURKEY	2 participants	8 participants	6 participants	16 participants
Region of Enrollment UKRAINE	65 participants	83 participants	73 participants	221 participants
Region of Enrollment UNITED STATES	3 participants	1 participants	2 participants	6 participants
Sex: Female, Male Female	129 Participants	119 Participants	103 Participants	351 Participants
Sex: Female, Male Male	117 Participants	129 Participants	142 Participants	388 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk
deaths Total, all-cause mortality	0 / 246	0 / 248	0 / 245	1 / 238	0 / 248	0 / 245
other Total, other adverse events	30 / 246	42 / 248	52 / 245	48 / 238	88 / 248	79 / 245
serious Total, serious adverse events	7 / 246	3 / 248	8 / 245	16 / 238	22 / 248	22 / 245

Outcome results

Primary

Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24

ACR 20 response: \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP. Treatment Failure (TF) criteria- discontinued study drug, initiated/increased dose of non-biologic disease-modifying antirheumatic drugs (DMARDs) or oral corticosteroids, initiated prohibited psoriatic arthritis treatment.

Time frame: Week 24

Population: Analysis population is full analysis set 1 (FAS1). Participants who achieved ACR 20 response at Week 24 and did not meet any treatment failure (TF) criteria before Week 24 were considered as responders. Participants who met 1 or more TF criteria or with missing data were considered as non-responders.

Arm	Measure	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24	32.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24	64.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24	63.7 percentage of participants

p-value: <0.00195% CI: [22.9, 39.5]Cochran-Mantel-Haenszel

p-value: <0.00195% CI: [22.4, 39.1]Cochran-Mantel-Haenszel

Secondary

ACR Components at Weeks 24, 28, 36, 44 and 52

ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (mg/dL).

Time frame: Weeks 24, 28, 36, 44 and 52

Population: Analysis population is FAS2. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: Swollen Joint Count	4.1 units on a scale	Standard Deviation 5.17
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: HAQ-DI score	0.9117 units on a scale	Standard Deviation 0.63353
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: Patient's Assessment of Pain	3.78 units on a scale	Standard Deviation 2.297
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: Swollen Joint Count	2.5 units on a scale	Standard Deviation 3.77
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: CRP	1.120 units on a scale	Standard Deviation 1.514
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: Patient's Assessment of Pain	4.66 units on a scale	Standard Deviation 2.341
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: Swollen Joint Count	2.1 units on a scale	Standard Deviation 3.19
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: PGA of Disease Activity	4.22 units on a scale	Standard Deviation 2.342
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: Patient's Assessment of Pain	5.21 units on a scale	Standard Deviation 2.368
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: Swollen Joint Count	2.1 units on a scale	Standard Deviation 3.59
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: HAQ-DI score	0.9069 units on a scale	Standard Deviation 0.63695
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: Tender Joint Count	7.4 units on a scale	Standard Deviation 10.24
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: Tender Joint Count	14.4 units on a scale	Standard Deviation 13.16
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: PGA of Disease Activity	2.06 units on a scale	Standard Deviation 1.649
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: Tender Joint Count	7.5 units on a scale	Standard Deviation 9.42
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: Tender Joint Count	11.7 units on a scale	Standard Deviation 11.87
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: PtGA of Disease Activity	3.68 units on a scale	Standard Deviation 2.318
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: Tender Joint Count	8.5 units on a scale	Standard Deviation 10
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: CRP	1.543 units on a scale	Standard Deviation 2.1572
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: HAQ-DI score	1.0457 units on a scale	Standard Deviation 0.59051
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: PtGA of Disease Activity	3.78 units on a scale	Standard Deviation 2.378
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: PGA of Disease Activity	1.90 units on a scale	Standard Deviation 1.654
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: PtGA of Disease Activity	3.84 units on a scale	Standard Deviation 2.295
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: CRP	0.920 units on a scale	Standard Deviation 1.4674
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: PGA of Disease Activity	2.28 units on a scale	Standard Deviation 1.594
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: PtGA of Disease Activity	4.75 units on a scale	Standard Deviation 2.338
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: CRP	0.858 units on a scale	Standard Deviation 1.0558
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: HAQ-DI score	0.9621 units on a scale	Standard Deviation 0.60695
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: PtGA of Disease Activity	5.29 units on a scale	Standard Deviation 2.367
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: CRP	0.907 units on a scale	Standard Deviation 1.5985
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: HAQ-DI score	1.1350 units on a scale	Standard Deviation 0.61984
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: Patient's Assessment of Pain	3.53 units on a scale	Standard Deviation 2.253
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: Swollen Joint Count	5.8 units on a scale	Standard Deviation 6.99
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: PGA of Disease Activity	3.27 units on a scale	Standard Deviation 1.93
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: Patient's Assessment of Pain	3.67 units on a scale	Standard Deviation 2.312
Guselkumab 100 mg q8w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: PtGA of Disease Activity	4.01 units on a scale	Standard Deviation 2.516
Guselkumab 100 mg q8w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: HAQ-DI score	0.8766 units on a scale	Standard Deviation 0.59893
Guselkumab 100 mg q8w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: HAQ-DI score	0.8497 units on a scale	Standard Deviation 0.61863
Guselkumab 100 mg q8w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: HAQ-DI score	0.8091 units on a scale	Standard Deviation 0.61588
Guselkumab 100 mg q8w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: HAQ-DI score	0.7927 units on a scale	Standard Deviation 0.59979
Guselkumab 100 mg q8w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: HAQ-DI score	0.7917 units on a scale	Standard Deviation 0.59527
Guselkumab 100 mg q8w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: CRP	0.961 units on a scale	Standard Deviation 1.2868
Guselkumab 100 mg q8w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: CRP	0.956 units on a scale	Standard Deviation 1.3749
Guselkumab 100 mg q8w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: CRP	0.892 units on a scale	Standard Deviation 1.3109
Guselkumab 100 mg q8w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: CRP	0.812 units on a scale	Standard Deviation 1.0139
Guselkumab 100 mg q8w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: CRP	0.937 units on a scale	Standard Deviation 1.2422
Guselkumab 100 mg q8w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: Swollen Joint Count	3.4 units on a scale	Standard Deviation 5.19
Guselkumab 100 mg q8w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: Swollen Joint Count	2.9 units on a scale	Standard Deviation 4.95
Guselkumab 100 mg q8w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: Swollen Joint Count	2.4 units on a scale	Standard Deviation 4.58
Guselkumab 100 mg q8w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: Swollen Joint Count	2.3 units on a scale	Standard Deviation 4.42
Guselkumab 100 mg q8w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: Swollen Joint Count	2.1 units on a scale	Standard Deviation 4.16
Guselkumab 100 mg q8w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: Tender Joint Count	9.1 units on a scale	Standard Deviation 9.94
Guselkumab 100 mg q8w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: Tender Joint Count	7.9 units on a scale	Standard Deviation 9.02
Guselkumab 100 mg q8w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: Tender Joint Count	7.0 units on a scale	Standard Deviation 8.72
Guselkumab 100 mg q8w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: Tender Joint Count	6.3 units on a scale	Standard Deviation 8.45
Guselkumab 100 mg q8w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: Tender Joint Count	6.2 units on a scale	Standard Deviation 8.18
Guselkumab 100 mg q8w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: Patient's Assessment of Pain	3.77 units on a scale	Standard Deviation 2.457
Guselkumab 100 mg q8w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: Patient's Assessment of Pain	3.50 units on a scale	Standard Deviation 2.311
Guselkumab 100 mg q8w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: Patient's Assessment of Pain	3.28 units on a scale	Standard Deviation 2.336
Guselkumab 100 mg q8w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: Patient's Assessment of Pain	3.22 units on a scale	Standard Deviation 2.37
Guselkumab 100 mg q8w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: Patient's Assessment of Pain	3.10 units on a scale	Standard Deviation 2.333
Guselkumab 100 mg q8w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: PGA of Disease Activity	1.77 units on a scale	Standard Deviation 1.645
Guselkumab 100 mg q8w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: PtGA of Disease Activity	3.76 units on a scale	Standard Deviation 2.348
Guselkumab 100 mg q8w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: PtGA of Disease Activity	3.52 units on a scale	Standard Deviation 2.39
Guselkumab 100 mg q8w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: PtGA of Disease Activity	3.36 units on a scale	Standard Deviation 2.447
Guselkumab 100 mg q8w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: PtGA of Disease Activity	3.23 units on a scale	Standard Deviation 2.383
Guselkumab 100 mg q8w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: PGA of Disease Activity	2.74 units on a scale	Standard Deviation 2.113
Guselkumab 100 mg q8w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: PGA of Disease Activity	2.44 units on a scale	Standard Deviation 1.941
Guselkumab 100 mg q8w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: PGA of Disease Activity	2.10 units on a scale	Standard Deviation 1.777
Guselkumab 100 mg q8w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: PGA of Disease Activity	1.97 units on a scale	Standard Deviation 1.842
Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: Patient's Assessment of Pain	3.20 units on a scale	Standard Deviation 2.242
Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: Swollen Joint Count	4.1 units on a scale	Standard Deviation 5.77
Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: PGA of Disease Activity	2.66 units on a scale	Standard Deviation 1.906
Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: Patient's Assessment of Pain	3.24 units on a scale	Standard Deviation 2.277
Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: CRP	0.910 units on a scale	Standard Deviation 1.2756
Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: HAQ-DI score	0.7376 units on a scale	Standard Deviation 0.56257
Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: Patient's Assessment of Pain	3.21 units on a scale	Standard Deviation 2.371
Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: CRP	0.992 units on a scale	Standard Deviation 1.9875
Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: PGA of Disease Activity	1.77 units on a scale	Standard Deviation 1.616
Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: PtGA of Disease Activity	3.93 units on a scale	Standard Deviation 2.276
Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: CRP	0.837 units on a scale	Standard Deviation 1.073
Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: PGA of Disease Activity	2.33 units on a scale	Standard Deviation 1.668
Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: PtGA of Disease Activity	3.62 units on a scale	Standard Deviation 2.275
Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: CRP	0.885 units on a scale	Standard Deviation 1.0299
Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: HAQ-DI score	0.7985 units on a scale	Standard Deviation 0.56677
Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: PtGA of Disease Activity	3.30 units on a scale	Standard Deviation 2.318
Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: CRP	0.790 units on a scale	Standard Deviation 0.839
Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: PGA of Disease Activity	1.93 units on a scale	Standard Deviation 1.631
Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: Tender Joint Count	8.6 units on a scale	Standard Deviation 10.03
Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: PtGA of Disease Activity	3.50 units on a scale	Standard Deviation 2.323
Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: Tender Joint Count	7.5 units on a scale	Standard Deviation 9.25
Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: Tender Joint Count	10.5 units on a scale	Standard Deviation 11.82
Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: HAQ-DI score	0.7364 units on a scale	Standard Deviation 0.58655
Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: Tender Joint Count	7.0 units on a scale	Standard Deviation 9.42
Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: Swollen Joint Count	2.5 units on a scale	Standard Deviation 4.83
Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: PGA of Disease Activity	2.06 units on a scale	Standard Deviation 1.716
Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: Tender Joint Count	7.3 units on a scale	Standard Deviation 9.46
Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: Swollen Joint Count	2.8 units on a scale	Standard Deviation 5.65
Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: PtGA of Disease Activity	3.28 units on a scale	Standard Deviation 2.354
Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: Patient's Assessment of Pain	3.70 units on a scale	Standard Deviation 2.193
Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: Swollen Joint Count	2.7 units on a scale	Standard Deviation 4.67
Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: HAQ-DI score	0.7804 units on a scale	Standard Deviation 0.57721
Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: Patient's Assessment of Pain	3.45 units on a scale	Standard Deviation 2.259
Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: Swollen Joint Count	3.2 units on a scale	Standard Deviation 5.53
Guselkumab 100 mg q4w	ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: HAQ-DI score	0.8194 units on a scale	Standard Deviation 0.57287

Secondary

ACR Components at Weeks 52, 68, 76, 84 and 100

Time frame: Weeks 52, 68, 76, 84 and 100

Population: Analysis population is FAS3 which included all participants still on treatment at Week 52. Here, n (number analyzed) signifies the number of participants analyzed for specified categories at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: Patient's Assessment of Pain	3.26 units on a scale	Standard Deviation 2.313
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: CRP	0.880 units on a scale	Standard Deviation 1.3415
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: PGA of Disease Activity	1.45 units on a scale	Standard Deviation 1.469
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: Patient's Assessment of Pain	3.17 units on a scale	Standard Deviation 2.271
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: CRP	0.861 units on a scale	Standard Deviation 1.1586
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: Patient's Assessment of Pain	2.97 units on a scale	Standard Deviation 2.15
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: Swollen Joint Count	1.8 units on a scale	Standard Deviation 3.75
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: PGA of Disease Activity	1.63 units on a scale	Standard Deviation 1.514
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: Patient's Assessment of Pain	2.90 units on a scale	Standard Deviation 2.221
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: Swollen Joint Count	1.6 units on a scale	Standard Deviation 3.1
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: PGA of Disease Activity	1.89 units on a scale	Standard Deviation 1.654
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: PtGA of Disease Activity	3.68 units on a scale	Standard Deviation 2.331
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: CRP	0.904 units on a scale	Standard Deviation 1.6039
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: PtGA of Disease Activity	3.15 units on a scale	Standard Deviation 2.395
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: PtGA of Disease Activity	3.50 units on a scale	Standard Deviation 2.355
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: Tender Joint Count	7.4 units on a scale	Standard Deviation 10.3
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: PtGA of Disease Activity	3.09 units on a scale	Standard Deviation 2.273
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: PtGA of Disease Activity	3.25 units on a scale	Standard Deviation 2.356
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: Swollen Joint Count	2.1 units on a scale	Standard Deviation 3.58
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: HAQ-DI score	0.7692 units on a scale	Standard Deviation 0.5996
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: Tender Joint Count	6.0 units on a scale	Standard Deviation 8.83
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: CRP	0.898 units on a scale	Standard Deviation 1.3229
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: HAQ-DI score	0.8311 units on a scale	Standard Deviation 0.62101
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: Tender Joint Count	5.7 units on a scale	Standard Deviation 8.31
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: Swollen Joint Count	1.6 units on a scale	Standard Deviation 3.17
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: HAQ-DI score	0.8425 units on a scale	Standard Deviation 0.61757
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: Tender Joint Count	5.1 units on a scale	Standard Deviation 7.32
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: HAQ-DI score	0.8076 units on a scale	Standard Deviation 0.62465
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: HAQ-DI score	0.9073 units on a scale	Standard Deviation 0.63812
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: Tender Joint Count	5.5 units on a scale	Standard Deviation 8.44
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: CRP	0.903 units on a scale	Standard Deviation 1.4624
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: PGA of Disease Activity	1.39 units on a scale	Standard Deviation 1.51
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: Patient's Assessment of Pain	3.53 units on a scale	Standard Deviation 2.267
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: Swollen Joint Count	1.6 units on a scale	Standard Deviation 3.02
Placebo to Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: PGA of Disease Activity	1.55 units on a scale	Standard Deviation 1.492
Guselkumab 100 mg q8w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: PGA of Disease Activity	1.56 units on a scale	Standard Deviation 1.538
Guselkumab 100 mg q8w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: Swollen Joint Count	2.1 units on a scale	Standard Deviation 4.18
Guselkumab 100 mg q8w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: Swollen Joint Count	1.7 units on a scale	Standard Deviation 3.87
Guselkumab 100 mg q8w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: Swollen Joint Count	1.8 units on a scale	Standard Deviation 3.72
Guselkumab 100 mg q8w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: Swollen Joint Count	1.6 units on a scale	Standard Deviation 3.82
Guselkumab 100 mg q8w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: Swollen Joint Count	1.6 units on a scale	Standard Deviation 3.99
Guselkumab 100 mg q8w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: Tender Joint Count	6.3 units on a scale	Standard Deviation 8.2
Guselkumab 100 mg q8w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: Tender Joint Count	5.0 units on a scale	Standard Deviation 6.83
Guselkumab 100 mg q8w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: Tender Joint Count	5.2 units on a scale	Standard Deviation 7.18
Guselkumab 100 mg q8w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: Tender Joint Count	4.7 units on a scale	Standard Deviation 7.2
Guselkumab 100 mg q8w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: Tender Joint Count	4.7 units on a scale	Standard Deviation 6.8
Guselkumab 100 mg q8w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: Patient's Assessment of Pain	3.12 units on a scale	Standard Deviation 2.335
Guselkumab 100 mg q8w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: Patient's Assessment of Pain	2.68 units on a scale	Standard Deviation 2.24
Guselkumab 100 mg q8w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: Patient's Assessment of Pain	2.73 units on a scale	Standard Deviation 2.217
Guselkumab 100 mg q8w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: Patient's Assessment of Pain	2.67 units on a scale	Standard Deviation 2.181
Guselkumab 100 mg q8w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: Patient's Assessment of Pain	2.59 units on a scale	Standard Deviation 2.29
Guselkumab 100 mg q8w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: PtGA of Disease Activity	3.25 units on a scale	Standard Deviation 2.38
Guselkumab 100 mg q8w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: PtGA of Disease Activity	2.95 units on a scale	Standard Deviation 2.282
Guselkumab 100 mg q8w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: PtGA of Disease Activity	2.90 units on a scale	Standard Deviation 2.273
Guselkumab 100 mg q8w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: PtGA of Disease Activity	2.88 units on a scale	Standard Deviation 2.252
Guselkumab 100 mg q8w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: PtGA of Disease Activity	2.85 units on a scale	Standard Deviation 2.378
Guselkumab 100 mg q8w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: PGA of Disease Activity	1.78 units on a scale	Standard Deviation 1.647
Guselkumab 100 mg q8w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: PGA of Disease Activity	1.67 units on a scale	Standard Deviation 1.66
Guselkumab 100 mg q8w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: PGA of Disease Activity	1.51 units on a scale	Standard Deviation 1.619
Guselkumab 100 mg q8w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: PGA of Disease Activity	1.49 units on a scale	Standard Deviation 1.581
Guselkumab 100 mg q8w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: HAQ-DI score	0.7942 units on a scale	Standard Deviation 0.59711
Guselkumab 100 mg q8w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: HAQ-DI score	0.7625 units on a scale	Standard Deviation 0.59524
Guselkumab 100 mg q8w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: HAQ-DI score	0.6978 units on a scale	Standard Deviation 0.56588
Guselkumab 100 mg q8w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: HAQ-DI score	0.7134 units on a scale	Standard Deviation 0.59528
Guselkumab 100 mg q8w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: HAQ-DI score	0.6747 units on a scale	Standard Deviation 0.57213
Guselkumab 100 mg q8w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: CRP	0.930 units on a scale	Standard Deviation 1.2443
Guselkumab 100 mg q8w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: CRP	0.884 units on a scale	Standard Deviation 1.352
Guselkumab 100 mg q8w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: CRP	0.882 units on a scale	Standard Deviation 1.2504
Guselkumab 100 mg q8w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: CRP	0.856 units on a scale	Standard Deviation 1.1926
Guselkumab 100 mg q8w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: CRP	0.826 units on a scale	Standard Deviation 1.2277
Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: Patient's Assessment of Pain	3.17 units on a scale	Standard Deviation 2.343
Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: Swollen Joint Count	2.0 units on a scale	Standard Deviation 5.01
Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: PGA of Disease Activity	1.50 units on a scale	Standard Deviation 1.558
Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: Tender Joint Count	6.0 units on a scale	Standard Deviation 8.9
Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: CRP	0.872 units on a scale	Standard Deviation 1.3239
Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: PGA of Disease Activity	1.41 units on a scale	Standard Deviation 1.405
Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: Tender Joint Count	5.9 units on a scale	Standard Deviation 9.22
Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: CRP	0.796 units on a scale	Standard Deviation 1.1109
Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: HAQ-DI score	0.7317 units on a scale	Standard Deviation 0.5843
Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: Tender Joint Count	6.2 units on a scale	Standard Deviation 8.9
Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: Swollen Joint Count	2.3 units on a scale	Standard Deviation 4.59
Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: HAQ-DI score	0.6836 units on a scale	Standard Deviation 0.56049
Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: Tender Joint Count	6.3 units on a scale	Standard Deviation 9.27
Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: Swollen Joint Count	2.5 units on a scale	Standard Deviation 4.83
Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: HAQ-DI score	0.6996 units on a scale	Standard Deviation 0.55988
Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: CRP	0.839 units on a scale	Standard Deviation 1.1693
Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: HAQ-DI score	0.6775 units on a scale	Standard Deviation 0.5887
Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: Tender Joint Count	7.2 units on a scale	Standard Deviation 9.49
Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: Swollen Joint Count	2.0 units on a scale	Standard Deviation 3.79
Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: PtGA of Disease Activity	2.95 units on a scale	Standard Deviation 2.222
Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: PtGA of Disease Activity	2.85 units on a scale	Standard Deviation 2.213
Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: HAQ-DI score	0.6420 units on a scale	Standard Deviation 0.56838
Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: PtGA of Disease Activity	2.83 units on a scale	Standard Deviation 2.222
Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: PtGA of Disease Activity	3.24 units on a scale	Standard Deviation 2.322
Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: Swollen Joint Count	2.0 units on a scale	Standard Deviation 4.11
Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: PtGA of Disease Activity	2.60 units on a scale	Standard Deviation 2.165
Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: Patient's Assessment of Pain	2.57 units on a scale	Standard Deviation 2.138
Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: CRP	0.820 units on a scale	Standard Deviation 1.1227
Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: PGA of Disease Activity	1.77 units on a scale	Standard Deviation 1.617
Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: Patient's Assessment of Pain	2.65 units on a scale	Standard Deviation 2.217
Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: Patient's Assessment of Pain	2.70 units on a scale	Standard Deviation 2.115
Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: PGA of Disease Activity	1.61 units on a scale	Standard Deviation 1.466
Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: Patient's Assessment of Pain	2.64 units on a scale	Standard Deviation 2.105
Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: CRP	0.886 units on a scale	Standard Deviation 1.2366
Guselkumab 100 mg q4w	ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: PGA of Disease Activity	1.57 units on a scale	Standard Deviation 1.524

Secondary

Change From Baseline in 36-Item Short Form Health Survey (SF-36) Mental Component Summary (MCS) at Week 24

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

Time frame: Baseline and Week 24

Population: Analysis population is FAS1. Data after meeting one or more TF criteria were imputed as no change from baseline. Missing data were assumed to be missing at random (MAR) and imputed using multiple imputation (MI).

Arm	Measure	Value (LEAST_SQUARES_MEAN)
Placebo to Guselkumab 100 mg q4w	Change From Baseline in 36-Item Short Form Health Survey (SF-36) Mental Component Summary (MCS) at Week 24	2.14 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in 36-Item Short Form Health Survey (SF-36) Mental Component Summary (MCS) at Week 24	4.17 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in 36-Item Short Form Health Survey (SF-36) Mental Component Summary (MCS) at Week 24	4.22 units on a scale

p-value: 0.07295% CI: [0.56, 3.49]ANCOVA

p-value: 0.07295% CI: [0.6, 3.54]ANCOVA

Secondary

Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

Time frame: Baseline and Week 24

Arm	Measure	Value (LEAST_SQUARES_MEAN)
Placebo to Guselkumab 100 mg q4w	Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24	3.42 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24	7.39 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24	7.04 units on a scale

p-value: 0.01195% CI: [2.75, 5.2]ANCOVA

p-value: 0.01195% CI: [2.39, 4.85]ANCOVA

Secondary

Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52

Time frame: Baseline, Weeks 24, 28, 36, 44 and 52

Population: Analysis population is FAS2. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: Patient's Assessment of Pain	-2.75 units on a scale	Standard Deviation 2.659
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: Tender Joint Count	-9.7 units on a scale	Standard Deviation 10.78
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: CRP	-0.547 units on a scale	Standard Deviation 2.5657
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: PGA of Disease Activity	-4.39 units on a scale	Standard Deviation 2.052
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: Tender Joint Count	-7.0 units on a scale	Standard Deviation 10.91
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: CRP	-0.993 units on a scale	Standard Deviation 2.3669
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: PtGA of Disease Activity	-2.76 units on a scale	Standard Deviation 2.741
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: Swollen Joint Count	-10.2 units on a scale	Standard Deviation 6.79
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: CRP	-1.202 units on a scale	Standard Deviation 2.3234
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: Patient's Assessment of Pain	-2.62 units on a scale	Standard Deviation 2.64
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: Swollen Joint Count	-10.1 units on a scale	Standard Deviation 6.77
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: CRP	-1.262 units on a scale	Standard Deviation 2.5377
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: PGA of Disease Activity	-4.61 units on a scale	Standard Deviation 2.043
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: Swollen Joint Count	-9.9 units on a scale	Standard Deviation 6.47
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: CRP	-1.237 units on a scale	Standard Deviation 2.8242
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: PtGA of Disease Activity	-1.79 units on a scale	Standard Deviation 2.543
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: Swollen Joint Count	-8.1 units on a scale	Standard Deviation 6.99
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: Swollen Joint Count	-6.4 units on a scale	Standard Deviation 7.25
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: Patient's Assessment of Pain	-2.51 units on a scale	Standard Deviation 2.588
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: PGA of Disease Activity	-4.77 units on a scale	Standard Deviation 2.007
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: PGA of Disease Activity	-2.45 units on a scale	Standard Deviation 2.248
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: Patient's Assessment of Pain	-1.63 units on a scale	Standard Deviation 2.42
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: HAQ-DI score	-0.1646 units on a scale	Standard Deviation 0.53253
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: PtGA of Disease Activity	-2.70 units on a scale	Standard Deviation 2.555
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: Patient's Assessment of Pain	-1.08 units on a scale	Standard Deviation 2.441
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: HAQ-DI score	-0.2547 units on a scale	Standard Deviation 0.50426
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: PtGA of Disease Activity	-1.25 units on a scale	Standard Deviation 2.601
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: Tender Joint Count	-14.1 units on a scale	Standard Deviation 11.39
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: HAQ-DI score	-0.3423 units on a scale	Standard Deviation 0.52951
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: PGA of Disease Activity	-3.42 units on a scale	Standard Deviation 2.189
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: Tender Joint Count	-14.0 units on a scale	Standard Deviation 11.02
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: HAQ-DI score	-0.3868 units on a scale	Standard Deviation 0.57065
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: PtGA of Disease Activity	-2.85 units on a scale	Standard Deviation 2.757
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: Tender Joint Count	-13.2 units on a scale	Standard Deviation 10.78
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: HAQ-DI score	-0.3848 units on a scale	Standard Deviation 0.58049
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: PtGA of Disease Activity	-2.99 units on a scale	Standard Deviation 2.569
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: PtGA of Disease Activity	-3.15 units on a scale	Standard Deviation 2.65
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: PtGA of Disease Activity	-3.29 units on a scale	Standard Deviation 2.558
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: PGA of Disease Activity	-3.84 units on a scale	Standard Deviation 2.316
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: PGA of Disease Activity	-4.16 units on a scale	Standard Deviation 2.175
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: PGA of Disease Activity	-4.49 units on a scale	Standard Deviation 2.116
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: PGA of Disease Activity	-4.55 units on a scale	Standard Deviation 2.139
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: PGA of Disease Activity	-4.78 units on a scale	Standard Deviation 1.996
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: HAQ-DI score	-0.4044 units on a scale	Standard Deviation 0.54194
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: HAQ-DI score	-0.4383 units on a scale	Standard Deviation 0.55648
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: HAQ-DI score	-0.4702 units on a scale	Standard Deviation 0.55698
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: HAQ-DI score	-0.4824 units on a scale	Standard Deviation 0.57091
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: HAQ-DI score	-0.4824 units on a scale	Standard Deviation 0.56167
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: CRP	-1.038 units on a scale	Standard Deviation 2.0932
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: CRP	-1.028 units on a scale	Standard Deviation 2.0476
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: CRP	-1.098 units on a scale	Standard Deviation 2.1102
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: CRP	-1.145 units on a scale	Standard Deviation 2.1378
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: CRP	-1.021 units on a scale	Standard Deviation 2.2289
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: Swollen Joint Count	-8.2 units on a scale	Standard Deviation 6.09
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: Swollen Joint Count	-8.8 units on a scale	Standard Deviation 5.98
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: Swollen Joint Count	-9.2 units on a scale	Standard Deviation 5.81
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: Swollen Joint Count	-9.3 units on a scale	Standard Deviation 6.24
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: Swollen Joint Count	-9.6 units on a scale	Standard Deviation 6.28
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: Tender Joint Count	-10.4 units on a scale	Standard Deviation 9.51
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: Tender Joint Count	-11.7 units on a scale	Standard Deviation 9.24
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: Tender Joint Count	-12.5 units on a scale	Standard Deviation 9.68
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: Tender Joint Count	-13.3 units on a scale	Standard Deviation 9.56
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: Tender Joint Count	-13.4 units on a scale	Standard Deviation 10.03
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: Patient's Assessment of Pain	-2.55 units on a scale	Standard Deviation 2.477
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: Patient's Assessment of Pain	-2.83 units on a scale	Standard Deviation 2.519
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: Patient's Assessment of Pain	-3.02 units on a scale	Standard Deviation 2.534
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: Patient's Assessment of Pain	-3.07 units on a scale	Standard Deviation 2.644
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: Patient's Assessment of Pain	-3.20 units on a scale	Standard Deviation 2.555
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: PtGA of Disease Activity	-2.52 units on a scale	Standard Deviation 2.49
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: PtGA of Disease Activity	-2.79 units on a scale	Standard Deviation 2.56
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: HAQ-DI score	-0.5082 units on a scale	Standard Deviation 0.58255
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: PGA of Disease Activity	-4.28 units on a scale	Standard Deviation 2.054
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: Tender Joint Count	-13.7 units on a scale	Standard Deviation 10.53
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: HAQ-DI score	-0.4652 units on a scale	Standard Deviation 0.56121
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: PtGA of Disease Activity	-2.70 units on a scale	Standard Deviation 2.382
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: Tender Joint Count	-14.6 units on a scale	Standard Deviation 10.31
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: HAQ-DI score	-0.5000 units on a scale	Standard Deviation 0.55438
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: Patient's Assessment of Pain	-2.89 units on a scale	Standard Deviation 2.681
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: Tender Joint Count	-15.2 units on a scale	Standard Deviation 10.25
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: HAQ-DI score	-0.4429 units on a scale	Standard Deviation 0.51556
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: PGA of Disease Activity	-3.93 units on a scale	Standard Deviation 2.227
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: Tender Joint Count	-15.0 units on a scale	Standard Deviation 10.51
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: HAQ-DI score	-0.4257 units on a scale	Standard Deviation 0.50337
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: PtGA of Disease Activity	-2.86 units on a scale	Standard Deviation 2.559
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: Patient's Assessment of Pain	-2.41 units on a scale	Standard Deviation 2.335
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: PGA of Disease Activity	-4.81 units on a scale	Standard Deviation 2.12
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: PtGA of Disease Activity	-2.40 units on a scale	Standard Deviation 2.383
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: Patient's Assessment of Pain	-2.66 units on a scale	Standard Deviation 2.416
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: PGA of Disease Activity	-4.70 units on a scale	Standard Deviation 2.084
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: Swollen Joint Count	-8.8 units on a scale	Standard Deviation 5.5
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: CRP	-0.937 units on a scale	Standard Deviation 2.4116
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: PtGA of Disease Activity	-3.06 units on a scale	Standard Deviation 2.527
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: Swollen Joint Count	-9.6 units on a scale	Standard Deviation 6.65
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: CRP	-0.861 units on a scale	Standard Deviation 2.8133
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: Patient's Assessment of Pain	-2.89 units on a scale	Standard Deviation 2.54
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: Swollen Joint Count	-10.2 units on a scale	Standard Deviation 6.76
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: CRP	-1.020 units on a scale	Standard Deviation 2.1985
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: PGA of Disease Activity	-4.53 units on a scale	Standard Deviation 2.173
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: Swollen Joint Count	-10.2 units on a scale	Standard Deviation 6.28
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: CRP	-0.976 units on a scale	Standard Deviation 2.1663
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: PtGA of Disease Activity	-3.01 units on a scale	Standard Deviation 2.445
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: Swollen Joint Count	-10.4 units on a scale	Standard Deviation 6.17
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: CRP	-1.052 units on a scale	Standard Deviation 2.1295
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: Patient's Assessment of Pain	-2.87 units on a scale	Standard Deviation 2.601
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: Tender Joint Count	-11.9 units on a scale	Standard Deviation 9.98

Secondary

Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100

Time frame: Baseline, Weeks 52, 68, 76, 84 and 100

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: CRP	-1.283 units on a scale	Standard Deviation 2.8163
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: PGA of Disease Activity	-5.13 units on a scale	Standard Deviation 2.04
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: Swollen Joint Count	-10.6 units on a scale	Standard Deviation 6.06
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: PGA of Disease Activity	-5.23 units on a scale	Standard Deviation 1.995
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: Patient's Assessment of Pain	-3.35 units on a scale	Standard Deviation 2.595
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: Tender Joint Count	-16.1 units on a scale	Standard Deviation 10.97
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: PGA of Disease Activity	-5.06 units on a scale	Standard Deviation 2.037
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: Patient's Assessment of Pain	-3.41 units on a scale	Standard Deviation 2.578
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: CRP	-1.212 units on a scale	Standard Deviation 2.3061
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: PGA of Disease Activity	-4.79 units on a scale	Standard Deviation 1.992
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: PtGA of Disease Activity	-2.87 units on a scale	Standard Deviation 2.761
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: Swollen Joint Count	-10.6 units on a scale	Standard Deviation 6.15
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: PtGA of Disease Activity	-3.40 units on a scale	Standard Deviation 2.846
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: PtGA of Disease Activity	-3.08 units on a scale	Standard Deviation 2.786
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: CRP	-1.244 units on a scale	Standard Deviation 2.5828
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: PtGA of Disease Activity	-3.46 units on a scale	Standard Deviation 2.752
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: PtGA of Disease Activity	-3.32 units on a scale	Standard Deviation 2.86
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: CRP	-1.262 units on a scale	Standard Deviation 2.8315
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: Tender Joint Count	-14.1 units on a scale	Standard Deviation 11.38
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: Swollen Joint Count	-10.7 units on a scale	Standard Deviation 6.76
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: HAQ-DI score	-0.5356 units on a scale	Standard Deviation 0.56707
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: Tender Joint Count	-15.7 units on a scale	Standard Deviation 10.94
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: HAQ-DI score	-0.5041 units on a scale	Standard Deviation 0.59716
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: Patient's Assessment of Pain	-3.18 units on a scale	Standard Deviation 2.724
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: HAQ-DI score	-0.4740 units on a scale	Standard Deviation 0.57852
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: Tender Joint Count	-16.6 units on a scale	Standard Deviation 11.33
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: CRP	-1.230 units on a scale	Standard Deviation 2.4262
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: HAQ-DI score	-0.4668 units on a scale	Standard Deviation 0.59226
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: Tender Joint Count	-16.3 units on a scale	Standard Deviation 11.27
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: Swollen Joint Count	-10.7 units on a scale	Standard Deviation 5.98
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: HAQ-DI score	-0.3899 units on a scale	Standard Deviation 0.5825
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: Patient's Assessment of Pain	-2.78 units on a scale	Standard Deviation 2.645
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: Swollen Joint Count	-10.2 units on a scale	Standard Deviation 6.72
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: PGA of Disease Activity	-5.26 units on a scale	Standard Deviation 2.098
Placebo to Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: Patient's Assessment of Pain	-3.10 units on a scale	Standard Deviation 2.707
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: CRP	-1.021 units on a scale	Standard Deviation 2.2301
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: Swollen Joint Count	-9.6 units on a scale	Standard Deviation 6.3
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: Swollen Joint Count	-10.0 units on a scale	Standard Deviation 6.5
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: Swollen Joint Count	-10.0 units on a scale	Standard Deviation 6.33
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: Swollen Joint Count	-10.1 units on a scale	Standard Deviation 6.34
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: Swollen Joint Count	-10.2 units on a scale	Standard Deviation 6.88
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: Tender Joint Count	-13.5 units on a scale	Standard Deviation 10.04
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: Tender Joint Count	-14.7 units on a scale	Standard Deviation 10.22
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: Tender Joint Count	-15.3 units on a scale	Standard Deviation 10.5
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: Tender Joint Count	-15.3 units on a scale	Standard Deviation 11.1
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: Patient's Assessment of Pain	-3.20 units on a scale	Standard Deviation 2.557
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: Patient's Assessment of Pain	-3.62 units on a scale	Standard Deviation 2.53
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: Patient's Assessment of Pain	-3.57 units on a scale	Standard Deviation 2.566
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: Patient's Assessment of Pain	-3.64 units on a scale	Standard Deviation 2.568
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: Patient's Assessment of Pain	-3.69 units on a scale	Standard Deviation 2.625
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: PtGA of Disease Activity	-3.29 units on a scale	Standard Deviation 2.553
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: PtGA of Disease Activity	-3.58 units on a scale	Standard Deviation 2.446
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: PtGA of Disease Activity	-3.63 units on a scale	Standard Deviation 2.512
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: PtGA of Disease Activity	-3.67 units on a scale	Standard Deviation 2.572
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: PtGA of Disease Activity	-3.67 units on a scale	Standard Deviation 2.612
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: PGA of Disease Activity	-4.77 units on a scale	Standard Deviation 2.001
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: PGA of Disease Activity	-4.98 units on a scale	Standard Deviation 1.992
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: PGA of Disease Activity	-4.86 units on a scale	Standard Deviation 2.044
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: PGA of Disease Activity	-5.06 units on a scale	Standard Deviation 2.074
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: PGA of Disease Activity	-5.05 units on a scale	Standard Deviation 2.011
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: HAQ-DI score	-0.4801 units on a scale	Standard Deviation 0.56246
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: HAQ-DI score	-0.5120 units on a scale	Standard Deviation 0.54928
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: HAQ-DI score	-0.5694 units on a scale	Standard Deviation 0.56421
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: HAQ-DI score	-0.5653 units on a scale	Standard Deviation 0.59488
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: HAQ-DI score	-0.5859 units on a scale	Standard Deviation 0.58199
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: Tender Joint Count	-14.8 units on a scale	Standard Deviation 10.15
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: CRP	-1.081 units on a scale	Standard Deviation 2.1585
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: CRP	-1.098 units on a scale	Standard Deviation 2.3654
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: CRP	-1.101 units on a scale	Standard Deviation 2.1216
Guselkumab 100 mg q8w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: CRP	-1.129 units on a scale	Standard Deviation 2.2261
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: Swollen Joint Count	-10.7 units on a scale	Standard Deviation 7.08
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: PGA of Disease Activity	-5.09 units on a scale	Standard Deviation 2.142
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: Patient's Assessment of Pain	-2.92 units on a scale	Standard Deviation 2.686
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: CRP	-0.940 units on a scale	Standard Deviation 2.3781
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: PGA of Disease Activity	-5.18 units on a scale	Standard Deviation 2.044
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: Tender Joint Count	-16.4 units on a scale	Standard Deviation 10.7
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: CRP	-1.060 units on a scale	Standard Deviation 2.3334
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: HAQ-DI score	-0.5111 units on a scale	Standard Deviation 0.58347
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: Tender Joint Count	-16.0 units on a scale	Standard Deviation 11.22
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: Swollen Joint Count	-10.7 units on a scale	Standard Deviation 6.18
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: HAQ-DI score	-0.5631 units on a scale	Standard Deviation 0.54528
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: Tender Joint Count	-16.1 units on a scale	Standard Deviation 10.91
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: Swollen Joint Count	-10.4 units on a scale	Standard Deviation 6.16
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: HAQ-DI score	-0.5448 units on a scale	Standard Deviation 0.54739
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: Tender Joint Count	-16.0 units on a scale	Standard Deviation 11.02
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: CRP	-1.017 units on a scale	Standard Deviation 2.2801
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: HAQ-DI score	-0.5656 units on a scale	Standard Deviation 0.57921
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: Tender Joint Count	-15.2 units on a scale	Standard Deviation 10.45
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: PtGA of Disease Activity	-3.38 units on a scale	Standard Deviation 2.501
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: PtGA of Disease Activity	-3.49 units on a scale	Standard Deviation 2.5
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: Swollen Joint Count	-10.9 units on a scale	Standard Deviation 7.22
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: PtGA of Disease Activity	-3.50 units on a scale	Standard Deviation 2.579
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: PtGA of Disease Activity	-3.09 units on a scale	Standard Deviation 2.523
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: HAQ-DI score	-0.6000 units on a scale	Standard Deviation 0.56858
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: PtGA of Disease Activity	-3.73 units on a scale	Standard Deviation 2.493
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: Patient's Assessment of Pain	-3.52 units on a scale	Standard Deviation 2.615
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: Swollen Joint Count	-10.8 units on a scale	Standard Deviation 6.66
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: PGA of Disease Activity	-4.82 units on a scale	Standard Deviation 2.117
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: Patient's Assessment of Pain	-3.42 units on a scale	Standard Deviation 2.669
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: CRP	-1.042 units on a scale	Standard Deviation 2.06
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: PGA of Disease Activity	-5.01 units on a scale	Standard Deviation 2.105
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: Patient's Assessment of Pain	-3.38 units on a scale	Standard Deviation 2.62
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: CRP	-0.959 units on a scale	Standard Deviation 2.4188
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: PGA of Disease Activity	-5.03 units on a scale	Standard Deviation 2.078
Guselkumab 100 mg q4w	Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: Patient's Assessment of Pain	-3.46 units on a scale	Standard Deviation 2.574

Secondary

Change From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among Participants With Spondylitis and Peripheral Arthritis and BASDAI Score>0 at Baseline

Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis and peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.

Time frame: Baseline, Weeks 52, 76 and 100

Population: Analysis population is FAS3 among participants with spondylitis and peripheral arthritis and BASDAI Score\>0 at baseline. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among Participants With Spondylitis and Peripheral Arthritis and BASDAI Score>0 at Baseline	Week 76	-3.311 units on a scale	Standard Deviation 2.6106
Placebo to Guselkumab 100 mg q4w	Change From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among Participants With Spondylitis and Peripheral Arthritis and BASDAI Score>0 at Baseline	Week 52	-2.986 units on a scale	Standard Deviation 2.4945
Placebo to Guselkumab 100 mg q4w	Change From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among Participants With Spondylitis and Peripheral Arthritis and BASDAI Score>0 at Baseline	Week 100	-3.718 units on a scale	Standard Deviation 2.396
Guselkumab 100 mg q8w	Change From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among Participants With Spondylitis and Peripheral Arthritis and BASDAI Score>0 at Baseline	Week 76	-3.377 units on a scale	Standard Deviation 2.5969
Guselkumab 100 mg q8w	Change From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among Participants With Spondylitis and Peripheral Arthritis and BASDAI Score>0 at Baseline	Week 52	-2.923 units on a scale	Standard Deviation 2.5194
Guselkumab 100 mg q8w	Change From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among Participants With Spondylitis and Peripheral Arthritis and BASDAI Score>0 at Baseline	Week 100	-3.472 units on a scale	Standard Deviation 2.5233
Guselkumab 100 mg q4w	Change From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among Participants With Spondylitis and Peripheral Arthritis and BASDAI Score>0 at Baseline	Week 52	-3.084 units on a scale	Standard Deviation 2.1843
Guselkumab 100 mg q4w	Change From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among Participants With Spondylitis and Peripheral Arthritis and BASDAI Score>0 at Baseline	Week 100	-3.330 units on a scale	Standard Deviation 2.1598
Guselkumab 100 mg q4w	Change From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among Participants With Spondylitis and Peripheral Arthritis and BASDAI Score>0 at Baseline	Week 76	-3.129 units on a scale	Standard Deviation 2.1122

Secondary

Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score at Weeks 24 and 52 Among Participants With Spondylitis and Peripheral Arthritis at Baseline

Time frame: Baseline, Weeks 24 and 52

Population: Analysis population is FAS2 among the participants with spondylitis and peripheral arthritis and BASDAI score \>0 at baseline. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score at Weeks 24 and 52 Among Participants With Spondylitis and Peripheral Arthritis at Baseline	Week 24	-1.374 units on a scale	Standard Deviation 2.4269
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score at Weeks 24 and 52 Among Participants With Spondylitis and Peripheral Arthritis at Baseline	Week 52	-2.986 units on a scale	Standard Deviation 2.4945
Guselkumab 100 mg q8w	Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score at Weeks 24 and 52 Among Participants With Spondylitis and Peripheral Arthritis at Baseline	Week 24	-2.652 units on a scale	Standard Deviation 2.3825
Guselkumab 100 mg q8w	Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score at Weeks 24 and 52 Among Participants With Spondylitis and Peripheral Arthritis at Baseline	Week 52	-2.883 units on a scale	Standard Deviation 2.5193
Guselkumab 100 mg q4w	Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score at Weeks 24 and 52 Among Participants With Spondylitis and Peripheral Arthritis at Baseline	Week 24	-2.674 units on a scale	Standard Deviation 1.9941
Guselkumab 100 mg q4w	Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score at Weeks 24 and 52 Among Participants With Spondylitis and Peripheral Arthritis at Baseline	Week 52	-3.084 units on a scale	Standard Deviation 2.1843

Secondary

Change From Baseline in Dactylitis Score at Weeks 24 and 52 Among the Participants With Dactylitis at Baseline

The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. A higher score indicates more severe dactylitis. Negative changes from baseline indicate improvement in dactylitis.

Time frame: Baseline, Weeks 24 and 52

Population: Analysis population is FAS2 among the participants with dactylitis at baseline. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Dactylitis Score at Weeks 24 and 52 Among the Participants With Dactylitis at Baseline	Week 24	-4.6 units on a scale	Standard Deviation 7.88
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Dactylitis Score at Weeks 24 and 52 Among the Participants With Dactylitis at Baseline	Week 52	-7.4 units on a scale	Standard Deviation 9.18
Guselkumab 100 mg q8w	Change From Baseline in Dactylitis Score at Weeks 24 and 52 Among the Participants With Dactylitis at Baseline	Week 24	-6.1 units on a scale	Standard Deviation 7.83
Guselkumab 100 mg q8w	Change From Baseline in Dactylitis Score at Weeks 24 and 52 Among the Participants With Dactylitis at Baseline	Week 52	-7.3 units on a scale	Standard Deviation 9.74
Guselkumab 100 mg q4w	Change From Baseline in Dactylitis Score at Weeks 24 and 52 Among the Participants With Dactylitis at Baseline	Week 24	-6.6 units on a scale	Standard Deviation 7.84
Guselkumab 100 mg q4w	Change From Baseline in Dactylitis Score at Weeks 24 and 52 Among the Participants With Dactylitis at Baseline	Week 52	-7.4 units on a scale	Standard Deviation 8.59

Secondary

Change From Baseline in Dactylitis Scores at Week 24 Among the Participants With Dactylitis at Baseline

The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Negative changes from baseline indicate improvement of dactylitis. The outcome measure was planned to be reported for pooled population from CNTO1959PSA3001 and CNTO1959PSA3002 studies.

Time frame: Baseline and Week 24

Population: Analysis population is FAS1 among participants with dactylitis at baseline pooled from both from CNTO1959PSA3001 (NCT03162796) and CNTO1959PSA3002 (NCT03158285) studies. Data after meeting 1 or more TF criteria were imputed as no change from baseline. Missing data were assumed missing at random and imputed using multiple imputation.

Arm	Measure	Value (LEAST_SQUARES_MEAN)
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Dactylitis Scores at Week 24 Among the Participants With Dactylitis at Baseline	-4.21 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Dactylitis Scores at Week 24 Among the Participants With Dactylitis at Baseline	-6.10 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Dactylitis Scores at Week 24 Among the Participants With Dactylitis at Baseline	-5.97 units on a scale

p-value: <0.00195% CI: [-2.99, -0.79]ANCOVA

p-value: 0.00295% CI: [-2.87, -0.66]ANCOVA

Secondary

Change From Baseline in Dactylitis Scores at Weeks 2, 4, 8, 16 and 24 Among the Participants With Dactylitis at Baseline

The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Negative changes from baseline indicate improvement of dactylitis.

Time frame: Baseline, Weeks 2, 4, 8, 16 and 24

Population: Analysis population is FAS1 among participants with dactylitis at baseline. Data after meeting 1 or more TF criteria were imputed as no change from baseline. Missing data were assumed missing at random and imputed using multiple imputation.

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Dactylitis Scores at Weeks 2, 4, 8, 16 and 24 Among the Participants With Dactylitis at Baseline	Week 16	-3.40 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Dactylitis Scores at Weeks 2, 4, 8, 16 and 24 Among the Participants With Dactylitis at Baseline	Week 8	-2.17 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Dactylitis Scores at Weeks 2, 4, 8, 16 and 24 Among the Participants With Dactylitis at Baseline	Week 2	-0.21 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Dactylitis Scores at Weeks 2, 4, 8, 16 and 24 Among the Participants With Dactylitis at Baseline	Week 4	-1.10 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Dactylitis Scores at Weeks 2, 4, 8, 16 and 24 Among the Participants With Dactylitis at Baseline	Week 24	-4.03 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Dactylitis Scores at Weeks 2, 4, 8, 16 and 24 Among the Participants With Dactylitis at Baseline	Week 8	-3.17 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Dactylitis Scores at Weeks 2, 4, 8, 16 and 24 Among the Participants With Dactylitis at Baseline	Week 2	-1.11 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Dactylitis Scores at Weeks 2, 4, 8, 16 and 24 Among the Participants With Dactylitis at Baseline	Week 4	-2.11 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Dactylitis Scores at Weeks 2, 4, 8, 16 and 24 Among the Participants With Dactylitis at Baseline	Week 16	-4.88 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Dactylitis Scores at Weeks 2, 4, 8, 16 and 24 Among the Participants With Dactylitis at Baseline	Week 24	-5.95 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Dactylitis Scores at Weeks 2, 4, 8, 16 and 24 Among the Participants With Dactylitis at Baseline	Week 24	-5.88 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Dactylitis Scores at Weeks 2, 4, 8, 16 and 24 Among the Participants With Dactylitis at Baseline	Week 16	-4.80 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Dactylitis Scores at Weeks 2, 4, 8, 16 and 24 Among the Participants With Dactylitis at Baseline	Week 2	-0.78 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Dactylitis Scores at Weeks 2, 4, 8, 16 and 24 Among the Participants With Dactylitis at Baseline	Week 8	-3.11 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Dactylitis Scores at Weeks 2, 4, 8, 16 and 24 Among the Participants With Dactylitis at Baseline	Week 4	-1.56 units on a scale

Secondary

Change From Baseline in Dactylitis Scores at Weeks 52, 76 and 100 Among the Participants With Dactylitis at Baseline

The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Negative changes from baseline indicate improvement of dactylitis.

Time frame: Baseline, Weeks 52, 76 and 100

Population: Analysis population is FAS3 among the participants with dactylitis at baseline. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Dactylitis Scores at Weeks 52, 76 and 100 Among the Participants With Dactylitis at Baseline	Week 76	-8.0 units on a scale	Standard Deviation 9.55
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Dactylitis Scores at Weeks 52, 76 and 100 Among the Participants With Dactylitis at Baseline	Week 100	-8.1 units on a scale	Standard Deviation 9.63
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Dactylitis Scores at Weeks 52, 76 and 100 Among the Participants With Dactylitis at Baseline	Week 52	-7.4 units on a scale	Standard Deviation 9.22
Guselkumab 100 mg q8w	Change From Baseline in Dactylitis Scores at Weeks 52, 76 and 100 Among the Participants With Dactylitis at Baseline	Week 52	-7.3 units on a scale	Standard Deviation 9.78
Guselkumab 100 mg q8w	Change From Baseline in Dactylitis Scores at Weeks 52, 76 and 100 Among the Participants With Dactylitis at Baseline	Week 76	-7.8 units on a scale	Standard Deviation 10.24
Guselkumab 100 mg q8w	Change From Baseline in Dactylitis Scores at Weeks 52, 76 and 100 Among the Participants With Dactylitis at Baseline	Week 100	-7.9 units on a scale	Standard Deviation 10.12
Guselkumab 100 mg q4w	Change From Baseline in Dactylitis Scores at Weeks 52, 76 and 100 Among the Participants With Dactylitis at Baseline	Week 100	-7.9 units on a scale	Standard Deviation 9.14
Guselkumab 100 mg q4w	Change From Baseline in Dactylitis Scores at Weeks 52, 76 and 100 Among the Participants With Dactylitis at Baseline	Week 76	-7.6 units on a scale	Standard Deviation 8.93
Guselkumab 100 mg q4w	Change From Baseline in Dactylitis Scores at Weeks 52, 76 and 100 Among the Participants With Dactylitis at Baseline	Week 52	-7.4 units on a scale	Standard Deviation 8.66

Secondary

Change From Baseline in DAPSA at Weeks 52, 68, 76, 84 and 100

DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL, value \<lower limit of quantification \[LLOQ\] is considered equal to half of the value of LLOQ for numerical calculations), patient assessment of pain (0-10cm VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. The assessment does not have a score range with an upper or lower bound.

Time frame: Baseline, Weeks 52, 68, 76, 84 and 100

Population: Analysis population is FAS3 which included all participants still on treatment at Week 52. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in DAPSA at Weeks 52, 68, 76, 84 and 100	Week 84	-35.240 units on a scale	Standard Deviation 17.7891
Placebo to Guselkumab 100 mg q4w	Change From Baseline in DAPSA at Weeks 52, 68, 76, 84 and 100	Week 76	-34.391 units on a scale	Standard Deviation 17.4074
Placebo to Guselkumab 100 mg q4w	Change From Baseline in DAPSA at Weeks 52, 68, 76, 84 and 100	Week 52	-31.274 units on a scale	Standard Deviation 18.89
Placebo to Guselkumab 100 mg q4w	Change From Baseline in DAPSA at Weeks 52, 68, 76, 84 and 100	Week 68	-33.918 units on a scale	Standard Deviation 18.0463
Placebo to Guselkumab 100 mg q4w	Change From Baseline in DAPSA at Weeks 52, 68, 76, 84 and 100	Week 100	-34.819 units on a scale	Standard Deviation 17.9807
Guselkumab 100 mg q8w	Change From Baseline in DAPSA at Weeks 52, 68, 76, 84 and 100	Week 76	-33.062 units on a scale	Standard Deviation 17.5186
Guselkumab 100 mg q8w	Change From Baseline in DAPSA at Weeks 52, 68, 76, 84 and 100	Week 52	-30.604 units on a scale	Standard Deviation 17.5366
Guselkumab 100 mg q8w	Change From Baseline in DAPSA at Weeks 52, 68, 76, 84 and 100	Week 68	-33.146 units on a scale	Standard Deviation 18.1727
Guselkumab 100 mg q8w	Change From Baseline in DAPSA at Weeks 52, 68, 76, 84 and 100	Week 84	-33.622 units on a scale	Standard Deviation 18.0612
Guselkumab 100 mg q8w	Change From Baseline in DAPSA at Weeks 52, 68, 76, 84 and 100	Week 100	-34.019 units on a scale	Standard Deviation 19.2678
Guselkumab 100 mg q4w	Change From Baseline in DAPSA at Weeks 52, 68, 76, 84 and 100	Week 100	-35.549 units on a scale	Standard Deviation 16.5533
Guselkumab 100 mg q4w	Change From Baseline in DAPSA at Weeks 52, 68, 76, 84 and 100	Week 84	-34.570 units on a scale	Standard Deviation 18.2685
Guselkumab 100 mg q4w	Change From Baseline in DAPSA at Weeks 52, 68, 76, 84 and 100	Week 52	-32.563 units on a scale	Standard Deviation 16.4765
Guselkumab 100 mg q4w	Change From Baseline in DAPSA at Weeks 52, 68, 76, 84 and 100	Week 76	-34.590 units on a scale	Standard Deviation 16.5401
Guselkumab 100 mg q4w	Change From Baseline in DAPSA at Weeks 52, 68, 76, 84 and 100	Week 68	-34.900 units on a scale	Standard Deviation 17.5749

Secondary

Change From Baseline in DAS28 (CRP) at Weeks 2, 4, 8, 12, 16, 20 and 24

Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20 and 24

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)
Placebo to Guselkumab 100 mg q4w	Change From Baseline in DAS28 (CRP) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 4	-0.44 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in DAS28 (CRP) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 16	-0.88 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in DAS28 (CRP) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 12	-0.85 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in DAS28 (CRP) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 2	-0.29 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in DAS28 (CRP) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 24	-0.97 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in DAS28 (CRP) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 20	-1.00 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in DAS28 (CRP) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 8	-0.59 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in DAS28 (CRP) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 12	-1.27 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in DAS28 (CRP) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 2	-0.42 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in DAS28 (CRP) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 4	-0.62 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in DAS28 (CRP) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 8	-0.99 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in DAS28 (CRP) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 16	-1.39 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in DAS28 (CRP) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 20	-1.52 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in DAS28 (CRP) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 24	-1.59 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in DAS28 (CRP) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 16	-1.37 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in DAS28 (CRP) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 4	-0.65 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in DAS28 (CRP) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 24	-1.62 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in DAS28 (CRP) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 20	-1.56 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in DAS28 (CRP) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 12	-1.22 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in DAS28 (CRP) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 8	-0.98 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in DAS28 (CRP) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 2	-0.43 units on a scale

Secondary

Change From Baseline in DAS28 (CRP) Score at Weeks 24, 28, 36, 44 and 52

Time frame: Baseline, Weeks 24, 28, 36, 44 and 52

Population: Analysis population is FAS2. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in DAS28 (CRP) Score at Weeks 24, 28, 36, 44 and 52	Week 44	-2.04 units on a scale	Standard Deviation 1.098
Placebo to Guselkumab 100 mg q4w	Change From Baseline in DAS28 (CRP) Score at Weeks 24, 28, 36, 44 and 52	Week 36	-1.92 units on a scale	Standard Deviation 1.086
Placebo to Guselkumab 100 mg q4w	Change From Baseline in DAS28 (CRP) Score at Weeks 24, 28, 36, 44 and 52	Week 24	-1.02 units on a scale	Standard Deviation 1.101
Placebo to Guselkumab 100 mg q4w	Change From Baseline in DAS28 (CRP) Score at Weeks 24, 28, 36, 44 and 52	Week 28	-1.38 units on a scale	Standard Deviation 1.099
Placebo to Guselkumab 100 mg q4w	Change From Baseline in DAS28 (CRP) Score at Weeks 24, 28, 36, 44 and 52	Week 52	-2.14 units on a scale	Standard Deviation 1.142
Guselkumab 100 mg q8w	Change From Baseline in DAS28 (CRP) Score at Weeks 24, 28, 36, 44 and 52	Week 36	-1.97 units on a scale	Standard Deviation 1.114
Guselkumab 100 mg q8w	Change From Baseline in DAS28 (CRP) Score at Weeks 24, 28, 36, 44 and 52	Week 24	-1.63 units on a scale	Standard Deviation 1.051
Guselkumab 100 mg q8w	Change From Baseline in DAS28 (CRP) Score at Weeks 24, 28, 36, 44 and 52	Week 28	-1.78 units on a scale	Standard Deviation 1.038
Guselkumab 100 mg q8w	Change From Baseline in DAS28 (CRP) Score at Weeks 24, 28, 36, 44 and 52	Week 44	-2.09 units on a scale	Standard Deviation 1.107
Guselkumab 100 mg q8w	Change From Baseline in DAS28 (CRP) Score at Weeks 24, 28, 36, 44 and 52	Week 52	-2.08 units on a scale	Standard Deviation 1.121
Guselkumab 100 mg q4w	Change From Baseline in DAS28 (CRP) Score at Weeks 24, 28, 36, 44 and 52	Week 52	-2.11 units on a scale	Standard Deviation 1.128
Guselkumab 100 mg q4w	Change From Baseline in DAS28 (CRP) Score at Weeks 24, 28, 36, 44 and 52	Week 44	-2.08 units on a scale	Standard Deviation 1.063
Guselkumab 100 mg q4w	Change From Baseline in DAS28 (CRP) Score at Weeks 24, 28, 36, 44 and 52	Week 24	-1.68 units on a scale	Standard Deviation 0.976
Guselkumab 100 mg q4w	Change From Baseline in DAS28 (CRP) Score at Weeks 24, 28, 36, 44 and 52	Week 36	-2.08 units on a scale	Standard Deviation 1.088
Guselkumab 100 mg q4w	Change From Baseline in DAS28 (CRP) Score at Weeks 24, 28, 36, 44 and 52	Week 28	-1.86 units on a scale	Standard Deviation 1.066

Secondary

Change From Baseline in DAS28 (CRP) Score at Weeks 52, 68, 76, 84 and 100

Time frame: Baseline, Weeks 52, 68, 76, 84 and 100

Population: Analysis population is FAS3 which included all participants still on treatment at Week 52. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in DAS28 (CRP) Score at Weeks 52, 68, 76, 84 and 100	Week 52	-2.14 units on a scale	Standard Deviation 1.142
Placebo to Guselkumab 100 mg q4w	Change From Baseline in DAS28 (CRP) Score at Weeks 52, 68, 76, 84 and 100	Week 68	-2.29 units on a scale	Standard Deviation 1.132
Placebo to Guselkumab 100 mg q4w	Change From Baseline in DAS28 (CRP) Score at Weeks 52, 68, 76, 84 and 100	Week 76	-2.35 units on a scale	Standard Deviation 1.11
Placebo to Guselkumab 100 mg q4w	Change From Baseline in DAS28 (CRP) Score at Weeks 52, 68, 76, 84 and 100	Week 84	-2.40 units on a scale	Standard Deviation 1.087
Placebo to Guselkumab 100 mg q4w	Change From Baseline in DAS28 (CRP) Score at Weeks 52, 68, 76, 84 and 100	Week 100	-2.42 units on a scale	Standard Deviation 1.144
Guselkumab 100 mg q8w	Change From Baseline in DAS28 (CRP) Score at Weeks 52, 68, 76, 84 and 100	Week 68	-2.25 units on a scale	Standard Deviation 1.17
Guselkumab 100 mg q8w	Change From Baseline in DAS28 (CRP) Score at Weeks 52, 68, 76, 84 and 100	Week 76	-2.24 units on a scale	Standard Deviation 1.147
Guselkumab 100 mg q8w	Change From Baseline in DAS28 (CRP) Score at Weeks 52, 68, 76, 84 and 100	Week 100	-2.37 units on a scale	Standard Deviation 1.215
Guselkumab 100 mg q8w	Change From Baseline in DAS28 (CRP) Score at Weeks 52, 68, 76, 84 and 100	Week 84	-2.35 units on a scale	Standard Deviation 1.181
Guselkumab 100 mg q8w	Change From Baseline in DAS28 (CRP) Score at Weeks 52, 68, 76, 84 and 100	Week 52	-2.08 units on a scale	Standard Deviation 1.124
Guselkumab 100 mg q4w	Change From Baseline in DAS28 (CRP) Score at Weeks 52, 68, 76, 84 and 100	Week 84	-2.31 units on a scale	Standard Deviation 1.156
Guselkumab 100 mg q4w	Change From Baseline in DAS28 (CRP) Score at Weeks 52, 68, 76, 84 and 100	Week 68	-2.30 units on a scale	Standard Deviation 1.143
Guselkumab 100 mg q4w	Change From Baseline in DAS28 (CRP) Score at Weeks 52, 68, 76, 84 and 100	Week 100	-2.36 units on a scale	Standard Deviation 1.12
Guselkumab 100 mg q4w	Change From Baseline in DAS28 (CRP) Score at Weeks 52, 68, 76, 84 and 100	Week 52	-2.14 units on a scale	Standard Deviation 1.118
Guselkumab 100 mg q4w	Change From Baseline in DAS28 (CRP) Score at Weeks 52, 68, 76, 84 and 100	Week 76	-2.24 units on a scale	Standard Deviation 1.087

Secondary

Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Weeks 2, 4, 8, 12, 16, 20 and 24

Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20 and 24

Population: Analysis population is FAS1. Data after meeting 1 or more TF criteria were imputed as no change from baseline. Missing data were assumed missing at random. The LS mean is based on MMRM model that included data from all visits for all participants included in the model.

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 4	-7.6695 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 16	-14.8556 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 12	-14.2915 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 2	-4.6447 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 24	-15.8489 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 20	-16.1375 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 8	-10.4480 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 12	-18.9772 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 2	-6.7838 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 4	-9.9687 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 8	-15.3303 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 16	-21.6939 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 20	-23.3163 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 24	-24.0359 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 16	-21.4722 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 4	-10.2484 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 24	-25.1583 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 20	-24.6844 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 12	-19.9687 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 8	-15.8657 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 2	-6.3783 units on a scale

Secondary

Change From Baseline in Disease Activity Score (DAS28) (C-reactive Protein [CRP]) Score at Week 24

The Disease Activity Index Score (DAS28) based on C-Reactive Protein (CRP) is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative changes from baseline indicate improvement of arthritis.

Time frame: Baseline and Week 24

Arm	Measure	Value (LEAST_SQUARES_MEAN)
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Disease Activity Score (DAS28) (C-reactive Protein [CRP]) Score at Week 24	-0.97 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Disease Activity Score (DAS28) (C-reactive Protein [CRP]) Score at Week 24	-1.59 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Disease Activity Score (DAS28) (C-reactive Protein [CRP]) Score at Week 24	-1.62 units on a scale

p-value: <0.00195% CI: [-0.8, -0.43]ANCOVA

p-value: <0.00195% CI: [-0.83, -0.47]ANCOVA

Secondary

Change From Baseline in DLQI Score at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. Negative changes from baseline indicate improvement of life quality impacted by psoriasis.

Time frame: Baseline, Weeks 24 and 52

Population: Analysis population is FAS2 among the participants with \>=3% BSA psoriatic involvement and an IGA Score of \>=2 (mild) at baseline. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in DLQI Score at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	-2.142 units on a scale	Standard Deviation 6.4593
Placebo to Guselkumab 100 mg q4w	Change From Baseline in DLQI Score at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	-8.815 units on a scale	Standard Deviation 7.2714
Guselkumab 100 mg q8w	Change From Baseline in DLQI Score at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	-8.901 units on a scale	Standard Deviation 7.3657
Guselkumab 100 mg q8w	Change From Baseline in DLQI Score at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	-9.235 units on a scale	Standard Deviation 7.384
Guselkumab 100 mg q4w	Change From Baseline in DLQI Score at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	-9.249 units on a scale	Standard Deviation 7.0988
Guselkumab 100 mg q4w	Change From Baseline in DLQI Score at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	-9.839 units on a scale	Standard Deviation 6.8777

Secondary

Change From Baseline in DLQI Score at Weeks 52, 76 and 100 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

Time frame: Baseline, Weeks 52, 76 and 100

Population: Analysis population is FAS3 among the participants with \>=3% BSA psoriatic involvement and an IGA Score of \>=2 (mild) at baseline. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in DLQI Score at Weeks 52, 76 and 100 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 76	-10.090 units on a scale	Standard Deviation 7.0888
Placebo to Guselkumab 100 mg q4w	Change From Baseline in DLQI Score at Weeks 52, 76 and 100 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	-8.855 units on a scale	Standard Deviation 7.2738
Placebo to Guselkumab 100 mg q4w	Change From Baseline in DLQI Score at Weeks 52, 76 and 100 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 100	-10.130 units on a scale	Standard Deviation 7.2798
Guselkumab 100 mg q8w	Change From Baseline in DLQI Score at Weeks 52, 76 and 100 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 76	-9.180 units on a scale	Standard Deviation 7.2977
Guselkumab 100 mg q8w	Change From Baseline in DLQI Score at Weeks 52, 76 and 100 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	-9.272 units on a scale	Standard Deviation 7.3903
Guselkumab 100 mg q8w	Change From Baseline in DLQI Score at Weeks 52, 76 and 100 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 100	-9.291 units on a scale	Standard Deviation 7.2851
Guselkumab 100 mg q4w	Change From Baseline in DLQI Score at Weeks 52, 76 and 100 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	-9.873 units on a scale	Standard Deviation 6.8832
Guselkumab 100 mg q4w	Change From Baseline in DLQI Score at Weeks 52, 76 and 100 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 100	-9.635 units on a scale	Standard Deviation 7.0884
Guselkumab 100 mg q4w	Change From Baseline in DLQI Score at Weeks 52, 76 and 100 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 76	-9.610 units on a scale	Standard Deviation 7.0383

Secondary

Change From Baseline in DLQI Score at Weeks 8, 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

Time frame: Baseline, Weeks 8, 16 and 24

Population: Analysis population is FAS1 among participants with \>=3% BSA of psoriasis and an IGA score \>=2 (mild) at baseline. Data after meeting 1 or more TF criteria were imputed as no change from baseline. Missing data were assumed missing at random. LS mean is based on MMRM model that included data from all visits for all participants included in model.

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)
Placebo to Guselkumab 100 mg q4w	Change From Baseline in DLQI Score at Weeks 8, 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 16	-2.410 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in DLQI Score at Weeks 8, 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 8	-1.653 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in DLQI Score at Weeks 8, 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	-2.129 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in DLQI Score at Weeks 8, 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 16	-8.545 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in DLQI Score at Weeks 8, 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 8	-6.818 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in DLQI Score at Weeks 8, 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	-8.954 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in DLQI Score at Weeks 8, 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 8	-6.396 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in DLQI Score at Weeks 8, 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	-8.853 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in DLQI Score at Weeks 8, 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 16	-8.147 units on a scale

Secondary

Change From Baseline in Enthesitis Score (Based on LEI) at Week 24 Among the Participants With Enthesitis at Baseline

Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicate improvement of enthesitis. The outcome measure was planned to be reported for pooled population from CNTO1959PSA3001 and CNTO1959PSA3002 studies.

Time frame: Baseline and Week 24

Population: Analysis population is FAS1 among participants with enthesitis at baseline pooled from both CNTO1959PSA3001 (NCT03162796) and CNTO1959PSA3002 (NCT03158285) studies. Data after meeting 1 or more TF criteria were imputed as no change from baseline. Missing data were assumed missing at random and imputed using multiple imputation.

Arm	Measure	Value (LEAST_SQUARES_MEAN)
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Enthesitis Score (Based on LEI) at Week 24 Among the Participants With Enthesitis at Baseline	-1.02 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Enthesitis Score (Based on LEI) at Week 24 Among the Participants With Enthesitis at Baseline	-1.52 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Enthesitis Score (Based on LEI) at Week 24 Among the Participants With Enthesitis at Baseline	-1.59 units on a scale

p-value: <0.00195% CI: [-0.77, -0.23]ANCOVA

p-value: <0.00195% CI: [-0.83, -0.31]ANCOVA

Secondary

Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 2, 4, 8, 16, and 24 Among the Participants With Enthesitis at Baseline

Time frame: Baseline, Weeks 2, 4, 8, 16 and 24

Population: Analysis population is FAS1 among participants with enthesitis at baseline. Data after meeting 1 or more TF criteria were imputed as no change from baseline. Missing data were assumed missing at random and imputed using multiple imputation.

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 2, 4, 8, 16, and 24 Among the Participants With Enthesitis at Baseline	Week 16	-0.94 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 2, 4, 8, 16, and 24 Among the Participants With Enthesitis at Baseline	Week 8	-0.67 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 2, 4, 8, 16, and 24 Among the Participants With Enthesitis at Baseline	Week 2	-0.33 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 2, 4, 8, 16, and 24 Among the Participants With Enthesitis at Baseline	Week 4	-0.46 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 2, 4, 8, 16, and 24 Among the Participants With Enthesitis at Baseline	Week 24	-1.03 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 2, 4, 8, 16, and 24 Among the Participants With Enthesitis at Baseline	Week 8	-0.92 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 2, 4, 8, 16, and 24 Among the Participants With Enthesitis at Baseline	Week 2	-0.37 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 2, 4, 8, 16, and 24 Among the Participants With Enthesitis at Baseline	Week 4	-0.56 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 2, 4, 8, 16, and 24 Among the Participants With Enthesitis at Baseline	Week 16	-1.37 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 2, 4, 8, 16, and 24 Among the Participants With Enthesitis at Baseline	Week 24	-1.60 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 2, 4, 8, 16, and 24 Among the Participants With Enthesitis at Baseline	Week 24	-1.52 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 2, 4, 8, 16, and 24 Among the Participants With Enthesitis at Baseline	Week 16	-1.42 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 2, 4, 8, 16, and 24 Among the Participants With Enthesitis at Baseline	Week 2	-0.49 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 2, 4, 8, 16, and 24 Among the Participants With Enthesitis at Baseline	Week 8	-0.88 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 2, 4, 8, 16, and 24 Among the Participants With Enthesitis at Baseline	Week 4	-0.69 units on a scale

Secondary

Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 24 and 52 Among the Participants With Enthesitis at Baseline

Time frame: Baseline, Weeks 24 and 52

Population: Analysis population is FAS2 among the participants with enthesitis (LEI) at baseline. Here n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 24 and 52 Among the Participants With Enthesitis at Baseline	Week 24	-1.1 units on a scale	Standard Deviation 1.66
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 24 and 52 Among the Participants With Enthesitis at Baseline	Week 52	-2.1 units on a scale	Standard Deviation 1.61
Guselkumab 100 mg q8w	Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 24 and 52 Among the Participants With Enthesitis at Baseline	Week 24	-1.6 units on a scale	Standard Deviation 1.75
Guselkumab 100 mg q8w	Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 24 and 52 Among the Participants With Enthesitis at Baseline	Week 52	-1.9 units on a scale	Standard Deviation 1.65
Guselkumab 100 mg q4w	Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 24 and 52 Among the Participants With Enthesitis at Baseline	Week 24	-1.6 units on a scale	Standard Deviation 1.63
Guselkumab 100 mg q4w	Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 24 and 52 Among the Participants With Enthesitis at Baseline	Week 52	-2.0 units on a scale	Standard Deviation 1.78

Secondary

Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 52, 76 and 100 Among the Participants With Enthesitis at Baseline

Time frame: Baseline, Weeks 52, 76 and 100

Population: Analysis population is FAS3 among the participants with enthesitis (LEI) at baseline. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 52, 76 and 100 Among the Participants With Enthesitis at Baseline	Week 52	-2.1 units on a scale	Standard Deviation 1.59
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 52, 76 and 100 Among the Participants With Enthesitis at Baseline	Week 100	-2.4 units on a scale	Standard Deviation 1.7
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 52, 76 and 100 Among the Participants With Enthesitis at Baseline	Week 76	-2.3 units on a scale	Standard Deviation 1.52
Guselkumab 100 mg q8w	Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 52, 76 and 100 Among the Participants With Enthesitis at Baseline	Week 52	-1.9 units on a scale	Standard Deviation 1.66
Guselkumab 100 mg q8w	Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 52, 76 and 100 Among the Participants With Enthesitis at Baseline	Week 76	-2.1 units on a scale	Standard Deviation 1.66
Guselkumab 100 mg q8w	Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 52, 76 and 100 Among the Participants With Enthesitis at Baseline	Week 100	-2.1 units on a scale	Standard Deviation 1.65
Guselkumab 100 mg q4w	Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 52, 76 and 100 Among the Participants With Enthesitis at Baseline	Week 100	-2.2 units on a scale	Standard Deviation 1.8
Guselkumab 100 mg q4w	Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 52, 76 and 100 Among the Participants With Enthesitis at Baseline	Week 76	-2.2 units on a scale	Standard Deviation 1.69
Guselkumab 100 mg q4w	Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 52, 76 and 100 Among the Participants With Enthesitis at Baseline	Week 52	-2.1 units on a scale	Standard Deviation 1.72

Secondary

Change From Baseline in EQ-5D-5L at Weeks 16 and 24: EQ-5D Index

EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a weighted summary index (EQ-5D index), which ranges from 0 (dead) to 1.00 (full health). A higher score indicates better health and positive changes from baseline indicate improvement of health.

Time frame: Baseline, Weeks 16 and 24

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)
Placebo to Guselkumab 100 mg q4w	Change From Baseline in EQ-5D-5L at Weeks 16 and 24: EQ-5D Index	Week 16	0.058 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in EQ-5D-5L at Weeks 16 and 24: EQ-5D Index	Week 24	0.053 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in EQ-5D-5L at Weeks 16 and 24: EQ-5D Index	Week 16	0.112 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in EQ-5D-5L at Weeks 16 and 24: EQ-5D Index	Week 24	0.115 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in EQ-5D-5L at Weeks 16 and 24: EQ-5D Index	Week 16	0.101 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in EQ-5D-5L at Weeks 16 and 24: EQ-5D Index	Week 24	0.116 units on a scale

Secondary

Change From Baseline in EQ-5D-5L at Weeks 24 and 52: EQ-5D Index

Time frame: Baseline, Weeks 24 and 52

Population: Analysis population is FAS2. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in EQ-5D-5L at Weeks 24 and 52: EQ-5D Index	Week 24	0.060 units on a scale	Standard Deviation 0.1558
Placebo to Guselkumab 100 mg q4w	Change From Baseline in EQ-5D-5L at Weeks 24 and 52: EQ-5D Index	Week 52	0.137 units on a scale	Standard Deviation 0.1605
Guselkumab 100 mg q8w	Change From Baseline in EQ-5D-5L at Weeks 24 and 52: EQ-5D Index	Week 52	0.146 units on a scale	Standard Deviation 0.1587
Guselkumab 100 mg q8w	Change From Baseline in EQ-5D-5L at Weeks 24 and 52: EQ-5D Index	Week 24	0.124 units on a scale	Standard Deviation 0.1476
Guselkumab 100 mg q4w	Change From Baseline in EQ-5D-5L at Weeks 24 and 52: EQ-5D Index	Week 24	0.117 units on a scale	Standard Deviation 0.1307
Guselkumab 100 mg q4w	Change From Baseline in EQ-5D-5L at Weeks 24 and 52: EQ-5D Index	Week 52	0.135 units on a scale	Standard Deviation 0.1469

Secondary

Change From Baseline in EQ-5D-5L at Weeks 24 and 52: EQ-VAS

EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a vertical line VAS with scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). A higher score indicates better health and positive changes from baseline indicate improvement of health status.

Time frame: Baseline, Weeks 24 and 52

Population: Analysis population is FAS2. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in EQ-5D-5L at Weeks 24 and 52: EQ-VAS	Week 24	8.456 units on a scale	Standard Deviation 25.7204
Placebo to Guselkumab 100 mg q4w	Change From Baseline in EQ-5D-5L at Weeks 24 and 52: EQ-VAS	Week 52	21.474 units on a scale	Standard Deviation 25.5974
Guselkumab 100 mg q8w	Change From Baseline in EQ-5D-5L at Weeks 24 and 52: EQ-VAS	Week 24	19.282 units on a scale	Standard Deviation 23.522
Guselkumab 100 mg q8w	Change From Baseline in EQ-5D-5L at Weeks 24 and 52: EQ-VAS	Week 52	23.295 units on a scale	Standard Deviation 23.627
Guselkumab 100 mg q4w	Change From Baseline in EQ-5D-5L at Weeks 24 and 52: EQ-VAS	Week 24	17.500 units on a scale	Standard Deviation 22.6981
Guselkumab 100 mg q4w	Change From Baseline in EQ-5D-5L at Weeks 24 and 52: EQ-VAS	Week 52	19.983 units on a scale	Standard Deviation 24.7643

Secondary

Change From Baseline in EQ-5D-5L at Weeks 52, 76 and 100: EQ-5D Index

Time frame: Baseline, Weeks 52, 76 and 100

Population: Analysis population is FAS3. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in EQ-5D-5L at Weeks 52, 76 and 100: EQ-5D Index	Week 76	0.154 units on a scale	Standard Deviation 0.1744
Placebo to Guselkumab 100 mg q4w	Change From Baseline in EQ-5D-5L at Weeks 52, 76 and 100: EQ-5D Index	Week 52	0.138 units on a scale	Standard Deviation 0.1608
Placebo to Guselkumab 100 mg q4w	Change From Baseline in EQ-5D-5L at Weeks 52, 76 and 100: EQ-5D Index	Week 100	0.164 units on a scale	Standard Deviation 0.1605
Guselkumab 100 mg q8w	Change From Baseline in EQ-5D-5L at Weeks 52, 76 and 100: EQ-5D Index	Week 76	0.169 units on a scale	Standard Deviation 0.1564
Guselkumab 100 mg q8w	Change From Baseline in EQ-5D-5L at Weeks 52, 76 and 100: EQ-5D Index	Week 52	0.150 units on a scale	Standard Deviation 0.1445
Guselkumab 100 mg q8w	Change From Baseline in EQ-5D-5L at Weeks 52, 76 and 100: EQ-5D Index	Week 100	0.164 units on a scale	Standard Deviation 0.1596
Guselkumab 100 mg q4w	Change From Baseline in EQ-5D-5L at Weeks 52, 76 and 100: EQ-5D Index	Week 52	0.138 units on a scale	Standard Deviation 0.1458
Guselkumab 100 mg q4w	Change From Baseline in EQ-5D-5L at Weeks 52, 76 and 100: EQ-5D Index	Week 100	0.156 units on a scale	Standard Deviation 0.1543
Guselkumab 100 mg q4w	Change From Baseline in EQ-5D-5L at Weeks 52, 76 and 100: EQ-5D Index	Week 76	0.147 units on a scale	Standard Deviation 0.1471

Secondary

Change From Baseline in EQ-5D-5L at Weeks 52, 76 and 100: EQ-VAS

Time frame: Baseline, Weeks 52, 76 and 100

Population: Analysis population is FAS3. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in EQ-5D-5L at Weeks 52, 76 and 100: EQ-VAS	Week 76	24.176 units on a scale	Standard Deviation 27.7205
Placebo to Guselkumab 100 mg q4w	Change From Baseline in EQ-5D-5L at Weeks 52, 76 and 100: EQ-VAS	Week 52	21.608 units on a scale	Standard Deviation 25.5992
Placebo to Guselkumab 100 mg q4w	Change From Baseline in EQ-5D-5L at Weeks 52, 76 and 100: EQ-VAS	Week 100	25.901 units on a scale	Standard Deviation 28.4028
Guselkumab 100 mg q8w	Change From Baseline in EQ-5D-5L at Weeks 52, 76 and 100: EQ-VAS	Week 76	25.053 units on a scale	Standard Deviation 26.0372
Guselkumab 100 mg q8w	Change From Baseline in EQ-5D-5L at Weeks 52, 76 and 100: EQ-VAS	Week 52	23.392 units on a scale	Standard Deviation 23.699
Guselkumab 100 mg q8w	Change From Baseline in EQ-5D-5L at Weeks 52, 76 and 100: EQ-VAS	Week 100	27.152 units on a scale	Standard Deviation 26.5221
Guselkumab 100 mg q4w	Change From Baseline in EQ-5D-5L at Weeks 52, 76 and 100: EQ-VAS	Week 52	20.190 units on a scale	Standard Deviation 24.8348
Guselkumab 100 mg q4w	Change From Baseline in EQ-5D-5L at Weeks 52, 76 and 100: EQ-VAS	Week 100	25.909 units on a scale	Standard Deviation 26.0995
Guselkumab 100 mg q4w	Change From Baseline in EQ-5D-5L at Weeks 52, 76 and 100: EQ-VAS	Week 76	22.251 units on a scale	Standard Deviation 24.6934

Secondary

Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) at Weeks 16 and 24: EQ-VAS

Time frame: Baseline, Weeks 16 and 24

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)
Placebo to Guselkumab 100 mg q4w	Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) at Weeks 16 and 24: EQ-VAS	Week 16	6.477 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) at Weeks 16 and 24: EQ-VAS	Week 24	6.796 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) at Weeks 16 and 24: EQ-VAS	Week 16	17.496 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) at Weeks 16 and 24: EQ-VAS	Week 24	18.371 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) at Weeks 16 and 24: EQ-VAS	Week 16	14.646 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) at Weeks 16 and 24: EQ-VAS	Week 24	18.089 units on a scale

Secondary

Change From Baseline in FACIT-Fatigue Score at Weeks 24 and 52

The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.

Time frame: Baseline, Weeks 24 and 52

Population: Analysis population is FAS2. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in FACIT-Fatigue Score at Weeks 24 and 52	Week 24	3.844 units on a scale	Standard Deviation 9.044
Placebo to Guselkumab 100 mg q4w	Change From Baseline in FACIT-Fatigue Score at Weeks 24 and 52	Week 52	7.548 units on a scale	Standard Deviation 9.3745
Guselkumab 100 mg q8w	Change From Baseline in FACIT-Fatigue Score at Weeks 24 and 52	Week 24	8.034 units on a scale	Standard Deviation 9.8888
Guselkumab 100 mg q8w	Change From Baseline in FACIT-Fatigue Score at Weeks 24 and 52	Week 52	8.927 units on a scale	Standard Deviation 9.4646
Guselkumab 100 mg q4w	Change From Baseline in FACIT-Fatigue Score at Weeks 24 and 52	Week 24	6.970 units on a scale	Standard Deviation 8.6274
Guselkumab 100 mg q4w	Change From Baseline in FACIT-Fatigue Score at Weeks 24 and 52	Week 52	7.686 units on a scale	Standard Deviation 9.0833

Secondary

Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 52, 76 and 100

Time frame: Baseline, Weeks 52, 76 and 100

Population: Analysis population is FAS3. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 52, 76 and 100	Week 76	9.167 units on a scale	Standard Deviation 9.0455
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 52, 76 and 100	Week 52	7.692 units on a scale	Standard Deviation 9.3071
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 52, 76 and 100	Week 100	9.435 units on a scale	Standard Deviation 9.4513
Guselkumab 100 mg q8w	Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 52, 76 and 100	Week 76	9.596 units on a scale	Standard Deviation 10.4788
Guselkumab 100 mg q8w	Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 52, 76 and 100	Week 52	8.935 units on a scale	Standard Deviation 9.5033
Guselkumab 100 mg q8w	Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 52, 76 and 100	Week 100	10.107 units on a scale	Standard Deviation 10.2076
Guselkumab 100 mg q4w	Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 52, 76 and 100	Week 52	7.699 units on a scale	Standard Deviation 9.1417
Guselkumab 100 mg q4w	Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 52, 76 and 100	Week 100	9.127 units on a scale	Standard Deviation 8.9948
Guselkumab 100 mg q4w	Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 52, 76 and 100	Week 76	8.632 units on a scale	Standard Deviation 8.8429

Secondary

Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 8, 16, and 24

Time frame: Baseline, Weeks 8, 16 and 24

Population: Analysis population is FAS1. Data after meeting 1 or more TF criteria were imputed as no change from baseline. Missing data were assumed MAR. The LS mean is based on MMRM model that included data from all visits for all participants included in the model.

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 8, 16, and 24	Week 16	3.696 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 8, 16, and 24	Week 8	2.451 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 8, 16, and 24	Week 24	3.559 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 8, 16, and 24	Week 16	6.977 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 8, 16, and 24	Week 8	5.031 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 8, 16, and 24	Week 24	7.550 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 8, 16, and 24	Week 8	4.850 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 8, 16, and 24	Week 24	7.111 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 8, 16, and 24	Week 16	6.598 units on a scale

Secondary

Change From Baseline in GRAPPA Composite Score (GRACE) at Weeks 52, 76 and 100

GRACE index is a composite PsA disease activity score converted from Arithmetic Mean of Desirability Function (AMDF), derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), patient's global assessment of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100=poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), patient's global assessment of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL=25.355 + \[2.367\*HAQ-DI\]-\[0.234\*SF-PCS\]-\[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score ranges from 0-100, higher scores= better quality of life) and SF-MCS (score ranges from 0-100, higher scores= better quality of life). Total score is from 0-10, lower score=better response. Higher score indicates more active disease activity. Negative change from baseline indicates improvement of PsA disease activity.

Time frame: Baseline, Weeks 52, 76 and 100

Population: Analysis population is FAS3 which included all participants still on treatment at Week 52. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in GRAPPA Composite Score (GRACE) at Weeks 52, 76 and 100	Week 76	-3.499 units on a scale	Standard Deviation 1.6303
Placebo to Guselkumab 100 mg q4w	Change From Baseline in GRAPPA Composite Score (GRACE) at Weeks 52, 76 and 100	Week 52	-3.105 units on a scale	Standard Deviation 1.6208
Placebo to Guselkumab 100 mg q4w	Change From Baseline in GRAPPA Composite Score (GRACE) at Weeks 52, 76 and 100	Week 100	-3.561 units on a scale	Standard Deviation 1.6389
Guselkumab 100 mg q8w	Change From Baseline in GRAPPA Composite Score (GRACE) at Weeks 52, 76 and 100	Week 76	-3.528 units on a scale	Standard Deviation 1.5778
Guselkumab 100 mg q8w	Change From Baseline in GRAPPA Composite Score (GRACE) at Weeks 52, 76 and 100	Week 52	-3.266 units on a scale	Standard Deviation 1.6443
Guselkumab 100 mg q8w	Change From Baseline in GRAPPA Composite Score (GRACE) at Weeks 52, 76 and 100	Week 100	-3.656 units on a scale	Standard Deviation 1.6071
Guselkumab 100 mg q4w	Change From Baseline in GRAPPA Composite Score (GRACE) at Weeks 52, 76 and 100	Week 52	-3.298 units on a scale	Standard Deviation 1.5457
Guselkumab 100 mg q4w	Change From Baseline in GRAPPA Composite Score (GRACE) at Weeks 52, 76 and 100	Week 100	-3.664 units on a scale	Standard Deviation 1.5205
Guselkumab 100 mg q4w	Change From Baseline in GRAPPA Composite Score (GRACE) at Weeks 52, 76 and 100	Week 76	-3.541 units on a scale	Standard Deviation 1.5048

Secondary

Change From Baseline in Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Composite Score (GRACE) at Weeks 16 and 24

Time frame: Baseline, Weeks 16 and 24

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Composite Score (GRACE) at Weeks 16 and 24	Week 16	-1.029 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Composite Score (GRACE) at Weeks 16 and 24	Week 24	-1.198 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Composite Score (GRACE) at Weeks 16 and 24	Week 16	-2.326 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Composite Score (GRACE) at Weeks 16 and 24	Week 24	-2.593 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Composite Score (GRACE) at Weeks 16 and 24	Week 16	-2.214 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Composite Score (GRACE) at Weeks 16 and 24	Week 24	-2.589 units on a scale

Secondary

Change From Baseline in Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 24 and 52

GRACE index is a composite PsA disease activity score converted from AMDF, which was derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), patient's global assessment of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100= poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), patient's global assessment of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL =25.355 + \[2.367\*HAQ-DI\] - \[0.234\*SF-PCS\] - \[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score ranges from 0 to 100, higher scores= better quality of life) and SF-MCS (score ranges from 0 to 100, higher scores= better quality of life). The total score is from 0-10, where lower score indicates better response. Higher score indicates more active disease activity. Negative change from baseline indicates improvement of PsA disease activity.

Time frame: Baseline, Weeks 24 and 52

Population: Analysis population is FAS2. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 24 and 52	Week 24	-1.260 units on a scale	Standard Deviation 1.4909
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 24 and 52	Week 52	-3.085 units on a scale	Standard Deviation 1.6277
Guselkumab 100 mg q8w	Change From Baseline in Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 24 and 52	Week 24	-2.658 units on a scale	Standard Deviation 1.677
Guselkumab 100 mg q8w	Change From Baseline in Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 24 and 52	Week 52	-3.271 units on a scale	Standard Deviation 1.6453
Guselkumab 100 mg q4w	Change From Baseline in Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 24 and 52	Week 24	-2.672 units on a scale	Standard Deviation 1.4589
Guselkumab 100 mg q4w	Change From Baseline in Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 24 and 52	Week 52	-3.267 units on a scale	Standard Deviation 1.5646

Secondary

Change From Baseline in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52

HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.

Time frame: Baseline, Weeks 24, 28, 36, 44 and 52

Population: Analysis population is FAS2. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52	Week 44	-0.3868 units on a scale	Standard Deviation 0.57065
Placebo to Guselkumab 100 mg q4w	Change From Baseline in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52	Week 36	-0.3423 units on a scale	Standard Deviation 0.52951
Placebo to Guselkumab 100 mg q4w	Change From Baseline in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52	Week 24	-0.1646 units on a scale	Standard Deviation 0.53253
Placebo to Guselkumab 100 mg q4w	Change From Baseline in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52	Week 52	-0.3848 units on a scale	Standard Deviation 0.58049
Placebo to Guselkumab 100 mg q4w	Change From Baseline in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52	Week 28	-0.2547 units on a scale	Standard Deviation 0.50426
Guselkumab 100 mg q8w	Change From Baseline in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52	Week 36	-0.4702 units on a scale	Standard Deviation 0.55698
Guselkumab 100 mg q8w	Change From Baseline in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52	Week 28	-0.4383 units on a scale	Standard Deviation 0.55648
Guselkumab 100 mg q8w	Change From Baseline in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52	Week 24	-0.4044 units on a scale	Standard Deviation 0.54194
Guselkumab 100 mg q8w	Change From Baseline in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52	Week 44	-0.4824 units on a scale	Standard Deviation 0.57091
Guselkumab 100 mg q8w	Change From Baseline in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52	Week 52	-0.4824 units on a scale	Standard Deviation 0.56167
Guselkumab 100 mg q4w	Change From Baseline in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52	Week 52	-0.5082 units on a scale	Standard Deviation 0.58255
Guselkumab 100 mg q4w	Change From Baseline in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52	Week 44	-0.4652 units on a scale	Standard Deviation 0.56121
Guselkumab 100 mg q4w	Change From Baseline in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52	Week 24	-0.4257 units on a scale	Standard Deviation 0.50337
Guselkumab 100 mg q4w	Change From Baseline in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52	Week 36	-0.5000 units on a scale	Standard Deviation 0.55438
Guselkumab 100 mg q4w	Change From Baseline in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52	Week 28	-0.4429 units on a scale	Standard Deviation 0.51556

Secondary

Change From Baseline in HAQ-DI Score at Weeks 2, 4, 8, 12, 16, 20 and 24

HAQ-DI score assess functional status of participant. It is a 20 question instrument that assess the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative changes from baseline indicate improvement of physical function.

Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)
Placebo to Guselkumab 100 mg q4w	Change From Baseline in HAQ-DI Score at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 4	-0.0722 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in HAQ-DI Score at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 16	-0.1167 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in HAQ-DI Score at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 12	-0.1332 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in HAQ-DI Score at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 2	-0.0594 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in HAQ-DI Score at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 24	-0.1300 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in HAQ-DI Score at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 20	-0.1565 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in HAQ-DI Score at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 8	-0.0942 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in HAQ-DI Score at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 12	-0.2870 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in HAQ-DI Score at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 2	-0.1423 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in HAQ-DI Score at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 4	-0.1472 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in HAQ-DI Score at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 8	-0.2294 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in HAQ-DI Score at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 16	-0.3177 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in HAQ-DI Score at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 20	-0.3536 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in HAQ-DI Score at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 24	-0.3672 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in HAQ-DI Score at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 16	-0.3442 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in HAQ-DI Score at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 4	-0.1605 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in HAQ-DI Score at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 24	-0.4004 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in HAQ-DI Score at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 20	-0.4019 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in HAQ-DI Score at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 12	-0.3010 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in HAQ-DI Score at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 8	-0.2336 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in HAQ-DI Score at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 2	-0.0795 units on a scale

Secondary

Change From Baseline in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100

HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3, where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.

Time frame: Baseline, Weeks 52, 68, 76, 84 and 100

Population: Analysis population is FAS3 which included all participants still on treatment at Week 52. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100	Week 84	-0.5041 units on a scale	Standard Deviation 0.59716
Placebo to Guselkumab 100 mg q4w	Change From Baseline in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100	Week 76	-0.4740 units on a scale	Standard Deviation 0.57852
Placebo to Guselkumab 100 mg q4w	Change From Baseline in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100	Week 52	-0.3899 units on a scale	Standard Deviation 0.5825
Placebo to Guselkumab 100 mg q4w	Change From Baseline in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100	Week 68	-0.4668 units on a scale	Standard Deviation 0.59226
Placebo to Guselkumab 100 mg q4w	Change From Baseline in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100	Week 100	-0.5356 units on a scale	Standard Deviation 0.56707
Guselkumab 100 mg q8w	Change From Baseline in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100	Week 76	-0.5694 units on a scale	Standard Deviation 0.56421
Guselkumab 100 mg q8w	Change From Baseline in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100	Week 52	-0.4801 units on a scale	Standard Deviation 0.56246
Guselkumab 100 mg q8w	Change From Baseline in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100	Week 68	-0.5120 units on a scale	Standard Deviation 0.54928
Guselkumab 100 mg q8w	Change From Baseline in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100	Week 84	-0.5653 units on a scale	Standard Deviation 0.59488
Guselkumab 100 mg q8w	Change From Baseline in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100	Week 100	-0.5859 units on a scale	Standard Deviation 0.58199
Guselkumab 100 mg q4w	Change From Baseline in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100	Week 100	-0.6000 units on a scale	Standard Deviation 0.56858
Guselkumab 100 mg q4w	Change From Baseline in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100	Week 84	-0.5656 units on a scale	Standard Deviation 0.57921
Guselkumab 100 mg q4w	Change From Baseline in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100	Week 52	-0.5111 units on a scale	Standard Deviation 0.58347
Guselkumab 100 mg q4w	Change From Baseline in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100	Week 76	-0.5448 units on a scale	Standard Deviation 0.54739
Guselkumab 100 mg q4w	Change From Baseline in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100	Week 68	-0.5631 units on a scale	Standard Deviation 0.54528

Secondary

Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24

Time frame: Baseline and Week 24

Arm	Measure	Value (LEAST_SQUARES_MEAN)
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24	-0.1300 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24	-0.3672 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24	-0.4004 units on a scale

p-value: <0.00195% CI: [-0.321, -0.1534]ANCOVA

p-value: <0.00195% CI: [-0.3544, -0.1864]ANCOVA

Secondary

Change From Baseline in mCPDAI Score at Weeks 52, 76 and 100

The mCPDAI assessed 4 domains (joints, skin, entheses, and dactylitis). The mCPDAI scores were calculated using the following assessments: joints (66 swollen and 68 tender joint counts), HAQ-DI score, PASI, dactylitis, and enthesitis. Within each domain a score (range 0-3) was assigned, where 0= Not involved, 1= Mild, 2= Moderate and 3= Severe. The scores for each domain were then added together to give a final score range of 0 to 12. A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity.

Time frame: Baseline, Weeks 52, 76 and 100

Population: Analysis population is FAS3 which included all participants still on treatment at Week 52. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in mCPDAI Score at Weeks 52, 76 and 100	Week 76	-4.39 units on a scale	Standard Deviation 2.425
Placebo to Guselkumab 100 mg q4w	Change From Baseline in mCPDAI Score at Weeks 52, 76 and 100	Week 52	-3.78 units on a scale	Standard Deviation 2.392
Placebo to Guselkumab 100 mg q4w	Change From Baseline in mCPDAI Score at Weeks 52, 76 and 100	Week 100	-4.44 units on a scale	Standard Deviation 2.484
Guselkumab 100 mg q8w	Change From Baseline in mCPDAI Score at Weeks 52, 76 and 100	Week 76	-4.16 units on a scale	Standard Deviation 2.539
Guselkumab 100 mg q8w	Change From Baseline in mCPDAI Score at Weeks 52, 76 and 100	Week 52	-3.83 units on a scale	Standard Deviation 2.458
Guselkumab 100 mg q8w	Change From Baseline in mCPDAI Score at Weeks 52, 76 and 100	Week 100	-4.38 units on a scale	Standard Deviation 2.433
Guselkumab 100 mg q4w	Change From Baseline in mCPDAI Score at Weeks 52, 76 and 100	Week 52	-4.14 units on a scale	Standard Deviation 2.358
Guselkumab 100 mg q4w	Change From Baseline in mCPDAI Score at Weeks 52, 76 and 100	Week 100	-4.52 units on a scale	Standard Deviation 2.519
Guselkumab 100 mg q4w	Change From Baseline in mCPDAI Score at Weeks 52, 76 and 100	Week 76	-4.47 units on a scale	Standard Deviation 2.347

Secondary

Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Week 16 and 24

Time frame: Baseline, Weeks 16 and 24

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Week 16 and 24	Week 16	-1.18 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Week 16 and 24	Week 24	-1.30 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Week 16 and 24	Week 16	-2.39 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Week 16 and 24	Week 24	-2.94 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Week 16 and 24	Week 16	-2.57 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Week 16 and 24	Week 24	-3.09 units on a scale

Secondary

Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Weeks 24 and 52

Time frame: Baseline, Weeks 24 and 52

Population: Analysis population is FAS2. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Weeks 24 and 52	Week 24	-1.34 units on a scale	Standard Deviation 2.144
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Weeks 24 and 52	Week 52	-3.75 units on a scale	Standard Deviation 2.391
Guselkumab 100 mg q8w	Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Weeks 24 and 52	Week 52	-3.84 units on a scale	Standard Deviation 2.449
Guselkumab 100 mg q8w	Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Weeks 24 and 52	Week 24	-2.97 units on a scale	Standard Deviation 2.382
Guselkumab 100 mg q4w	Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Weeks 24 and 52	Week 24	-3.32 units on a scale	Standard Deviation 2.098
Guselkumab 100 mg q4w	Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Weeks 24 and 52	Week 52	-4.10 units on a scale	Standard Deviation 2.387

Secondary

Change From Baseline in Modified Van Der Heijde-Sharp (vdH-S) Score at Week 24

Modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. Positive changes from baseline in the modified vdH-S total, erosion and JSN scores indicate progression of joint damage.

Time frame: Baseline and Week 24

Population: FAS1 for structural damage (FAS1-SD) included all participants who received at least 1 dose (complete/partial) of study agent according to randomized treatment group regardless of treatment actually received. Observed data were used regardless if 1 or more TF criteria were met. Missing data were assumed to be MAR and imputed using MI.

Arm	Measure	Value (LEAST_SQUARES_MEAN)
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Modified Van Der Heijde-Sharp (vdH-S) Score at Week 24	0.95 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Modified Van Der Heijde-Sharp (vdH-S) Score at Week 24	0.52 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Modified Van Der Heijde-Sharp (vdH-S) Score at Week 24	0.29 units on a scale

p-value: 0.07295% CI: [-0.9, 0.03]ANCOVA

p-value: 0.01195% CI: [-1.13, -0.19]ANCOVA

Secondary

Change From Baseline in Modified vdH-S Erosion Score at Week 24

Time frame: Baseline and Week 24

Population: Analysis population is FAS1-SD. Observed data were used regardless if 1 or more TF criteria were met. Missing data were assumed to be missing at random and imputed using multiple imputation.

Arm	Measure	Value (LEAST_SQUARES_MEAN)
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Modified vdH-S Erosion Score at Week 24	0.58 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Modified vdH-S Erosion Score at Week 24	0.36 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Modified vdH-S Erosion Score at Week 24	0.13 units on a scale

Secondary

Change From Baseline in Modified vdH-S Erosion Score at Week 52

Time frame: Baseline and Week 52

Population: FAS2 for structural damage (FAS2-SD) among all randomized participants who were continuing study treatment at Week 24. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure.

Arm	Measure	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Modified vdH-S Erosion Score at Week 52	0.92 units on a scale	Standard Deviation 2.497
Guselkumab 100 mg q8w	Change From Baseline in Modified vdH-S Erosion Score at Week 52	0.67 units on a scale	Standard Deviation 2.707
Guselkumab 100 mg q4w	Change From Baseline in Modified vdH-S Erosion Score at Week 52	0.70 units on a scale	Standard Deviation 2.631

Secondary

Change From Baseline in Modified vdH-S Joint Space Narrowing (JSN) Score at Week 24

The modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). The JSN score is the total JSN score in 40 joints of the two hands and 12 joints of the 2 feet. Each joint is scored from 0 to 4 with 0 indicating no JSN, and 4 indicating a complete loss of joint space, bony ankylosis, or complete luxation, for a maximum JSN score of 208. Higher score indicates more severe joint space narrowing. A positive change from baseline in the modified vdH-S JSN score indicates progression of joint space narrowing.

Time frame: Baseline and Week 24

Arm	Measure	Value (LEAST_SQUARES_MEAN)
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Modified vdH-S Joint Space Narrowing (JSN) Score at Week 24	0.37 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Modified vdH-S Joint Space Narrowing (JSN) Score at Week 24	0.16 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Modified vdH-S Joint Space Narrowing (JSN) Score at Week 24	0.16 units on a scale

Secondary

Change From Baseline in Modified vdH-S JSN Score at Week 52

Time frame: Baseline and Week 52

Arm	Measure	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Modified vdH-S JSN Score at Week 52	0.33 units on a scale	Standard Deviation 1.356
Guselkumab 100 mg q8w	Change From Baseline in Modified vdH-S JSN Score at Week 52	0.29 units on a scale	Standard Deviation 1.272
Guselkumab 100 mg q4w	Change From Baseline in Modified vdH-S JSN Score at Week 52	0.38 units on a scale	Standard Deviation 1.633

Secondary

Change From Baseline in Modified vdH-S Score at Week 52

Time frame: Baseline and Week 52

Arm	Measure	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Modified vdH-S Score at Week 52	1.25 units on a scale	Standard Deviation 3.508
Guselkumab 100 mg q8w	Change From Baseline in Modified vdH-S Score at Week 52	0.97 units on a scale	Standard Deviation 3.623
Guselkumab 100 mg q4w	Change From Baseline in Modified vdH-S Score at Week 52	1.07 units on a scale	Standard Deviation 3.843

Secondary

Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 24

Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand (Hand erosion score) scored according to 0 (no erosion) to 5 (complete collapse of bone) for a maximum hand erosion score of 200, and 12 joints of 2 feet (each side of the foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum foot erosion score of 120. Higher scores indicate more joint damage. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum Hand JSN score of 160 and maximum Foot JSN score of 48. Higher scores indicate more joint damage. Hand Score (sum of Hand Erosion Score and Hand JSN Score) scored as 0-360 and Foot score (sum of foot erosion score and foot JSN score) scored as 0-168. Higher scores indicate more joint damage.

Time frame: Baseline and Week 24

Population: Analysis population is FAS1-SD. Observed data were summarized regardless if 1 or more TF criteria were met. Here, 'n' (number analyzed) signifies the number of participants analyzed for a specified score.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 24	Hand Erosion Score	0.40 units on a scale	Standard Deviation 1.555
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 24	Hand JSN Score	0.26 units on a scale	Standard Deviation 1.106
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 24	Hand Score	0.66 units on a scale	Standard Deviation 2.441
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 24	Foot Erosion Score	0.14 units on a scale	Standard Deviation 0.801
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 24	Foot JSN Score	0.10 units on a scale	Standard Deviation 0.516
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 24	Foot Score	0.24 units on a scale	Standard Deviation 1.116
Guselkumab 100 mg q8w	Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 24	Foot Score	0.17 units on a scale	Standard Deviation 1.18
Guselkumab 100 mg q8w	Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 24	Hand Erosion Score	0.18 units on a scale	Standard Deviation 1.28
Guselkumab 100 mg q8w	Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 24	Foot Erosion Score	0.15 units on a scale	Standard Deviation 0.982
Guselkumab 100 mg q8w	Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 24	Foot JSN Score	0.02 units on a scale	Standard Deviation 0.516
Guselkumab 100 mg q8w	Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 24	Hand JSN Score	0.10 units on a scale	Standard Deviation 0.637
Guselkumab 100 mg q8w	Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 24	Hand Score	0.28 units on a scale	Standard Deviation 1.649
Guselkumab 100 mg q4w	Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 24	Hand JSN Score	0.08 units on a scale	Standard Deviation 0.607
Guselkumab 100 mg q4w	Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 24	Hand Score	0.05 units on a scale	Standard Deviation 1.881
Guselkumab 100 mg q4w	Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 24	Foot Score	0.21 units on a scale	Standard Deviation 1.21
Guselkumab 100 mg q4w	Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 24	Foot Erosion Score	0.14 units on a scale	Standard Deviation 0.894
Guselkumab 100 mg q4w	Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 24	Hand Erosion Score	-0.03 units on a scale	Standard Deviation 1.514
Guselkumab 100 mg q4w	Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 24	Foot JSN Score	0.07 units on a scale	Standard Deviation 0.632

Secondary

Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 52

Time frame: Baseline and Week 52

Population: FAS2 for structural damage (FAS2-SD) among all randomized participants who were continuing study treatment at Week 24. Here, 'n' (number analyzed) signifies the number of participants analyzed for a specified score.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 52	Hand Erosion Score	0.66 units on a scale	Standard Deviation 1.815
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 52	Hand JSN Score	0.29 units on a scale	Standard Deviation 1.181
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 52	Hand Score	0.95 units on a scale	Standard Deviation 2.706
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 52	Foot Erosion Score	0.26 units on a scale	Standard Deviation 1.014
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 52	Foot JSN Score	0.04 units on a scale	Standard Deviation 0.353
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 52	Foot Score	0.30 units on a scale	Standard Deviation 1.22
Guselkumab 100 mg q8w	Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 52	Foot Score	0.40 units on a scale	Standard Deviation 1.687
Guselkumab 100 mg q8w	Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 52	Hand Erosion Score	0.37 units on a scale	Standard Deviation 1.969
Guselkumab 100 mg q8w	Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 52	Foot Erosion Score	0.30 units on a scale	Standard Deviation 1.339
Guselkumab 100 mg q8w	Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 52	Foot JSN Score	0.10 units on a scale	Standard Deviation 0.66
Guselkumab 100 mg q8w	Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 52	Hand JSN Score	0.19 units on a scale	Standard Deviation 0.913
Guselkumab 100 mg q8w	Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 52	Hand Score	0.56 units on a scale	Standard Deviation 2.589
Guselkumab 100 mg q4w	Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 52	Hand JSN Score	0.22 units on a scale	Standard Deviation 1.235
Guselkumab 100 mg q4w	Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 52	Hand Score	0.57 units on a scale	Standard Deviation 2.759
Guselkumab 100 mg q4w	Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 52	Foot Score	0.50 units on a scale	Standard Deviation 1.939
Guselkumab 100 mg q4w	Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 52	Foot Erosion Score	0.34 units on a scale	Standard Deviation 1.413
Guselkumab 100 mg q4w	Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 52	Hand Erosion Score	0.35 units on a scale	Standard Deviation 1.83
Guselkumab 100 mg q4w	Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 52	Foot JSN Score	0.16 units on a scale	Standard Deviation 0.864

Secondary

Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales: physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health. The scores 0-100 (where higher scores indicated a better quality of life) from each subscale of SF-36 were normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better health status. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

Time frame: Baseline, Weeks 24 and 52

Population: Analysis population is FAS2. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 24: Bodily Pain Score	3.882 units on a scale	Standard Deviation 8.3009
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 52: Physical Function Score	7.722 units on a scale	Standard Deviation 8.948
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 24: Role-physical Score	3.695 units on a scale	Standard Deviation 7.595
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 52: Role-physical Score	6.560 units on a scale	Standard Deviation 8.5399
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 24: Physical Function Score	3.602 units on a scale	Standard Deviation 7.7388
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 52: Bodily Pain Score	8.460 units on a scale	Standard Deviation 8.4659
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 24: General Health Score	2.255 units on a scale	Standard Deviation 7.2176
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 52: General Health Score	6.396 units on a scale	Standard Deviation 8.5589
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 24: Vitality Score	4.224 units on a scale	Standard Deviation 9.0878
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 52: Vitality Score	7.879 units on a scale	Standard Deviation 9.416
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 24: Social Function Score	3.088 units on a scale	Standard Deviation 10.433
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 52: Social Function Score	6.278 units on a scale	Standard Deviation 10.9444
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 24: Role-emotional Score	1.910 units on a scale	Standard Deviation 10.0772
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 52: Role-emotional Score	4.057 units on a scale	Standard Deviation 10.8795
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 24: Mental Health Score	2.583 units on a scale	Standard Deviation 9.2222
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 52: Mental Health Score	5.153 units on a scale	Standard Deviation 10.0724
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 52: Bodily Pain Score	10.238 units on a scale	Standard Deviation 8.7185
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 24: General Health Score	5.963 units on a scale	Standard Deviation 7.8794
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 52: General Health Score	7.173 units on a scale	Standard Deviation 7.2703
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 52: Role-emotional Score	4.970 units on a scale	Standard Deviation 10.1685
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 24: Vitality Score	7.914 units on a scale	Standard Deviation 9.4638
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 52: Vitality Score	8.646 units on a scale	Standard Deviation 9.5131
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 52: Mental Health Score	4.829 units on a scale	Standard Deviation 9.3665
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 24: Social Function Score	6.551 units on a scale	Standard Deviation 9.7076
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 24: Physical Function Score	7.052 units on a scale	Standard Deviation 8.502
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 24: Mental Health Score	4.605 units on a scale	Standard Deviation 9.7905
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 52: Physical Function Score	8.489 units on a scale	Standard Deviation 8.8599
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 52: Social Function Score	7.199 units on a scale	Standard Deviation 10.1315
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 24: Role-physical Score	6.897 units on a scale	Standard Deviation 7.724
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 52: Role-physical Score	7.677 units on a scale	Standard Deviation 8.2995
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 24: Bodily Pain Score	8.333 units on a scale	Standard Deviation 8.3852
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 24: Role-emotional Score	4.535 units on a scale	Standard Deviation 10.1304
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 24: Social Function Score	5.892 units on a scale	Standard Deviation 8.551
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 52: Bodily Pain Score	9.457 units on a scale	Standard Deviation 9.7977
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 24: Role-emotional Score	4.107 units on a scale	Standard Deviation 8.9473
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 24: Role-physical Score	6.381 units on a scale	Standard Deviation 7.2203
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 24: General Health Score	5.067 units on a scale	Standard Deviation 7.4182
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 52: Mental Health Score	4.741 units on a scale	Standard Deviation 9.3825
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 24: Physical Function Score	6.772 units on a scale	Standard Deviation 7.592
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 52: General Health Score	6.366 units on a scale	Standard Deviation 8.4199
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 52: Social Function Score	6.787 units on a scale	Standard Deviation 9.5326
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 24: Bodily Pain Score	7.833 units on a scale	Standard Deviation 7.339
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 24: Vitality Score	6.970 units on a scale	Standard Deviation 9.4889
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 52: Role-emotional Score	4.607 units on a scale	Standard Deviation 8.7627
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 52: Physical Function Score	8.374 units on a scale	Standard Deviation 8.7884
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 52: Vitality Score	7.654 units on a scale	Standard Deviation 9.3905
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 52: Role-physical Score	7.344 units on a scale	Standard Deviation 7.7145
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52	Week 24: Mental Health Score	4.752 units on a scale	Standard Deviation 8.9336

Secondary

Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100

Time frame: Baseline, Weeks 52, 76 and 100

Population: Analysis population is FAS3. Here, n (number analyzed) signifies the number of participants analyzed for specified categories at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 100: Role-emotional Score	4.784 units on a scale	Standard Deviation 11.9482
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 100: Role-physical Score	9.181 units on a scale	Standard Deviation 8.6596
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 100: Social Function Score	7.825 units on a scale	Standard Deviation 10.8558
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 52: Role-emotional Score	4.111 units on a scale	Standard Deviation 10.9413
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 76: Role-emotional Score	5.199 units on a scale	Standard Deviation 11.1875
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 52: Bodily Pain Score	8.536 units on a scale	Standard Deviation 8.4602
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 76: Social Function Score	7.509 units on a scale	Standard Deviation 10.4249
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 52: Mental Health Score	5.209 units on a scale	Standard Deviation 10.0958
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 100: Physical Function Score	9.738 units on a scale	Standard Deviation 9.8405
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 76: Mental Health Score	5.481 units on a scale	Standard Deviation 10.5927
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 76: Bodily Pain Score	10.368 units on a scale	Standard Deviation 9.1058
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 100: Mental Health Score	5.514 units on a scale	Standard Deviation 10.6204
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 100: Bodily Pain Score	10.696 units on a scale	Standard Deviation 9.3854
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 52: General Health Score	6.533 units on a scale	Standard Deviation 8.5245
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 52: Physical Function Score	7.757 units on a scale	Standard Deviation 8.9727
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 76: General Health Score	7.203 units on a scale	Standard Deviation 8.3372
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 52: Role-physical Score	6.538 units on a scale	Standard Deviation 8.5151
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 100: General Health Score	6.710 units on a scale	Standard Deviation 8.7265
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 52: Vitality Score	7.997 units on a scale	Standard Deviation 9.3878
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 76: Physical Function Score	8.824 units on a scale	Standard Deviation 9.6648
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 76: Vitality Score	8.859 units on a scale	Standard Deviation 9.4372
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 76: Role-physical Score	8.372 units on a scale	Standard Deviation 8.7202
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 100: Vitality Score	9.648 units on a scale	Standard Deviation 9.4778
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 52: Social Function Score	6.361 units on a scale	Standard Deviation 10.9927
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 52: Social Function Score	7.304 units on a scale	Standard Deviation 10.1003
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 76: Social Function Score	8.623 units on a scale	Standard Deviation 9.5176
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 100: Bodily Pain Score	11.585 units on a scale	Standard Deviation 10.3527
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 100: Physical Function Score	10.953 units on a scale	Standard Deviation 9.7761
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 100: Social Function Score	8.080 units on a scale	Standard Deviation 9.5383
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 100: Role-physical Score	9.342 units on a scale	Standard Deviation 9.1746
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 52: Vitality Score	8.695 units on a scale	Standard Deviation 9.5033
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 52: Role-emotional Score	4.998 units on a scale	Standard Deviation 10.1964
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 52: Physical Function Score	8.406 units on a scale	Standard Deviation 8.8407
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 52: General Health Score	7.097 units on a scale	Standard Deviation 7.25
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 76: Role-emotional Score	5.757 units on a scale	Standard Deviation 10.0737
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 100: Vitality Score	9.827 units on a scale	Standard Deviation 9.9348
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 76: Role-physical Score	9.171 units on a scale	Standard Deviation 8.5844
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 100: Role-emotional Score	5.720 units on a scale	Standard Deviation 10.1991
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 52: Bodily Pain Score	10.201 units on a scale	Standard Deviation 8.7312
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 76: General Health Score	7.470 units on a scale	Standard Deviation 7.6119
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 52: Mental Health Score	4.826 units on a scale	Standard Deviation 9.4038
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 76: Vitality Score	9.388 units on a scale	Standard Deviation 9.8618
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 76: Physical Function Score	9.807 units on a scale	Standard Deviation 9.5044
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 76: Mental Health Score	5.430 units on a scale	Standard Deviation 10.0802
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 100: General Health Score	7.066 units on a scale	Standard Deviation 7.5829
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 52: Role-physical Score	7.665 units on a scale	Standard Deviation 8.2925
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 100: Mental Health Score	5.477 units on a scale	Standard Deviation 10.1202
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 76: Bodily Pain Score	11.552 units on a scale	Standard Deviation 9.8591
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 100: Mental Health Score	6.148 units on a scale	Standard Deviation 8.8743
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 52: Physical Function Score	8.493 units on a scale	Standard Deviation 8.7691
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 76: Physical Function Score	9.294 units on a scale	Standard Deviation 8.202
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 100: Physical Function Score	10.126 units on a scale	Standard Deviation 8.9271
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 52: Role-physical Score	7.372 units on a scale	Standard Deviation 7.7581
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 76: Role-physical Score	8.579 units on a scale	Standard Deviation 7.6709
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 100: Role-physical Score	8.921 units on a scale	Standard Deviation 8.1775
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 52: Bodily Pain Score	9.525 units on a scale	Standard Deviation 9.8357
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 100: Bodily Pain Score	10.998 units on a scale	Standard Deviation 8.923
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 52: General Health Score	6.450 units on a scale	Standard Deviation 8.4316
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 76: General Health Score	6.761 units on a scale	Standard Deviation 7.9631
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 100: General Health Score	7.132 units on a scale	Standard Deviation 8.4887
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 52: Vitality Score	7.637 units on a scale	Standard Deviation 9.4393
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 76: Vitality Score	8.659 units on a scale	Standard Deviation 9.6026
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 100: Vitality Score	9.155 units on a scale	Standard Deviation 9.3569
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 52: Social Function Score	6.810 units on a scale	Standard Deviation 9.5118
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 76: Social Function Score	7.914 units on a scale	Standard Deviation 9.5191
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 100: Social Function Score	8.113 units on a scale	Standard Deviation 9.4847
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 52: Role-emotional Score	4.699 units on a scale	Standard Deviation 8.7759
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 76: Role-emotional Score	5.433 units on a scale	Standard Deviation 9.2389
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 100: Role-emotional Score	5.128 units on a scale	Standard Deviation 9.7998
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 52: Mental Health Score	4.839 units on a scale	Standard Deviation 9.4029
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 76: Mental Health Score	6.124 units on a scale	Standard Deviation 8.793
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100	Week 76: Bodily Pain Score	10.300 units on a scale	Standard Deviation 9.0504

Secondary

Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24

Time frame: Baseline and Weeks 8, 16 and 24

Population: Analysis population is FAS1. Data after meeting one or more TF criteria were imputed as no change from baseline. Missing data were assumed to be MAR. The LS mean is based on MMRM model that included data from all visits for all participants included in the model.

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 8: Physical Function Score	2.095 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 24: Bodily Pain Score	3.482 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 8: Bodily Pain Score	2.760 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 24: Physical Function Score	3.254 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 8: General Health Score	1.662 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 24: Role-emotional Score	1.813 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 24: Role-physical Score	3.365 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 16: General Health Score	2.520 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 8: Mental Health Score	1.081 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 8: Role-emotional Score	1.108 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 24: General Health Score	2.290 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 24: Social Function Score	2.978 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 8: Role-physical Score	2.619 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 8: Vitality Score	2.505 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 16: Mental Health Score	2.195 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 16: Physical Function Score	2.581 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 16: Vitality Score	3.554 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 16: Bodily Pain Score	3.086 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 24: Mental Health Score	2.335 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 24: Vitality Score	3.835 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 16: Role-emotional Score	1.530 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 16: Role-physical Score	2.965 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 8: Social Function Score	1.929 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 16: Social Function Score	2.884 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 8: Social Function Score	3.337 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 16: Social Function Score	5.584 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 24: Social Function Score	5.806 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 24: Role-physical Score	6.549 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 8: Role-emotional Score	2.459 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 16: Role-emotional Score	4.497 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 8: Bodily Pain Score	5.456 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 8: Mental Health Score	2.380 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 16: Physical Function Score	6.124 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 16: Mental Health Score	4.529 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 24: Mental Health Score	4.490 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 16: Bodily Pain Score	7.485 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 24: Bodily Pain Score	7.811 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 8: General Health Score	4.111 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 24: Physical Function Score	6.703 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 16: General Health Score	5.719 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 8: Physical Function Score	3.879 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 24: General Health Score	5.794 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 8: Vitality Score	4.286 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 8: Role-physical Score	3.599 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 16: Vitality Score	6.967 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 24: Role-emotional Score	4.382 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 24: Vitality Score	7.373 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 16: Role-physical Score	5.616 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 24: Mental Health Score	4.767 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 8: Physical Function Score	3.936 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 16: Physical Function Score	5.618 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 24: Physical Function Score	6.624 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 8: Role-physical Score	3.107 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 24: Role-physical Score	6.241 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 8: Bodily Pain Score	4.901 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 16: Bodily Pain Score	6.613 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 24: Bodily Pain Score	7.739 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 8: General Health Score	4.174 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 16: General Health Score	4.808 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 24: General Health Score	5.269 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 8: Vitality Score	4.669 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 16: Vitality Score	5.901 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 24: Vitality Score	7.009 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 8: Social Function Score	4.306 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 16: Social Function Score	5.022 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 24: Social Function Score	5.922 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 8: Role-emotional Score	2.294 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 16: Role-emotional Score	3.596 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 24: Role-emotional Score	4.255 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 8: Mental Health Score	3.048 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 16: Mental Health Score	3.896 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24	Week 16: Role-physical Score	4.942 units on a scale

Secondary

Change From Baseline in PASDAS Score at Weeks 52, 76 and 100

PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a composite score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0= 0 sites with tenderness to 6= worst possible score; 6 sites with tenderness), tender dactylitis count (scoring each digit from 0-3 \[where 0= no tenderness and 3= extreme tenderness\] and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score with score range 0-100 (higher score-better quality of life) of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.

Time frame: Baseline, Weeks 52, 76 and 100

Population: Analysis population is FAS3 which included all participants still on treatment at Week 52. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in PASDAS Score at Weeks 52, 76 and 100	Week 76	-3.503 units on a scale	Standard Deviation 1.4708
Placebo to Guselkumab 100 mg q4w	Change From Baseline in PASDAS Score at Weeks 52, 76 and 100	Week 52	-3.054 units on a scale	Standard Deviation 1.4954
Placebo to Guselkumab 100 mg q4w	Change From Baseline in PASDAS Score at Weeks 52, 76 and 100	Week 100	-3.574 units on a scale	Standard Deviation 1.4785
Guselkumab 100 mg q8w	Change From Baseline in PASDAS Score at Weeks 52, 76 and 100	Week 76	-3.418 units on a scale	Standard Deviation 1.5646
Guselkumab 100 mg q8w	Change From Baseline in PASDAS Score at Weeks 52, 76 and 100	Week 52	-3.189 units on a scale	Standard Deviation 1.5216
Guselkumab 100 mg q8w	Change From Baseline in PASDAS Score at Weeks 52, 76 and 100	Week 100	-3.586 units on a scale	Standard Deviation 1.5425
Guselkumab 100 mg q4w	Change From Baseline in PASDAS Score at Weeks 52, 76 and 100	Week 52	-3.184 units on a scale	Standard Deviation 1.4576
Guselkumab 100 mg q4w	Change From Baseline in PASDAS Score at Weeks 52, 76 and 100	Week 100	-3.549 units on a scale	Standard Deviation 1.4635
Guselkumab 100 mg q4w	Change From Baseline in PASDAS Score at Weeks 52, 76 and 100	Week 76	-3.436 units on a scale	Standard Deviation 1.4428

Secondary

Change From Baseline in PASI Score at Weeks 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. Negative change from baseline indicates improvement of psoriasis.

Time frame: Baseline, Weeks 16 and 24

Population: FAS1 among participants who had \>=3% BSA of psoriatic involvement and IGA score \>=2 (mild) at baseline. Data after meeting one or more TF criteria were imputed as no change from baseline. Missing data were assumed to be MAR. The LS mean is based on MMRM model that included data from all visits for all participants included in the model.

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)
Placebo to Guselkumab 100 mg q4w	Change From Baseline in PASI Score at Weeks 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 16	-3.482 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in PASI Score at Weeks 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	-3.904 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in PASI Score at Weeks 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 16	-11.151 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in PASI Score at Weeks 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	-11.407 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in PASI Score at Weeks 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 16	-11.278 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in PASI Score at Weeks 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	-11.471 units on a scale

Secondary

Change From Baseline in PASI Score at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

Time frame: Baseline, Weeks 24 and 52

Population: Analysis population is FAS2 among the participants who had \>=3% BSA of psoriatic involvement and an IGA score \>=2 (mild) at baseline. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in PASI Score at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	-2.989 units on a scale	Standard Deviation 6.1515
Placebo to Guselkumab 100 mg q4w	Change From Baseline in PASI Score at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	-11.016 units on a scale	Standard Deviation 9.9801
Guselkumab 100 mg q8w	Change From Baseline in PASI Score at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	-11.685 units on a scale	Standard Deviation 12.3496
Guselkumab 100 mg q8w	Change From Baseline in PASI Score at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	-11.977 units on a scale	Standard Deviation 12.0847
Guselkumab 100 mg q4w	Change From Baseline in PASI Score at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	-12.574 units on a scale	Standard Deviation 11.8391
Guselkumab 100 mg q4w	Change From Baseline in PASI Score at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	-12.857 units on a scale	Standard Deviation 11.3052

Secondary

Change From Baseline in PASI Score at Weeks 52, 76 and 100 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

Time frame: Baseline, Weeks 52, 76 and 100

Population: Analysis population is FAS3 among participants with \>=3% BSA Psoriatic Involvement and an IGA Score of \>=2 (mild) at baseline. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in PASI Score at Weeks 52, 76 and 100 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 76	-11.313 units on a scale	Standard Deviation 10.0631
Placebo to Guselkumab 100 mg q4w	Change From Baseline in PASI Score at Weeks 52, 76 and 100 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	-11.030 units on a scale	Standard Deviation 10.0077
Placebo to Guselkumab 100 mg q4w	Change From Baseline in PASI Score at Weeks 52, 76 and 100 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 100	-11.089 units on a scale	Standard Deviation 10.0239
Guselkumab 100 mg q8w	Change From Baseline in PASI Score at Weeks 52, 76 and 100 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 76	-11.991 units on a scale	Standard Deviation 12.2656
Guselkumab 100 mg q8w	Change From Baseline in PASI Score at Weeks 52, 76 and 100 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	-11.991 units on a scale	Standard Deviation 12.1194
Guselkumab 100 mg q8w	Change From Baseline in PASI Score at Weeks 52, 76 and 100 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 100	-12.101 units on a scale	Standard Deviation 12.1322
Guselkumab 100 mg q4w	Change From Baseline in PASI Score at Weeks 52, 76 and 100 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	-12.875 units on a scale	Standard Deviation 11.2905
Guselkumab 100 mg q4w	Change From Baseline in PASI Score at Weeks 52, 76 and 100 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 100	-13.274 units on a scale	Standard Deviation 11.9673
Guselkumab 100 mg q4w	Change From Baseline in PASI Score at Weeks 52, 76 and 100 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 76	-13.242 units on a scale	Standard Deviation 11.8845

Secondary

Change From Baseline in Psoriatic Arthritis Disease Activity (PASDAS) Score at Weeks 24 and 52

Time frame: Baseline, Weeks 24 and 52

Population: Analysis population is FAS2. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Psoriatic Arthritis Disease Activity (PASDAS) Score at Weeks 24 and 52	Week 24	-1.399 units on a scale	Standard Deviation 1.3169
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Psoriatic Arthritis Disease Activity (PASDAS) Score at Weeks 24 and 52	Week 52	-3.041 units on a scale	Standard Deviation 1.4979
Guselkumab 100 mg q8w	Change From Baseline in Psoriatic Arthritis Disease Activity (PASDAS) Score at Weeks 24 and 52	Week 24	-2.496 units on a scale	Standard Deviation 1.5024
Guselkumab 100 mg q8w	Change From Baseline in Psoriatic Arthritis Disease Activity (PASDAS) Score at Weeks 24 and 52	Week 52	-3.197 units on a scale	Standard Deviation 1.5212
Guselkumab 100 mg q4w	Change From Baseline in Psoriatic Arthritis Disease Activity (PASDAS) Score at Weeks 24 and 52	Week 24	-2.506 units on a scale	Standard Deviation 1.2578
Guselkumab 100 mg q4w	Change From Baseline in Psoriatic Arthritis Disease Activity (PASDAS) Score at Weeks 24 and 52	Week 52	-3.161 units on a scale	Standard Deviation 1.4646

Secondary

Change From Baseline in SF-36 MCS Score at Weeks 24 and 52

Time frame: Baseline, Weeks 24 and 52

Population: Analysis population is FAS2. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in SF-36 MCS Score at Weeks 24 and 52	Week 24	2.211 units on a scale	Standard Deviation 10.1368
Placebo to Guselkumab 100 mg q4w	Change From Baseline in SF-36 MCS Score at Weeks 24 and 52	Week 52	4.297 units on a scale	Standard Deviation 10.896
Guselkumab 100 mg q8w	Change From Baseline in SF-36 MCS Score at Weeks 24 and 52	Week 24	4.452 units on a scale	Standard Deviation 9.956
Guselkumab 100 mg q8w	Change From Baseline in SF-36 MCS Score at Weeks 24 and 52	Week 52	4.465 units on a scale	Standard Deviation 9.778
Guselkumab 100 mg q4w	Change From Baseline in SF-36 MCS Score at Weeks 24 and 52	Week 52	4.076 units on a scale	Standard Deviation 9.1101
Guselkumab 100 mg q4w	Change From Baseline in SF-36 MCS Score at Weeks 24 and 52	Week 24	4.128 units on a scale	Standard Deviation 9.1814

Secondary

Change From Baseline in SF-36 MCS Score at Weeks 52, 76 and 100

Time frame: Baseline, Weeks 52, 76 and 100

Population: Analysis population is FAS3. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in SF-36 MCS Score at Weeks 52, 76 and 100	Week 76	4.838 units on a scale	Standard Deviation 11.0526
Placebo to Guselkumab 100 mg q4w	Change From Baseline in SF-36 MCS Score at Weeks 52, 76 and 100	Week 52	4.383 units on a scale	Standard Deviation 10.9402
Placebo to Guselkumab 100 mg q4w	Change From Baseline in SF-36 MCS Score at Weeks 52, 76 and 100	Week 100	4.610 units on a scale	Standard Deviation 11.2527
Guselkumab 100 mg q8w	Change From Baseline in SF-36 MCS Score at Weeks 52, 76 and 100	Week 76	5.034 units on a scale	Standard Deviation 10.0334
Guselkumab 100 mg q8w	Change From Baseline in SF-36 MCS Score at Weeks 52, 76 and 100	Week 52	4.540 units on a scale	Standard Deviation 9.7848
Guselkumab 100 mg q8w	Change From Baseline in SF-36 MCS Score at Weeks 52, 76 and 100	Week 100	4.718 units on a scale	Standard Deviation 9.9014
Guselkumab 100 mg q4w	Change From Baseline in SF-36 MCS Score at Weeks 52, 76 and 100	Week 52	4.127 units on a scale	Standard Deviation 9.1368
Guselkumab 100 mg q4w	Change From Baseline in SF-36 MCS Score at Weeks 52, 76 and 100	Week 100	4.936 units on a scale	Standard Deviation 9.5935
Guselkumab 100 mg q4w	Change From Baseline in SF-36 MCS Score at Weeks 52, 76 and 100	Week 76	5.194 units on a scale	Standard Deviation 9.4899

Secondary

Change From Baseline in SF-36 MCS Score at Weeks 8, 16 and 24

Time frame: Baseline, Weeks 8, 16 and 24

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)
Placebo to Guselkumab 100 mg q4w	Change From Baseline in SF-36 MCS Score at Weeks 8, 16 and 24	Week 16	1.96 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in SF-36 MCS Score at Weeks 8, 16 and 24	Week 8	1.11 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in SF-36 MCS Score at Weeks 8, 16 and 24	Week 24	2.14 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in SF-36 MCS Score at Weeks 8, 16 and 24	Week 16	4.28 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in SF-36 MCS Score at Weeks 8, 16 and 24	Week 8	2.28 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in SF-36 MCS Score at Weeks 8, 16 and 24	Week 24	4.17 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in SF-36 MCS Score at Weeks 8, 16 and 24	Week 8	2.87 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in SF-36 MCS Score at Weeks 8, 16 and 24	Week 24	4.22 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in SF-36 MCS Score at Weeks 8, 16 and 24	Week 16	3.41 units on a scale

Secondary

Change From Baseline in SF-36 PCS Score at Weeks 24 and 52

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

Time frame: Baseline, Weeks 24 and 52

Population: Analysis population is FAS2. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in SF-36 PCS Score at Weeks 24 and 52	Week 24	3.782 units on a scale	Standard Deviation 7.1776
Placebo to Guselkumab 100 mg q4w	Change From Baseline in SF-36 PCS Score at Weeks 24 and 52	Week 52	8.124 units on a scale	Standard Deviation 8.2192
Guselkumab 100 mg q8w	Change From Baseline in SF-36 PCS Score at Weeks 24 and 52	Week 24	7.838 units on a scale	Standard Deviation 8.0335
Guselkumab 100 mg q8w	Change From Baseline in SF-36 PCS Score at Weeks 24 and 52	Week 52	9.511 units on a scale	Standard Deviation 8.3176
Guselkumab 100 mg q4w	Change From Baseline in SF-36 PCS Score at Weeks 24 and 52	Week 24	7.183 units on a scale	Standard Deviation 6.9793
Guselkumab 100 mg q4w	Change From Baseline in SF-36 PCS Score at Weeks 24 and 52	Week 52	8.960 units on a scale	Standard Deviation 8.5891

Secondary

Change From Baseline in SF-36 PCS Score at Weeks 52, 76 and 100

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

Time frame: Baseline, Weeks 52, 76 and 100

Population: Analysis population is FAS3. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in SF-36 PCS Score at Weeks 52, 76 and 100	Week 76	9.762 units on a scale	Standard Deviation 8.5908
Placebo to Guselkumab 100 mg q4w	Change From Baseline in SF-36 PCS Score at Weeks 52, 76 and 100	Week 52	8.170 units on a scale	Standard Deviation 8.2195
Placebo to Guselkumab 100 mg q4w	Change From Baseline in SF-36 PCS Score at Weeks 52, 76 and 100	Week 100	10.508 units on a scale	Standard Deviation 8.6819
Guselkumab 100 mg q8w	Change From Baseline in SF-36 PCS Score at Weeks 52, 76 and 100	Week 76	10.814 units on a scale	Standard Deviation 9.029
Guselkumab 100 mg q8w	Change From Baseline in SF-36 PCS Score at Weeks 52, 76 and 100	Week 52	9.438 units on a scale	Standard Deviation 8.2854
Guselkumab 100 mg q8w	Change From Baseline in SF-36 PCS Score at Weeks 52, 76 and 100	Week 100	11.282 units on a scale	Standard Deviation 9.2753
Guselkumab 100 mg q4w	Change From Baseline in SF-36 PCS Score at Weeks 52, 76 and 100	Week 52	9.023 units on a scale	Standard Deviation 8.6263
Guselkumab 100 mg q4w	Change From Baseline in SF-36 PCS Score at Weeks 52, 76 and 100	Week 100	10.559 units on a scale	Standard Deviation 8.7449
Guselkumab 100 mg q4w	Change From Baseline in SF-36 PCS Score at Weeks 52, 76 and 100	Week 76	9.707 units on a scale	Standard Deviation 8.501

Secondary

Change From Baseline in SF-36 PCS Score at Weeks 8, 16 and 24

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

Time frame: Baseline, Weeks 8, 16 and 24

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)
Placebo to Guselkumab 100 mg q4w	Change From Baseline in SF-36 PCS Score at Weeks 8, 16 and 24	Week 16	3.03 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in SF-36 PCS Score at Weeks 8, 16 and 24	Week 8	2.75 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in SF-36 PCS Score at Weeks 8, 16 and 24	Week 24	3.42 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in SF-36 PCS Score at Weeks 8, 16 and 24	Week 16	6.65 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in SF-36 PCS Score at Weeks 8, 16 and 24	Week 8	4.83 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in SF-36 PCS Score at Weeks 8, 16 and 24	Week 24	7.39 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in SF-36 PCS Score at Weeks 8, 16 and 24	Week 8	4.34 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in SF-36 PCS Score at Weeks 8, 16 and 24	Week 24	7.04 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in SF-36 PCS Score at Weeks 8, 16 and 24	Week 16	5.93 units on a scale

Secondary

Change From Baseline in the Disease Activity Index for Psoriatic Arthritis (DAPSA) Score at Weeks 24, 28, 36, 44 and 52

DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL), patient assessment of pain (0-10cm VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. The assessment does not have a score range with an upper or lower bound.

Time frame: Baseline, Weeks 24, 28, 36, 44 and 52

Population: Analysis population is FAS2. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in the Disease Activity Index for Psoriatic Arthritis (DAPSA) Score at Weeks 24, 28, 36, 44 and 52	Week 44	-30.754 units on a scale	Standard Deviation 18.5016
Placebo to Guselkumab 100 mg q4w	Change From Baseline in the Disease Activity Index for Psoriatic Arthritis (DAPSA) Score at Weeks 24, 28, 36, 44 and 52	Week 52	-31.209 units on a scale	Standard Deviation 18.9981
Placebo to Guselkumab 100 mg q4w	Change From Baseline in the Disease Activity Index for Psoriatic Arthritis (DAPSA) Score at Weeks 24, 28, 36, 44 and 52	Week 28	-22.199 units on a scale	Standard Deviation 17.9394
Placebo to Guselkumab 100 mg q4w	Change From Baseline in the Disease Activity Index for Psoriatic Arthritis (DAPSA) Score at Weeks 24, 28, 36, 44 and 52	Week 36	-29.251 units on a scale	Standard Deviation 18.1137
Placebo to Guselkumab 100 mg q4w	Change From Baseline in the Disease Activity Index for Psoriatic Arthritis (DAPSA) Score at Weeks 24, 28, 36, 44 and 52	Week 24	-16.377 units on a scale	Standard Deviation 19.1814
Guselkumab 100 mg q8w	Change From Baseline in the Disease Activity Index for Psoriatic Arthritis (DAPSA) Score at Weeks 24, 28, 36, 44 and 52	Week 28	-26.573 units on a scale	Standard Deviation 15.5254
Guselkumab 100 mg q8w	Change From Baseline in the Disease Activity Index for Psoriatic Arthritis (DAPSA) Score at Weeks 24, 28, 36, 44 and 52	Week 44	-30.108 units on a scale	Standard Deviation 16.6013
Guselkumab 100 mg q8w	Change From Baseline in the Disease Activity Index for Psoriatic Arthritis (DAPSA) Score at Weeks 24, 28, 36, 44 and 52	Week 24	-24.718 units on a scale	Standard Deviation 16.7967
Guselkumab 100 mg q8w	Change From Baseline in the Disease Activity Index for Psoriatic Arthritis (DAPSA) Score at Weeks 24, 28, 36, 44 and 52	Week 52	-30.512 units on a scale	Standard Deviation 17.5074
Guselkumab 100 mg q8w	Change From Baseline in the Disease Activity Index for Psoriatic Arthritis (DAPSA) Score at Weeks 24, 28, 36, 44 and 52	Week 36	-28.889 units on a scale	Standard Deviation 16.4372
Guselkumab 100 mg q4w	Change From Baseline in the Disease Activity Index for Psoriatic Arthritis (DAPSA) Score at Weeks 24, 28, 36, 44 and 52	Week 52	-32.282 units on a scale	Standard Deviation 16.632
Guselkumab 100 mg q4w	Change From Baseline in the Disease Activity Index for Psoriatic Arthritis (DAPSA) Score at Weeks 24, 28, 36, 44 and 52	Week 24	-26.578 units on a scale	Standard Deviation 15.3393
Guselkumab 100 mg q4w	Change From Baseline in the Disease Activity Index for Psoriatic Arthritis (DAPSA) Score at Weeks 24, 28, 36, 44 and 52	Week 28	-29.613 units on a scale	Standard Deviation 17.6129
Guselkumab 100 mg q4w	Change From Baseline in the Disease Activity Index for Psoriatic Arthritis (DAPSA) Score at Weeks 24, 28, 36, 44 and 52	Week 36	-31.782 units on a scale	Standard Deviation 16.7698
Guselkumab 100 mg q4w	Change From Baseline in the Disease Activity Index for Psoriatic Arthritis (DAPSA) Score at Weeks 24, 28, 36, 44 and 52	Week 44	-32.126 units on a scale	Standard Deviation 15.7605

Secondary

Change From Baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 8, 16 and 24

Time frame: Baseline, Weeks 8, 16 and 24

Population: Analysis population is FAS1. Data after meeting 1 or more TF criteria were imputed as no change from baseline. Missing data were assumed missing at random. The LS mean is based on Mixed-effect repeated measures (MMRM) model that included data from all visits for all participants included in the model.

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)
Placebo to Guselkumab 100 mg q4w	Change From Baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 8, 16 and 24	Week 16	-1.158 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 8, 16 and 24	Week 8	-0.863 units on a scale
Placebo to Guselkumab 100 mg q4w	Change From Baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 8, 16 and 24	Week 24	-1.336 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 8, 16 and 24	Week 16	-2.110 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 8, 16 and 24	Week 8	-1.452 units on a scale
Guselkumab 100 mg q8w	Change From Baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 8, 16 and 24	Week 24	-2.403 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 8, 16 and 24	Week 8	-1.413 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 8, 16 and 24	Week 24	-2.399 units on a scale
Guselkumab 100 mg q4w	Change From Baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 8, 16 and 24	Week 16	-1.994 units on a scale

Secondary

Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Activity Impairment Outside of Work ) at Weeks 16 and 24

Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAI-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.

Time frame: Baseline, Weeks 16 and 24

Population: Analysis population is FAS1. Data after meeting 1/more TF criteria imputed as no change from baseline. Missing data assumed MAR. LS mean is based on MMRM model that included data from all visits for all participants included in model. Here, N (number of participants analyzed) signifies number of participants evaluable for this outcome measure.

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Activity Impairment Outside of Work ) at Weeks 16 and 24	Week 16	-10.569 percentage of activity impairment
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Activity Impairment Outside of Work ) at Weeks 16 and 24	Week 24	-10.320 percentage of activity impairment
Guselkumab 100 mg q8w	Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Activity Impairment Outside of Work ) at Weeks 16 and 24	Week 16	-17.107 percentage of activity impairment
Guselkumab 100 mg q8w	Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Activity Impairment Outside of Work ) at Weeks 16 and 24	Week 24	-21.467 percentage of activity impairment
Guselkumab 100 mg q4w	Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Activity Impairment Outside of Work ) at Weeks 16 and 24	Week 16	-17.029 percentage of activity impairment
Guselkumab 100 mg q4w	Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Activity Impairment Outside of Work ) at Weeks 16 and 24	Week 24	-20.480 percentage of activity impairment

Secondary

Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Impairment While Working) at Weeks 16 and 24

Time frame: Baseline, Weeks 16 and 24

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Impairment While Working) at Weeks 16 and 24	Week 16	-10.281 percentage of impairment
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Impairment While Working) at Weeks 16 and 24	Week 24	-10.157 percentage of impairment
Guselkumab 100 mg q8w	Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Impairment While Working) at Weeks 16 and 24	Week 16	-16.054 percentage of impairment
Guselkumab 100 mg q8w	Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Impairment While Working) at Weeks 16 and 24	Week 24	-19.366 percentage of impairment
Guselkumab 100 mg q4w	Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Impairment While Working) at Weeks 16 and 24	Week 16	-15.083 percentage of impairment
Guselkumab 100 mg q4w	Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Impairment While Working) at Weeks 16 and 24	Week 24	-19.492 percentage of impairment

Secondary

Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Overall Work Impairment) at Weeks 16 and 24

Work Productivity and Activity Impairment was assessed using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) of PsA (WPAi-PsA). The WPAI-PsA consisted of 6 questions to determine employment status, hours missed from work due to PsA, hours missed from work for other reasons, hours actually worked, the degree to which PsA affected work productivity while at work and the degree to which PsA affected activities outside of work during the past 7 days. WPAI outcomes included percent work time missed due to PsA, percent impairment while working due to PsA, percent overall work impairment due to PsA, and percent activity impairment outside of work due to PsA. These WPAI outcomes were expressed as impairment percentages (0-100, 0=no impairment and 100=100% impaired), with higher numbers indicating greater impairment and less productivity. Negative changes from baseline indicate improvement of work productivity and activity impairment.

Time frame: Baseline, Weeks 16 and 24

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Overall Work Impairment) at Weeks 16 and 24	Week 16	-11.232 percentage of overall work impairment
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Overall Work Impairment) at Weeks 16 and 24	Week 24	-10.869 percentage of overall work impairment
Guselkumab 100 mg q8w	Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Overall Work Impairment) at Weeks 16 and 24	Week 16	-15.926 percentage of overall work impairment
Guselkumab 100 mg q8w	Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Overall Work Impairment) at Weeks 16 and 24	Week 24	-19.711 percentage of overall work impairment
Guselkumab 100 mg q4w	Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Overall Work Impairment) at Weeks 16 and 24	Week 16	-15.808 percentage of overall work impairment
Guselkumab 100 mg q4w	Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Overall Work Impairment) at Weeks 16 and 24	Week 24	-20.023 percentage of overall work impairment

Secondary

Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Work Time Missed) at Weeks 16 and 24

Time frame: Baseline, Weeks 16 and 24

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Work Time Missed) at Weeks 16 and 24	Week 16	-4.553 percentage of work time missed
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Work Time Missed) at Weeks 16 and 24	Week 24	-3.491 percentage of work time missed
Guselkumab 100 mg q8w	Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Work Time Missed) at Weeks 16 and 24	Week 16	-3.451 percentage of work time missed
Guselkumab 100 mg q8w	Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Work Time Missed) at Weeks 16 and 24	Week 24	-3.103 percentage of work time missed
Guselkumab 100 mg q4w	Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Work Time Missed) at Weeks 16 and 24	Week 16	-4.717 percentage of work time missed
Guselkumab 100 mg q4w	Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Work Time Missed) at Weeks 16 and 24	Week 24	-3.827 percentage of work time missed

Secondary

Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire Scores (Percent Work Time Missed) at Weeks 24 and 52

Time frame: Baseline, Weeks 24 and 52

Population: Analysis population is FAS2. Here, N (number of participants analyzed) signifies number of participants evaluable for this outcome measure. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire Scores (Percent Work Time Missed) at Weeks 24 and 52	Week 24	-5.64 units on a scale	Standard Deviation 28.355
Placebo to Guselkumab 100 mg q4w	Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire Scores (Percent Work Time Missed) at Weeks 24 and 52	Week 52	-5.37 units on a scale	Standard Deviation 25.365
Guselkumab 100 mg q8w	Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire Scores (Percent Work Time Missed) at Weeks 24 and 52	Week 24	-3.77 units on a scale	Standard Deviation 28.029
Guselkumab 100 mg q8w	Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire Scores (Percent Work Time Missed) at Weeks 24 and 52	Week 52	-4.47 units on a scale	Standard Deviation 20.454
Guselkumab 100 mg q4w	Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire Scores (Percent Work Time Missed) at Weeks 24 and 52	Week 24	-1.20 units on a scale	Standard Deviation 17.127
Guselkumab 100 mg q4w	Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire Scores (Percent Work Time Missed) at Weeks 24 and 52	Week 52	-1.74 units on a scale	Standard Deviation 17.084

Secondary

Change From Baseline in WPAI Scores (Percent Activity Impairment Outside of Work) at Weeks 24 and 52

Time frame: Baseline, Weeks 24 and 52

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in WPAI Scores (Percent Activity Impairment Outside of Work) at Weeks 24 and 52	Week 24	-10.80 units on a scale	Standard Deviation 26.131
Placebo to Guselkumab 100 mg q4w	Change From Baseline in WPAI Scores (Percent Activity Impairment Outside of Work) at Weeks 24 and 52	Week 52	-24.13 units on a scale	Standard Deviation 27.436
Guselkumab 100 mg q8w	Change From Baseline in WPAI Scores (Percent Activity Impairment Outside of Work) at Weeks 24 and 52	Week 24	-23.03 units on a scale	Standard Deviation 25.559
Guselkumab 100 mg q8w	Change From Baseline in WPAI Scores (Percent Activity Impairment Outside of Work) at Weeks 24 and 52	Week 52	-27.14 units on a scale	Standard Deviation 25.657
Guselkumab 100 mg q4w	Change From Baseline in WPAI Scores (Percent Activity Impairment Outside of Work) at Weeks 24 and 52	Week 52	-26.11 units on a scale	Standard Deviation 25.361
Guselkumab 100 mg q4w	Change From Baseline in WPAI Scores (Percent Activity Impairment Outside of Work) at Weeks 24 and 52	Week 24	-21.07 units on a scale	Standard Deviation 21.493

Secondary

Change From Baseline in WPAI Scores (Percent Activity Impairment Outside of Work) Weeks 52, 76 and 100

Time frame: Baseline, Weeks 52, 76 and 100

Population: Analysis population is FAS3. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in WPAI Scores (Percent Activity Impairment Outside of Work) Weeks 52, 76 and 100	Week 76	-28.05 units on a scale	Standard Deviation 26.411
Placebo to Guselkumab 100 mg q4w	Change From Baseline in WPAI Scores (Percent Activity Impairment Outside of Work) Weeks 52, 76 and 100	Week 52	-24.67 units on a scale	Standard Deviation 27.106
Placebo to Guselkumab 100 mg q4w	Change From Baseline in WPAI Scores (Percent Activity Impairment Outside of Work) Weeks 52, 76 and 100	Week 100	-30.70 units on a scale	Standard Deviation 28.632
Guselkumab 100 mg q8w	Change From Baseline in WPAI Scores (Percent Activity Impairment Outside of Work) Weeks 52, 76 and 100	Week 76	-31.38 units on a scale	Standard Deviation 25.449
Guselkumab 100 mg q8w	Change From Baseline in WPAI Scores (Percent Activity Impairment Outside of Work) Weeks 52, 76 and 100	Week 100	-30.98 units on a scale	Standard Deviation 26.65
Guselkumab 100 mg q8w	Change From Baseline in WPAI Scores (Percent Activity Impairment Outside of Work) Weeks 52, 76 and 100	Week 52	-27.16 units on a scale	Standard Deviation 25.662
Guselkumab 100 mg q4w	Change From Baseline in WPAI Scores (Percent Activity Impairment Outside of Work) Weeks 52, 76 and 100	Week 76	-28.70 units on a scale	Standard Deviation 24.635
Guselkumab 100 mg q4w	Change From Baseline in WPAI Scores (Percent Activity Impairment Outside of Work) Weeks 52, 76 and 100	Week 52	-26.24 units on a scale	Standard Deviation 25.113
Guselkumab 100 mg q4w	Change From Baseline in WPAI Scores (Percent Activity Impairment Outside of Work) Weeks 52, 76 and 100	Week 100	-30.68 units on a scale	Standard Deviation 25.305

Secondary

Change From Baseline in WPAI Scores (Percent Impairment While Working) at Weeks 24 and 52

Time frame: Baseline, Weeks 24 and 52

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in WPAI Scores (Percent Impairment While Working) at Weeks 24 and 52	Week 52	-21.27 units on a scale	Standard Deviation 31.502
Placebo to Guselkumab 100 mg q4w	Change From Baseline in WPAI Scores (Percent Impairment While Working) at Weeks 24 and 52	Week 24	-12.14 units on a scale	Standard Deviation 29.027
Guselkumab 100 mg q8w	Change From Baseline in WPAI Scores (Percent Impairment While Working) at Weeks 24 and 52	Week 52	-27.93 units on a scale	Standard Deviation 25.263
Guselkumab 100 mg q8w	Change From Baseline in WPAI Scores (Percent Impairment While Working) at Weeks 24 and 52	Week 24	-21.28 units on a scale	Standard Deviation 25.621
Guselkumab 100 mg q4w	Change From Baseline in WPAI Scores (Percent Impairment While Working) at Weeks 24 and 52	Week 24	-20.08 units on a scale	Standard Deviation 22.084
Guselkumab 100 mg q4w	Change From Baseline in WPAI Scores (Percent Impairment While Working) at Weeks 24 and 52	Week 52	-22.10 units on a scale	Standard Deviation 26.172

Secondary

Change From Baseline in WPAI Scores (Percent Impairment While Working) at Weeks 52, 76 and 100

Time frame: Baseline, Weeks 52, 76 and 100

Population: Analysis population is FAS3. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure. Here, n (number analyzed) signifies the number of participants analyzed for specified categories at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in WPAI Scores (Percent Impairment While Working) at Weeks 52, 76 and 100	Week 76	-26.90 units on a scale	Standard Deviation 28.965
Placebo to Guselkumab 100 mg q4w	Change From Baseline in WPAI Scores (Percent Impairment While Working) at Weeks 52, 76 and 100	Week 52	-21.81 units on a scale	Standard Deviation 31.391
Placebo to Guselkumab 100 mg q4w	Change From Baseline in WPAI Scores (Percent Impairment While Working) at Weeks 52, 76 and 100	Week 100	-30.73 units on a scale	Standard Deviation 30.933
Guselkumab 100 mg q8w	Change From Baseline in WPAI Scores (Percent Impairment While Working) at Weeks 52, 76 and 100	Week 76	-29.91 units on a scale	Standard Deviation 24.549
Guselkumab 100 mg q8w	Change From Baseline in WPAI Scores (Percent Impairment While Working) at Weeks 52, 76 and 100	Week 52	-27.93 units on a scale	Standard Deviation 25.263
Guselkumab 100 mg q8w	Change From Baseline in WPAI Scores (Percent Impairment While Working) at Weeks 52, 76 and 100	Week 100	-30.65 units on a scale	Standard Deviation 24.771
Guselkumab 100 mg q4w	Change From Baseline in WPAI Scores (Percent Impairment While Working) at Weeks 52, 76 and 100	Week 52	-22.62 units on a scale	Standard Deviation 26.058
Guselkumab 100 mg q4w	Change From Baseline in WPAI Scores (Percent Impairment While Working) at Weeks 52, 76 and 100	Week 100	-27.77 units on a scale	Standard Deviation 26.119
Guselkumab 100 mg q4w	Change From Baseline in WPAI Scores (Percent Impairment While Working) at Weeks 52, 76 and 100	Week 76	-26.13 units on a scale	Standard Deviation 25.412

Secondary

Change From Baseline in WPAI Scores (Percent Overall Work Impairment) at Weeks 24 and 52

Time frame: Baseline, Weeks 24 and 52

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in WPAI Scores (Percent Overall Work Impairment) at Weeks 24 and 52	Week 24	-13.42 units on a scale	Standard Deviation 29.916
Placebo to Guselkumab 100 mg q4w	Change From Baseline in WPAI Scores (Percent Overall Work Impairment) at Weeks 24 and 52	Week 52	-22.06 units on a scale	Standard Deviation 32.092
Guselkumab 100 mg q8w	Change From Baseline in WPAI Scores (Percent Overall Work Impairment) at Weeks 24 and 52	Week 24	-21.68 units on a scale	Standard Deviation 27.065
Guselkumab 100 mg q8w	Change From Baseline in WPAI Scores (Percent Overall Work Impairment) at Weeks 24 and 52	Week 52	-28.19 units on a scale	Standard Deviation 25.536
Guselkumab 100 mg q4w	Change From Baseline in WPAI Scores (Percent Overall Work Impairment) at Weeks 24 and 52	Week 24	-20.90 units on a scale	Standard Deviation 22.814
Guselkumab 100 mg q4w	Change From Baseline in WPAI Scores (Percent Overall Work Impairment) at Weeks 24 and 52	Week 52	-22.24 units on a scale	Standard Deviation 26.92

Secondary

Change From Baseline in WPAI Scores (Percent Overall Work Impairment) at Weeks 52, 76 and 100

Time frame: Baseline, Weeks 52, 76 and 100

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in WPAI Scores (Percent Overall Work Impairment) at Weeks 52, 76 and 100	Week 76	-27.98 units on a scale	Standard Deviation 29.709
Placebo to Guselkumab 100 mg q4w	Change From Baseline in WPAI Scores (Percent Overall Work Impairment) at Weeks 52, 76 and 100	Week 52	-22.61 units on a scale	Standard Deviation 31.979
Placebo to Guselkumab 100 mg q4w	Change From Baseline in WPAI Scores (Percent Overall Work Impairment) at Weeks 52, 76 and 100	Week 100	-31.87 units on a scale	Standard Deviation 31.013
Guselkumab 100 mg q8w	Change From Baseline in WPAI Scores (Percent Overall Work Impairment) at Weeks 52, 76 and 100	Week 76	-30.27 units on a scale	Standard Deviation 26.058
Guselkumab 100 mg q8w	Change From Baseline in WPAI Scores (Percent Overall Work Impairment) at Weeks 52, 76 and 100	Week 52	-28.19 units on a scale	Standard Deviation 25.536
Guselkumab 100 mg q8w	Change From Baseline in WPAI Scores (Percent Overall Work Impairment) at Weeks 52, 76 and 100	Week 100	-31.75 units on a scale	Standard Deviation 25.615
Guselkumab 100 mg q4w	Change From Baseline in WPAI Scores (Percent Overall Work Impairment) at Weeks 52, 76 and 100	Week 52	-22.79 units on a scale	Standard Deviation 26.793
Guselkumab 100 mg q4w	Change From Baseline in WPAI Scores (Percent Overall Work Impairment) at Weeks 52, 76 and 100	Week 100	-25.21 units on a scale	Standard Deviation 26.317
Guselkumab 100 mg q4w	Change From Baseline in WPAI Scores (Percent Overall Work Impairment) at Weeks 52, 76 and 100	Week 76	-26.21 units on a scale	Standard Deviation 28.115

Secondary

Change From Baseline in WPAI Scores (Percent Work Time Missed) at Weeks 52, 76 and 100

Time frame: Baseline, Weeks 52, 76 and 100

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline in WPAI Scores (Percent Work Time Missed) at Weeks 52, 76 and 100	Week 76	-5.92 units on a scale	Standard Deviation 26.032
Placebo to Guselkumab 100 mg q4w	Change From Baseline in WPAI Scores (Percent Work Time Missed) at Weeks 52, 76 and 100	Week 52	-5.45 units on a scale	Standard Deviation 25.544
Placebo to Guselkumab 100 mg q4w	Change From Baseline in WPAI Scores (Percent Work Time Missed) at Weeks 52, 76 and 100	Week 100	-8.81 units on a scale	Standard Deviation 24.313
Guselkumab 100 mg q8w	Change From Baseline in WPAI Scores (Percent Work Time Missed) at Weeks 52, 76 and 100	Week 76	-6.22 units on a scale	Standard Deviation 23.133
Guselkumab 100 mg q8w	Change From Baseline in WPAI Scores (Percent Work Time Missed) at Weeks 52, 76 and 100	Week 52	-4.50 units on a scale	Standard Deviation 20.53
Guselkumab 100 mg q8w	Change From Baseline in WPAI Scores (Percent Work Time Missed) at Weeks 52, 76 and 100	Week 100	-5.81 units on a scale	Standard Deviation 21.606
Guselkumab 100 mg q4w	Change From Baseline in WPAI Scores (Percent Work Time Missed) at Weeks 52, 76 and 100	Week 52	-1.83 units on a scale	Standard Deviation 17.191
Guselkumab 100 mg q4w	Change From Baseline in WPAI Scores (Percent Work Time Missed) at Weeks 52, 76 and 100	Week 100	-1.56 units on a scale	Standard Deviation 16.956
Guselkumab 100 mg q4w	Change From Baseline in WPAI Scores (Percent Work Time Missed) at Weeks 52, 76 and 100	Week 76	-2.39 units on a scale	Standard Deviation 19.277

Secondary

Change From Baseline to Week 100 in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores)

Time frame: Baseline to Week 100

Population: FAS3 for structural damage (FAS3-SD) included all randomized participants who were continuing study treatment at Week 52. Here, n (number analyzed) signifies the number of participants analyzed at specified category.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change From Baseline to Week 100 in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores)	Hand Erosion Score	0.67 units on a scale	Standard Deviation 2.917
Placebo to Guselkumab 100 mg q4w	Change From Baseline to Week 100 in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores)	Hand JSN Score	0.35 units on a scale	Standard Deviation 2.443
Placebo to Guselkumab 100 mg q4w	Change From Baseline to Week 100 in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores)	Hand Score	1.02 units on a scale	Standard Deviation 5.244
Placebo to Guselkumab 100 mg q4w	Change From Baseline to Week 100 in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores)	Foot Erosion Score	0.34 units on a scale	Standard Deviation 1.596
Placebo to Guselkumab 100 mg q4w	Change From Baseline to Week 100 in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores)	Foot JSN Score	0.13 units on a scale	Standard Deviation 0.912
Placebo to Guselkumab 100 mg q4w	Change From Baseline to Week 100 in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores)	Foot Score	0.48 units on a scale	Standard Deviation 2.373
Guselkumab 100 mg q8w	Change From Baseline to Week 100 in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores)	Foot Score	0.48 units on a scale	Standard Deviation 1.652
Guselkumab 100 mg q8w	Change From Baseline to Week 100 in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores)	Hand Erosion Score	0.67 units on a scale	Standard Deviation 2.807
Guselkumab 100 mg q8w	Change From Baseline to Week 100 in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores)	Foot Erosion Score	0.33 units on a scale	Standard Deviation 1.362
Guselkumab 100 mg q8w	Change From Baseline to Week 100 in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores)	Foot JSN Score	0.15 units on a scale	Standard Deviation 0.652
Guselkumab 100 mg q8w	Change From Baseline to Week 100 in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores)	Hand JSN Score	0.34 units on a scale	Standard Deviation 1.247
Guselkumab 100 mg q8w	Change From Baseline to Week 100 in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores)	Hand Score	1.02 units on a scale	Standard Deviation 3.815
Guselkumab 100 mg q4w	Change From Baseline to Week 100 in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores)	Hand JSN Score	0.32 units on a scale	Standard Deviation 1.845
Guselkumab 100 mg q4w	Change From Baseline to Week 100 in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores)	Hand Score	0.81 units on a scale	Standard Deviation 4.532
Guselkumab 100 mg q4w	Change From Baseline to Week 100 in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores)	Foot Score	0.87 units on a scale	Standard Deviation 3.761
Guselkumab 100 mg q4w	Change From Baseline to Week 100 in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores)	Foot Erosion Score	0.53 units on a scale	Standard Deviation 2.436
Guselkumab 100 mg q4w	Change From Baseline to Week 100 in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores)	Hand Erosion Score	0.49 units on a scale	Standard Deviation 3.007
Guselkumab 100 mg q4w	Change From Baseline to Week 100 in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores)	Foot JSN Score	0.34 units on a scale	Standard Deviation 1.608

Secondary

Change in Modified vdH-s Erosion Score From Baseline to Week 100

Time frame: Baseline to Week 100

Population: FAS3 for structural damage (FAS3-SD) included all randomized participants who were continuing study treatment at Week 52. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure.

Arm	Measure	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change in Modified vdH-s Erosion Score From Baseline to Week 100	1.01 units on a scale	Standard Deviation 4.034
Guselkumab 100 mg q8w	Change in Modified vdH-s Erosion Score From Baseline to Week 100	1.01 units on a scale	Standard Deviation 3.355
Guselkumab 100 mg q4w	Change in Modified vdH-s Erosion Score From Baseline to Week 100	1.02 units on a scale	Standard Deviation 4.676

Secondary

Change in Modified vdH-S Erosion Score From Week 24 to Week 52

Time frame: From Week 24 to Week 52

Arm	Measure	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change in Modified vdH-S Erosion Score From Week 24 to Week 52	0.17 units on a scale	Standard Deviation 1.277
Guselkumab 100 mg q8w	Change in Modified vdH-S Erosion Score From Week 24 to Week 52	0.10 units on a scale	Standard Deviation 1.422
Guselkumab 100 mg q4w	Change in Modified vdH-S Erosion Score From Week 24 to Week 52	0.39 units on a scale	Standard Deviation 1.725

Secondary

Change in Modified vdH-s Erosion Score From Week 52 to Week 100

Time frame: From Week 52 to Week 100

Arm	Measure	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change in Modified vdH-s Erosion Score From Week 52 to Week 100	0.09 units on a scale	Standard Deviation 1.978
Guselkumab 100 mg q8w	Change in Modified vdH-s Erosion Score From Week 52 to Week 100	0.26 units on a scale	Standard Deviation 1.751
Guselkumab 100 mg q4w	Change in Modified vdH-s Erosion Score From Week 52 to Week 100	0.45 units on a scale	Standard Deviation 2.9

Secondary

Change in Modified vdH-s JSN Score From Baseline to Week 100

Time frame: Baseline to Week 100

Arm	Measure	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change in Modified vdH-s JSN Score From Baseline to Week 100	0.49 units on a scale	Standard Deviation 2.984
Guselkumab 100 mg q8w	Change in Modified vdH-s JSN Score From Baseline to Week 100	0.50 units on a scale	Standard Deviation 1.387
Guselkumab 100 mg q4w	Change in Modified vdH-s JSN Score From Baseline to Week 100	0.66 units on a scale	Standard Deviation 2.722

Secondary

Change in Modified vdH-S JSN Score From Week 24 to Week 52

Time frame: From Week 24 to Week 52

Arm	Measure	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change in Modified vdH-S JSN Score From Week 24 to Week 52	0.07 units on a scale	Standard Deviation 0.635
Guselkumab 100 mg q8w	Change in Modified vdH-S JSN Score From Week 24 to Week 52	0.13 units on a scale	Standard Deviation 0.705
Guselkumab 100 mg q4w	Change in Modified vdH-S JSN Score From Week 24 to Week 52	0.23 units on a scale	Standard Deviation 1.088

Secondary

Change in Modified vdH-s JSN Score From Week 52 to Week 100

Time frame: From Week 52 to Week 100

Arm	Measure	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change in Modified vdH-s JSN Score From Week 52 to Week 100	0.04 units on a scale	Standard Deviation 1.904
Guselkumab 100 mg q8w	Change in Modified vdH-s JSN Score From Week 52 to Week 100	0.20 units on a scale	Standard Deviation 0.917
Guselkumab 100 mg q4w	Change in Modified vdH-s JSN Score From Week 52 to Week 100	0.30 units on a scale	Standard Deviation 1.319

Secondary

Change in Modified vdH-S Score From Baseline to Week 100

Time frame: Baseline to Week 100

Arm	Measure	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change in Modified vdH-S Score From Baseline to Week 100	1.49 units on a scale	Standard Deviation 6.859
Guselkumab 100 mg q8w	Change in Modified vdH-S Score From Baseline to Week 100	1.50 units on a scale	Standard Deviation 4.393
Guselkumab 100 mg q4w	Change in Modified vdH-S Score From Baseline to Week 100	1.68 units on a scale	Standard Deviation 7.018

Secondary

Change in Total Modified vdH-S Score From Week 24 to Week 52

Time frame: From Week 24 to Week 52

Arm	Measure	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change in Total Modified vdH-S Score From Week 24 to Week 52	0.25 units on a scale	Standard Deviation 1.635
Guselkumab 100 mg q8w	Change in Total Modified vdH-S Score From Week 24 to Week 52	0.23 units on a scale	Standard Deviation 1.808
Guselkumab 100 mg q4w	Change in Total Modified vdH-S Score From Week 24 to Week 52	0.62 units on a scale	Standard Deviation 2.53

Secondary

Change in Total Modified vdH-S Score From Week 52 to Week 100

Time frame: From Week 52 to Week 100

Arm	Measure	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Change in Total Modified vdH-S Score From Week 52 to Week 100	0.13 units on a scale	Standard Deviation 3.742
Guselkumab 100 mg q8w	Change in Total Modified vdH-S Score From Week 52 to Week 100	0.46 units on a scale	Standard Deviation 2.419
Guselkumab 100 mg q4w	Change in Total Modified vdH-S Score From Week 52 to Week 100	0.75 units on a scale	Standard Deviation 4.021

Secondary

Percentage of Participants Who Achieved >=0.35 Improvement From Baseline in HAQ-DI Score Through Week 24 Among Participants With HAQ-DI Score >=0.35 at Baseline

HAQ-DI score assess functional status of participant. It is a 20 question instrument that assess the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3, where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.

Time frame: Weeks 2, 4, 8, 12, 16, 20 and 24

Population: FAS1 among participants with HAQ-DI \>=0.35 at baseline. Participants with HAQ-DI \>=0.35 improvement from baseline at specific timepoint and did not meet any TF criteria before, were considered responders at that time point. Participants who met 1 or more TF criteria before or with missing data at that time point were considered non-responders.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=0.35 Improvement From Baseline in HAQ-DI Score Through Week 24 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 8	28.0 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=0.35 Improvement From Baseline in HAQ-DI Score Through Week 24 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 20	38.6 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=0.35 Improvement From Baseline in HAQ-DI Score Through Week 24 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 16	30.9 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=0.35 Improvement From Baseline in HAQ-DI Score Through Week 24 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 4	23.7 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=0.35 Improvement From Baseline in HAQ-DI Score Through Week 24 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 2	19.9 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=0.35 Improvement From Baseline in HAQ-DI Score Through Week 24 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 24	31.4 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=0.35 Improvement From Baseline in HAQ-DI Score Through Week 24 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 12	31.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=0.35 Improvement From Baseline in HAQ-DI Score Through Week 24 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 16	50.0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=0.35 Improvement From Baseline in HAQ-DI Score Through Week 24 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 4	32.0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=0.35 Improvement From Baseline in HAQ-DI Score Through Week 24 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 8	43.4 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=0.35 Improvement From Baseline in HAQ-DI Score Through Week 24 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 12	47.4 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=0.35 Improvement From Baseline in HAQ-DI Score Through Week 24 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 20	48.7 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=0.35 Improvement From Baseline in HAQ-DI Score Through Week 24 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 24	50.0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=0.35 Improvement From Baseline in HAQ-DI Score Through Week 24 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 2	30.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=0.35 Improvement From Baseline in HAQ-DI Score Through Week 24 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 20	53.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=0.35 Improvement From Baseline in HAQ-DI Score Through Week 24 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 8	42.5 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=0.35 Improvement From Baseline in HAQ-DI Score Through Week 24 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 2	23.2 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=0.35 Improvement From Baseline in HAQ-DI Score Through Week 24 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 24	56.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=0.35 Improvement From Baseline in HAQ-DI Score Through Week 24 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 16	51.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=0.35 Improvement From Baseline in HAQ-DI Score Through Week 24 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 12	46.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=0.35 Improvement From Baseline in HAQ-DI Score Through Week 24 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 4	35.1 percentage of participants

Secondary

Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 24 and 52 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline

Time frame: Weeks 24 and 52

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 24 and 52 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 24: Participants with >=20% Improvement	44.0 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 24 and 52 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 52: Participants with >=20% Improvement	71.6 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 24 and 52 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 24: Participants with >=50% Improvement	22.0 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 24 and 52 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 52: Participants with >=50% Improvement	50.0 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 24 and 52 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 24: Participants with >=70% Improvement	8.8 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 24 and 52 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 52: Participants with >=70% Improvement	23.9 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 24 and 52 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 24: Participants with >=90% Improvement	2.2 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 24 and 52 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 52: Participants with >=90% Improvement	6.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 24 and 52 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 24: Participants with >=50% Improvement	40.6 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 24 and 52 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 24: Participants with >=90% Improvement	1.6 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 24 and 52 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 52: Participants with >=50% Improvement	42.2 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 24 and 52 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 24: Participants with >=70% Improvement	21.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 24 and 52 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 52: Participants with >=70% Improvement	26.6 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 24 and 52 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 24: Participants with >=20% Improvement	62.5 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 24 and 52 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 52: Participants with >=20% Improvement	70.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 24 and 52 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 52: Participants with >=90% Improvement	10.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 24 and 52 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 24: Participants with >=50% Improvement	39.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 24 and 52 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 52: Participants with >=20% Improvement	79.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 24 and 52 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 24: Participants with >=20% Improvement	73.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 24 and 52 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 52: Participants with >=50% Improvement	50.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 24 and 52 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 24: Participants with >=90% Improvement	3.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 24 and 52 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 52: Participants with >=70% Improvement	30.4 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 24 and 52 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 24: Participants with >=70% Improvement	16.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 24 and 52 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 52: Participants with >=90% Improvement	8.9 percentage of participants

Secondary

Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline

Time frame: Weeks 52, 76 and 100

Population: Analysis population is FAS3 among participants with spondylitis and peripheral arthritis and BASDAI score \>0 at Baseline. Here, n (number analyzed) signifies the number of participants analyzed for specified categories at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 100: Participants with >=70% Improvement	32.9 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 52: Participants with >=20% Improvement	71.6 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 52: Participants with >=90% Improvement	6.8 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 52: Participants with >=50% Improvement	50.0 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 76: Participants with >=90% Improvement	11.8 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 100: Participants with >=90% Improvement	18.3 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 76: Participants with >=70% Improvement	31.8 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 76: Participants with >=20% Improvement	74.1 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 76: Participants with >=50% Improvement	52.9 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 100: Participants with >=50% Improvement	59.8 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 52: Participants with >=70% Improvement	23.9 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 100: Participants with >=20% Improvement	87.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 76: Participants with >=70% Improvement	31.1 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 100: Participants with >=70% Improvement	39.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 52: Participants with >=70% Improvement	27.0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 76: Participants with >=50% Improvement	52.5 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 52: Participants with >=90% Improvement	11.1 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 76: Participants with >=20% Improvement	82.0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 100: Participants with >=20% Improvement	77.0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 76: Participants with >=90% Improvement	13.1 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 52: Participants with >=50% Improvement	42.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 100: Participants with >=50% Improvement	57.4 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 100: Participants with >=90% Improvement	11.5 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 52: Participants with >=20% Improvement	69.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 100: Participants with >=90% Improvement	9.2 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 52: Participants with >=20% Improvement	79.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 76: Participants with >=20% Improvement	81.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 100: Participants with >=20% Improvement	82.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 52: Participants with >=50% Improvement	50.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 76: Participants with >=50% Improvement	50.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 100: Participants with >=50% Improvement	55.3 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 52: Participants with >=70% Improvement	30.4 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 76: Participants with >=70% Improvement	26.0 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 100: Participants with >=70% Improvement	32.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 52: Participants with >=90% Improvement	8.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 76: Participants with >=90% Improvement	7.8 percentage of participants

Secondary

Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline

Time frame: Weeks 8, 16 and 24

Population: FAS1 with spondylitis and peripheral arthritis and BASDAI score \>0 at baseline. Participants with the specified improvement in BASDAI at specific time point and did not meet TF criteria before, considered responders at that time point. Participants who met 1/more TF criteria before or with missing data at that time point considered non-responders.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 8: Participants with >=20% Improvement	38.0 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 16: Participants with >=20% Improvement	39.1 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 24: Participants with >=20% Improvement	42.4 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 8: Participants with >=50% Improvement	6.5 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 16: Participants with >=50% Improvement	17.4 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 24: Participants with >=50% Improvement	21.7 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 8: Participants with >=70% Improvement	3.3 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 16: Participants with >=70% Improvement	5.4 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 24: Participants with >=70% Improvement	8.7 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 8: Participants with >=90% Improvement	0 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 16: Participants with >=90% Improvement	1.1 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 24: Participants with >=90% Improvement	2.2 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 24: Participants with >=90% Improvement	1.5 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 8: Participants with >=20% Improvement	46.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 8: Participants with >=70% Improvement	11.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 24: Participants with >=70% Improvement	20.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 16: Participants with >=20% Improvement	58.2 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 24: Participants with >=50% Improvement	38.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 16: Participants with >=90% Improvement	0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 24: Participants with >=20% Improvement	59.7 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 16: Participants with >=70% Improvement	23.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 16: Participants with >=50% Improvement	37.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 8: Participants with >=50% Improvement	17.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 8: Participants with >=90% Improvement	1.5 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 8: Participants with >=50% Improvement	18.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 16: Participants with >=50% Improvement	26.5 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 8: Participants with >=90% Improvement	0 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 24: Participants with >=50% Improvement	37.3 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 8: Participants with >=70% Improvement	4.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 16: Participants with >=70% Improvement	9.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 16: Participants with >=90% Improvement	2.4 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 8: Participants with >=20% Improvement	53.0 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 16: Participants with >=20% Improvement	69.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 24: Participants with >=70% Improvement	15.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 24: Participants with >=20% Improvement	68.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline	Week 24: Participants with >=90% Improvement	3.6 percentage of participants

Secondary

Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score at Weeks 52, 76 and 100

The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.

Time frame: Weeks 52, 76 and 100

Population: Analysis population is FAS3. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score at Weeks 52, 76 and 100	Week 76	70.6 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score at Weeks 52, 76 and 100	Week 52	68.7 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score at Weeks 52, 76 and 100	Week 100	72.0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score at Weeks 52, 76 and 100	Week 52	69.4 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score at Weeks 52, 76 and 100	Week 76	69.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score at Weeks 52, 76 and 100	Week 100	72.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score at Weeks 52, 76 and 100	Week 52	68.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score at Weeks 52, 76 and 100	Week 100	74.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score at Weeks 52, 76 and 100	Week 76	74.4 percentage of participants

Secondary

Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score Improvement at Weeks 24 and 52

The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.

Time frame: Weeks 24 and 52

Population: Analysis population is FAS2. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score Improvement at Weeks 24 and 52	Week 24	49.4 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score Improvement at Weeks 24 and 52	Week 52	68.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score Improvement at Weeks 24 and 52	Week 24	63.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score Improvement at Weeks 24 and 52	Week 52	69.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score Improvement at Weeks 24 and 52	Week 52	68.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score Improvement at Weeks 24 and 52	Week 24	62.8 percentage of participants

Secondary

Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score Improvement Through Week 24

The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.

Time frame: Weeks 8, 16 and 24

Population: Analysis population is FAS1. Participants who achieved \>=4-point improvement from baseline in FACIT-fatigue score at specific time point and did not meet any TF criteria before, were considered responders at that time point. Participants who met 1 or more TF criteria before or with missing data at that time point were considered non-responders.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score Improvement Through Week 24	Week 16	50.4 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score Improvement Through Week 24	Week 8	45.9 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score Improvement Through Week 24	Week 24	45.5 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score Improvement Through Week 24	Week 16	60.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score Improvement Through Week 24	Week 8	56.0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score Improvement Through Week 24	Week 24	60.5 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score Improvement Through Week 24	Week 8	51.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score Improvement Through Week 24	Week 24	59.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score Improvement Through Week 24	Week 16	56.7 percentage of participants

Secondary

Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score at Weeks 24 and 52 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. An improvement of 5 points was considered clinically meaningful.

Time frame: Weeks 24 and 52

Population: Analysis population is FAS2 among the participants with DLQI score \>=5, \>=3% BSA psoriatic involvement and an IGA score of \>=2 (mild) at baseline. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score at Weeks 24 and 52 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	40.7 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score at Weeks 24 and 52 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	84.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score at Weeks 24 and 52 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	85.4 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score at Weeks 24 and 52 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	92.2 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score at Weeks 24 and 52 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	90.3 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score at Weeks 24 and 52 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	89.4 percentage of participants

Secondary

Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score at Weeks 52, 76 and 100 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. An improvement of 5 points was considered clinically meaningful.

Time frame: Weeks 52, 76 and 100

Population: Analysis population is FAS3 among the participants with DLQI score \>=5, \>=3% BSA psoriatic involvement and an IGA score of \>=2 (mild) at baseline. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score at Weeks 52, 76 and 100 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 76	91.9 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score at Weeks 52, 76 and 100 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	84.8 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score at Weeks 52, 76 and 100 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 100	91.7 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score at Weeks 52, 76 and 100 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 76	89.0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score at Weeks 52, 76 and 100 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	92.2 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score at Weeks 52, 76 and 100 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 100	94.4 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score at Weeks 52, 76 and 100 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	89.4 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score at Weeks 52, 76 and 100 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 100	88.5 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score at Weeks 52, 76 and 100 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 76	90.1 percentage of participants

Secondary

Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score Through Week 24 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. An improvement of 5 points was considered clinically meaningful.

Time frame: Weeks 8, 16, 24

Population: FAS1 with DLQI\>=5, \>=3% BSA of psoriasis and IGA score \>=2 (mild) at baseline. Participants with \>=5-point improvement from baseline in DLQI score at specific time point and did not meet TF criteria before, considered responders at that time point. Participants who met 1/more TF criteria before or with missing data considered non-responders.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score Through Week 24 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 16	36.4 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score Through Week 24 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 8	30.1 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score Through Week 24 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	37.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score Through Week 24 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 16	79.5 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score Through Week 24 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 8	71.2 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score Through Week 24 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	83.3 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score Through Week 24 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 8	69.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score Through Week 24 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	86.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in DLQI Score Through Week 24 Among the Participants With DLQI Score >=5, >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 16	79.6 percentage of participants

Secondary

Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score at Weeks 24 and 52

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.

Time frame: Weeks 24 and 52

Population: Analysis population is FAS2. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score at Weeks 24 and 52	Week 24	32.5 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score at Weeks 24 and 52	Week 52	41.7 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score at Weeks 24 and 52	Week 24	40.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score at Weeks 24 and 52	Week 52	44.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score at Weeks 24 and 52	Week 24	36.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score at Weeks 24 and 52	Week 52	38.9 percentage of participants

Secondary

Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score at Weeks 52, 76 and 100

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.

Time frame: Weeks 52, 76 and 100

Population: Analysis population is FAS3. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score at Weeks 52, 76 and 100	Week 76	43.9 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score at Weeks 52, 76 and 100	Week 52	42.3 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score at Weeks 52, 76 and 100	Week 100	42.1 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score at Weeks 52, 76 and 100	Week 76	44.4 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score at Weeks 52, 76 and 100	Week 52	45.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score at Weeks 52, 76 and 100	Week 100	46.4 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score at Weeks 52, 76 and 100	Week 52	38.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score at Weeks 52, 76 and 100	Week 100	43.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score at Weeks 52, 76 and 100	Week 76	43.5 percentage of participants

Secondary

Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score Through Week 24

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.

Time frame: Week 8, 16 and 24

Population: Analysis population is FAS1. Participants who achieved \>=5-point improvement from baseline in SF-36 MCS score at specific time point and did not meet any TF criteria before, were considered as responders at that time point. Participants who met 1 or more TF criteria before or with missing data at that time point were considered as non-responders.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score Through Week 24	Week 16	31.7 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score Through Week 24	Week 8	26.4 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score Through Week 24	Week 24	30.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score Through Week 24	Week 24	37.5 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score Through Week 24	Week 8	33.1 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score Through Week 24	Week 16	42.3 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score Through Week 24	Week 16	31.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score Through Week 24	Week 8	27.3 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score Through Week 24	Week 24	34.3 percentage of participants

Secondary

Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score at Weeks 24 and 52

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.

Time frame: Weeks 24 and 52

Population: Analysis population is FAS2. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score at Weeks 24 and 52	Week 24	42.2 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score at Weeks 24 and 52	Week 52	63.0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score at Weeks 24 and 52	Week 24	63.4 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score at Weeks 24 and 52	Week 52	67.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score at Weeks 24 and 52	Week 52	65.5 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score at Weeks 24 and 52	Week 24	58.5 percentage of participants

Secondary

Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score at Weeks 52, 76 and 100

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.

Time frame: Weeks 52, 76 and 100

Population: Analysis population is FAS3. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score at Weeks 52, 76 and 100	Week 76	70.6 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score at Weeks 52, 76 and 100	Week 52	63.4 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score at Weeks 52, 76 and 100	Week 100	72.4 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score at Weeks 52, 76 and 100	Week 76	73.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score at Weeks 52, 76 and 100	Week 52	66.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score at Weeks 52, 76 and 100	Week 100	70.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score at Weeks 52, 76 and 100	Week 52	65.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score at Weeks 52, 76 and 100	Week 100	68.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score at Weeks 52, 76 and 100	Week 76	65.5 percentage of participants

Secondary

Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score Through Week 24

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.

Time frame: Week 8, 16 and 24

Population: Analysis population is FAS1. Participants who achieved \>=5-point improvement from baseline in SF-36 PCS score at specific time point and did not meet any TF criteria before, were considered as responders at that time point. Participants who met 1 or more TF criteria before or with missing data at that time point were considered as non-responders.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score Through Week 24	Week 16	35.8 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score Through Week 24	Week 8	37.8 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score Through Week 24	Week 24	40.2 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score Through Week 24	Week 16	59.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score Through Week 24	Week 8	45.2 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score Through Week 24	Week 24	60.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score Through Week 24	Week 8	41.2 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score Through Week 24	Week 24	55.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 PCS Score Through Week 24	Week 16	51.0 percentage of participants

Secondary

Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52 Among Participants With HAQ-DI Score >=0.35 at Baseline

HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.

Time frame: Weeks 24, 28, 36, 44 and 52

Population: Analysis population is FAS2 among participants with HAQ-DI score \>=0.35 at baseline and who achieved a HAQ-DI response at Week 52. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 44	50.9 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 36	48.4 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 24	34.1 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 28	42.4 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 52	50.5 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 36	58.2 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 24	52.5 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 28	58.4 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 44	60.0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 52	60.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 52	62.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 44	61.4 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 24	58.3 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 36	61.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 28	63.4 percentage of participants

Secondary

Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100 Among Participants With HAQ-DI Score >=0.35 at Baseline

HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3, where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.

Time frame: Weeks 52, 68, 76, 84 and 100

Population: Analysis population is FAS3 among participants with HAQ-DI score \>=0.35 at baseline. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 76	59.3 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 68	57.2 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 84	58.9 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 100	63.3 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 52	51.1 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 84	66.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 100	70.7 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 52	60.6 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 68	64.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 76	68.4 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 68	69.4 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 76	64.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 84	65.5 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 100	70.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100 Among Participants With HAQ-DI Score >=0.35 at Baseline	Week 52	63.3 percentage of participants

Secondary

Percentage of Participants Who Achieved ACR 20 Response at Weeks 24, 28, 36, 44 and 52

ACR 20 response was defined as \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

Time frame: Weeks 24, 28, 36, 44 and 52

Population: Full analysis set 2 (FAS2) included all randomized participants who were still on study treatment at Week 24. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 20 Response at Weeks 24, 28, 36, 44 and 52	Week 44	69.7 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 20 Response at Weeks 24, 28, 36, 44 and 52	Week 36	68.8 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 20 Response at Weeks 24, 28, 36, 44 and 52	Week 24	34.0 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 20 Response at Weeks 24, 28, 36, 44 and 52	Week 28	48.3 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 20 Response at Weeks 24, 28, 36, 44 and 52	Week 52	68.7 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 20 Response at Weeks 24, 28, 36, 44 and 52	Week 36	77.7 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 20 Response at Weeks 24, 28, 36, 44 and 52	Week 24	66.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 20 Response at Weeks 24, 28, 36, 44 and 52	Week 28	71.2 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 20 Response at Weeks 24, 28, 36, 44 and 52	Week 44	79.7 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 20 Response at Weeks 24, 28, 36, 44 and 52	Week 52	79.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 20 Response at Weeks 24, 28, 36, 44 and 52	Week 52	75.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 20 Response at Weeks 24, 28, 36, 44 and 52	Week 44	76.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 20 Response at Weeks 24, 28, 36, 44 and 52	Week 24	66.2 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 20 Response at Weeks 24, 28, 36, 44 and 52	Week 36	78.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 20 Response at Weeks 24, 28, 36, 44 and 52	Week 28	72.0 percentage of participants

Secondary

Percentage of Participants Who Achieved ACR 20 Response at Weeks 52, 68, 76, 84 and 100

Time frame: Weeks 52, 68, 76, 84 and 100

Population: Analysis population is full analysis set 3 (FAS3) which included all participants still on treatment at Week 52. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 20 Response at Weeks 52, 68, 76, 84 and 100	Week 84	80.1 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 20 Response at Weeks 52, 68, 76, 84 and 100	Week 76	75.6 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 20 Response at Weeks 52, 68, 76, 84 and 100	Week 52	68.7 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 20 Response at Weeks 52, 68, 76, 84 and 100	Week 68	77.0 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 20 Response at Weeks 52, 68, 76, 84 and 100	Week 100	79.2 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 20 Response at Weeks 52, 68, 76, 84 and 100	Week 76	83.1 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 20 Response at Weeks 52, 68, 76, 84 and 100	Week 52	78.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 20 Response at Weeks 52, 68, 76, 84 and 100	Week 68	85.2 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 20 Response at Weeks 52, 68, 76, 84 and 100	Week 84	85.1 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 20 Response at Weeks 52, 68, 76, 84 and 100	Week 100	82.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 20 Response at Weeks 52, 68, 76, 84 and 100	Week 100	84.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 20 Response at Weeks 52, 68, 76, 84 and 100	Week 84	80.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 20 Response at Weeks 52, 68, 76, 84 and 100	Week 52	77.0 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 20 Response at Weeks 52, 68, 76, 84 and 100	Week 76	82.5 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 20 Response at Weeks 52, 68, 76, 84 and 100	Week 68	80.7 percentage of participants

Secondary

Percentage of Participants Who Achieved ACR 20 Response Through Week 24

ACR 20 response was defined as \>= 20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.

Time frame: Weeks 2, 4, 8, 12, 16, 20 and 24

Population: Analysis population is FAS1. Participants who achieved ACR 20 response at a specific time point and did not meet any TF criteria before, were considered as responders at that time point. Participants who met 1 or more TF criteria before or with missing data at that time point were considered as non-responders.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 20 Response Through Week 24	Week 4	11.8 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 20 Response Through Week 24	Week 16	33.7 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 20 Response Through Week 24	Week 12	26.4 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 20 Response Through Week 24	Week 2	8.1 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 20 Response Through Week 24	Week 24	32.9 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 20 Response Through Week 24	Week 20	29.7 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 20 Response Through Week 24	Week 8	17.5 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 20 Response Through Week 24	Week 12	49.6 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 20 Response Through Week 24	Week 2	10.1 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 20 Response Through Week 24	Week 4	19.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 20 Response Through Week 24	Week 8	39.1 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 20 Response Through Week 24	Week 16	55.2 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 20 Response Through Week 24	Week 20	62.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 20 Response Through Week 24	Week 24	64.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 20 Response Through Week 24	Week 16	55.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 20 Response Through Week 24	Week 4	21.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 20 Response Through Week 24	Week 24	63.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 20 Response Through Week 24	Week 20	58.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 20 Response Through Week 24	Week 12	51.0 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 20 Response Through Week 24	Week 8	40.0 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 20 Response Through Week 24	Week 2	10.6 percentage of participants

Secondary

Percentage of Participants Who Achieved ACR 50 Response at Weeks 24, 28, 36, 44 and 52

ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

Time frame: Weeks 24, 28, 36, 44 and 52

Population: Analysis population is FAS2. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 50 Response at Weeks 24, 28, 36, 44 and 52	Week 24	15.2 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 50 Response at Weeks 24, 28, 36, 44 and 52	Week 44	43.8 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 50 Response at Weeks 24, 28, 36, 44 and 52	Week 36	39.3 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 50 Response at Weeks 24, 28, 36, 44 and 52	Week 52	43.7 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 50 Response at Weeks 24, 28, 36, 44 and 52	Week 28	22.7 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 50 Response at Weeks 24, 28, 36, 44 and 52	Week 36	44.1 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 50 Response at Weeks 24, 28, 36, 44 and 52	Week 24	32.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 50 Response at Weeks 24, 28, 36, 44 and 52	Week 28	41.4 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 50 Response at Weeks 24, 28, 36, 44 and 52	Week 44	48.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 50 Response at Weeks 24, 28, 36, 44 and 52	Week 52	51.3 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 50 Response at Weeks 24, 28, 36, 44 and 52	Week 52	49.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 50 Response at Weeks 24, 28, 36, 44 and 52	Week 44	48.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 50 Response at Weeks 24, 28, 36, 44 and 52	Week 24	34.3 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 50 Response at Weeks 24, 28, 36, 44 and 52	Week 36	45.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 50 Response at Weeks 24, 28, 36, 44 and 52	Week 28	40.5 percentage of participants

Secondary

Percentage of Participants Who Achieved ACR 50 Response at Weeks 52, 68, 76, 84 and 100

Time frame: Weeks 52, 68, 76, 84 and 100

Population: Analysis population is FAS3 which included all participants still on treatment at Week 52. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 50 Response at Weeks 52, 68, 76, 84 and 100	Week 52	44.3 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 50 Response at Weeks 52, 68, 76, 84 and 100	Week 84	56.3 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 50 Response at Weeks 52, 68, 76, 84 and 100	Week 76	50.9 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 50 Response at Weeks 52, 68, 76, 84 and 100	Week 100	55.2 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 50 Response at Weeks 52, 68, 76, 84 and 100	Week 68	49.5 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 50 Response at Weeks 52, 68, 76, 84 and 100	Week 76	56.0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 50 Response at Weeks 52, 68, 76, 84 and 100	Week 52	50.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 50 Response at Weeks 52, 68, 76, 84 and 100	Week 68	60.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 50 Response at Weeks 52, 68, 76, 84 and 100	Week 84	63.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 50 Response at Weeks 52, 68, 76, 84 and 100	Week 100	60.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 50 Response at Weeks 52, 68, 76, 84 and 100	Week 100	62.3 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 50 Response at Weeks 52, 68, 76, 84 and 100	Week 84	57.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 50 Response at Weeks 52, 68, 76, 84 and 100	Week 52	49.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 50 Response at Weeks 52, 68, 76, 84 and 100	Week 76	58.3 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 50 Response at Weeks 52, 68, 76, 84 and 100	Week 68	58.6 percentage of participants

Secondary

Percentage of Participants Who Achieved ACR 50 Response Through Week 24

ACR 50 response was defined as \>= 50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.

Time frame: Weeks 2, 4, 8, 12, 16, 20 and 24

Population: Analysis population is FAS1. Participants who achieved ACR 50 response at a specific time point and did not meet any TF criteria before, were considered as responders at that time point. Participants who met 1 or more TF criteria before or with missing data at that time point were considered as non-responders.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 50 Response Through Week 24	Week 4	1.2 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 50 Response Through Week 24	Week 16	9.3 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 50 Response Through Week 24	Week 12	6.1 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 50 Response Through Week 24	Week 2	0.4 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 50 Response Through Week 24	Week 24	14.2 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 50 Response Through Week 24	Week 20	16.3 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 50 Response Through Week 24	Week 8	4.1 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 50 Response Through Week 24	Week 12	19.0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 50 Response Through Week 24	Week 2	1.6 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 50 Response Through Week 24	Week 4	4.0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 50 Response Through Week 24	Week 8	10.1 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 50 Response Through Week 24	Week 16	28.6 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 50 Response Through Week 24	Week 20	31.5 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 50 Response Through Week 24	Week 24	31.5 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 50 Response Through Week 24	Week 16	20.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 50 Response Through Week 24	Week 4	3.3 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 50 Response Through Week 24	Week 24	33.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 50 Response Through Week 24	Week 20	29.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 50 Response Through Week 24	Week 12	16.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 50 Response Through Week 24	Week 8	11.0 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 50 Response Through Week 24	Week 2	0.4 percentage of participants

Secondary

Percentage of Participants Who Achieved ACR 70 Response at Weeks 24, 28, 36, 44 and 52

ACR 70 response was defined as \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

Time frame: Weeks 24, 28, 36, 44 and 52

Population: Analysis population is FAS2. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 70 Response at Weeks 24, 28, 36, 44 and 52	Week 44	20.9 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 70 Response at Weeks 24, 28, 36, 44 and 52	Week 36	15.4 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 70 Response at Weeks 24, 28, 36, 44 and 52	Week 24	4.6 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 70 Response at Weeks 24, 28, 36, 44 and 52	Week 28	7.6 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 70 Response at Weeks 24, 28, 36, 44 and 52	Week 52	19.2 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 70 Response at Weeks 24, 28, 36, 44 and 52	Week 36	27.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 70 Response at Weeks 24, 28, 36, 44 and 52	Week 24	19.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 70 Response at Weeks 24, 28, 36, 44 and 52	Week 28	21.1 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 70 Response at Weeks 24, 28, 36, 44 and 52	Week 44	29.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 70 Response at Weeks 24, 28, 36, 44 and 52	Week 52	29.5 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 70 Response at Weeks 24, 28, 36, 44 and 52	Week 52	28.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 70 Response at Weeks 24, 28, 36, 44 and 52	Week 44	24.4 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 70 Response at Weeks 24, 28, 36, 44 and 52	Week 24	13.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 70 Response at Weeks 24, 28, 36, 44 and 52	Week 36	24.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 70 Response at Weeks 24, 28, 36, 44 and 52	Week 28	21.1 percentage of participants

Secondary

Percentage of Participants Who Achieved ACR 70 Response at Weeks 52, 68, 76, 84 and 100

Time frame: Weeks 52, 68, 76, 84 and 100

Population: Analysis population is FAS3 which included all participants still on treatment at Week 52. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 70 Response at Weeks 52, 68, 76, 84 and 100	Week 84	29.6 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 70 Response at Weeks 52, 68, 76, 84 and 100	Week 76	27.9 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 70 Response at Weeks 52, 68, 76, 84 and 100	Week 52	19.5 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 70 Response at Weeks 52, 68, 76, 84 and 100	Week 68	27.8 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 70 Response at Weeks 52, 68, 76, 84 and 100	Week 100	34.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 70 Response at Weeks 52, 68, 76, 84 and 100	Week 76	36.4 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 70 Response at Weeks 52, 68, 76, 84 and 100	Week 52	29.7 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 70 Response at Weeks 52, 68, 76, 84 and 100	Week 68	35.5 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 70 Response at Weeks 52, 68, 76, 84 and 100	Week 84	42.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 70 Response at Weeks 52, 68, 76, 84 and 100	Week 100	39.3 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 70 Response at Weeks 52, 68, 76, 84 and 100	Week 100	38.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 70 Response at Weeks 52, 68, 76, 84 and 100	Week 84	39.4 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 70 Response at Weeks 52, 68, 76, 84 and 100	Week 52	28.3 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 70 Response at Weeks 52, 68, 76, 84 and 100	Week 76	32.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 70 Response at Weeks 52, 68, 76, 84 and 100	Week 68	36.1 percentage of participants

Secondary

Percentage of Participants Who Achieved ACR 70 Response Through Week 24

ACR 70 response was defined as \>= 70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.

Time frame: Weeks 2, 4, 8, 12, 16, 20 and 24

Population: Analysis population is FAS1. Participants who achieved ACR 70 response at a specific time point and did not meet any TF criteria before, were considered as responders at that time point. Participants who met 1 or more TF criteria before or with missing data at that time point were considered as non-responders.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 70 Response Through Week 24	Week 4	0.8 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 70 Response Through Week 24	Week 16	0.8 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 70 Response Through Week 24	Week 12	0.4 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 70 Response Through Week 24	Week 2	0 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 70 Response Through Week 24	Week 24	4.1 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 70 Response Through Week 24	Week 20	3.3 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 70 Response Through Week 24	Week 8	0.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 70 Response Through Week 24	Week 12	8.1 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 70 Response Through Week 24	Week 2	0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 70 Response Through Week 24	Week 4	0.4 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 70 Response Through Week 24	Week 8	3.6 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 70 Response Through Week 24	Week 16	13.7 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 70 Response Through Week 24	Week 20	15.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved ACR 70 Response Through Week 24	Week 24	18.5 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 70 Response Through Week 24	Week 16	8.2 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 70 Response Through Week 24	Week 4	0.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 70 Response Through Week 24	Week 24	13.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 70 Response Through Week 24	Week 20	13.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 70 Response Through Week 24	Week 12	4.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 70 Response Through Week 24	Week 8	2.0 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved ACR 70 Response Through Week 24	Week 2	0 percentage of participants

Secondary

Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 24, 28, 36, 44 and 52

Time frame: Weeks 24, 28, 36, 44 and 52

Population: Analysis population is FAS2. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 24, 28, 36, 44 and 52	Week 44	30.0 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 24, 28, 36, 44 and 52	Week 36	25.7 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 24, 28, 36, 44 and 52	Week 24	9.3 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 24, 28, 36, 44 and 52	Week 28	13.2 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 24, 28, 36, 44 and 52	Week 52	34.2 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 24, 28, 36, 44 and 52	Week 36	36.0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 24, 28, 36, 44 and 52	Week 24	25.6 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 24, 28, 36, 44 and 52	Week 28	27.5 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 24, 28, 36, 44 and 52	Week 44	38.4 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 24, 28, 36, 44 and 52	Week 52	39.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 24, 28, 36, 44 and 52	Week 52	39.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 24, 28, 36, 44 and 52	Week 44	38.0 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 24, 28, 36, 44 and 52	Week 24	24.4 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 24, 28, 36, 44 and 52	Week 36	39.5 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 24, 28, 36, 44 and 52	Week 28	30.4 percentage of participants

Secondary

Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 52, 68, 76, 84 and 100

Time frame: Weeks 52, 68, 76, 84 and 100

Population: Analysis population is FAS3 which included all participants still on treatment at Week 52. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 52, 68, 76, 84 and 100	Week 84	41.8 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 52, 68, 76, 84 and 100	Week 76	43.2 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 52, 68, 76, 84 and 100	Week 52	34.7 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 52, 68, 76, 84 and 100	Week 68	39.0 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 52, 68, 76, 84 and 100	Week 100	42.4 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 52, 68, 76, 84 and 100	Week 76	44.2 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 52, 68, 76, 84 and 100	Week 52	39.7 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 52, 68, 76, 84 and 100	Week 68	44.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 52, 68, 76, 84 and 100	Week 84	50.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 52, 68, 76, 84 and 100	Week 100	47.5 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 52, 68, 76, 84 and 100	Week 100	51.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 52, 68, 76, 84 and 100	Week 84	48.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 52, 68, 76, 84 and 100	Week 52	40.4 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 52, 68, 76, 84 and 100	Week 76	43.5 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 52, 68, 76, 84 and 100	Week 68	49.1 percentage of participants

Secondary

Percentage of Participants Who Achieved a DAS28 (CRP) Remission Through Week 24

Time frame: Weeks 2, 4, 8, 12, 16, 20 and 24

Population: Analysis population is FAS1. Participants who achieved a DAS28 (CRP) remission at a specific time point and did not meet any TF criteria before, were considered as responders at that time point. Participants who met 1 or more TF criteria before or with missing data at that time point were considered as non-responders.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission Through Week 24	Week 4	2.0 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission Through Week 24	Week 16	6.5 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission Through Week 24	Week 12	6.1 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission Through Week 24	Week 2	0.8 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission Through Week 24	Week 24	8.5 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission Through Week 24	Week 20	9.8 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission Through Week 24	Week 8	0.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission Through Week 24	Week 12	14.1 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission Through Week 24	Week 2	2.4 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission Through Week 24	Week 4	5.2 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission Through Week 24	Week 8	10.5 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission Through Week 24	Week 16	18.5 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission Through Week 24	Week 20	23.0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission Through Week 24	Week 24	24.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission Through Week 24	Week 16	16.3 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission Through Week 24	Week 4	4.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission Through Week 24	Week 24	23.3 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission Through Week 24	Week 20	21.2 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission Through Week 24	Week 12	11.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission Through Week 24	Week 8	9.0 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Remission Through Week 24	Week 2	2.4 percentage of participants

Secondary

Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 24, 28, 36, 44 and 52

DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. DAS28 (CRP) response criteria was defined as follows: Good response: \<=3.2 at visit and \>1.2 improvement; Moderate response: \>3.2 at visit and \>1.2 improvement or \<=5.1 at visit and \>0.6-1.2 improvement; No response: \<=0.6 improvement, or \>5.1 at visit and \<=1.2 improvement. The values are 0=best to 10=worst. A DAS28 (CRP) responder was defined as achieving a good or moderate DAS28 response at a specific visit.

Time frame: Weeks 24, 28, 36, 44 and 52

Population: Analysis population is FAS2. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 24, 28, 36, 44 and 52	Week 44	91.0 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 24, 28, 36, 44 and 52	Week 36	86.5 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 24, 28, 36, 44 and 52	Week 24	55.5 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 24, 28, 36, 44 and 52	Week 28	72.3 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 24, 28, 36, 44 and 52	Week 52	89.0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 24, 28, 36, 44 and 52	Week 36	86.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 24, 28, 36, 44 and 52	Week 24	79.0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 24, 28, 36, 44 and 52	Week 28	85.0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 24, 28, 36, 44 and 52	Week 44	91.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 24, 28, 36, 44 and 52	Week 52	89.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 24, 28, 36, 44 and 52	Week 52	89.4 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 24, 28, 36, 44 and 52	Week 44	91.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 24, 28, 36, 44 and 52	Week 24	83.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 24, 28, 36, 44 and 52	Week 36	92.5 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 24, 28, 36, 44 and 52	Week 28	85.9 percentage of participants

Secondary

Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 52, 68, 76, 84 and 100

Time frame: Weeks 52, 68, 76, 84 and 100

Population: Analysis population is FAS3 which included all participants still on treatment at Week 52. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 52, 68, 76, 84 and 100	Week 52	89.3 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 52, 68, 76, 84 and 100	Week 68	92.7 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 52, 68, 76, 84 and 100	Week 76	94.1 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 52, 68, 76, 84 and 100	Week 84	94.8 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 52, 68, 76, 84 and 100	Week 100	94.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 52, 68, 76, 84 and 100	Week 68	92.5 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 52, 68, 76, 84 and 100	Week 84	92.7 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 52, 68, 76, 84 and 100	Week 76	90.2 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 52, 68, 76, 84 and 100	Week 100	90.6 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 52, 68, 76, 84 and 100	Week 52	89.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 52, 68, 76, 84 and 100	Week 100	92.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 52, 68, 76, 84 and 100	Week 68	92.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 52, 68, 76, 84 and 100	Week 52	90.2 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 52, 68, 76, 84 and 100	Week 76	93.3 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 52, 68, 76, 84 and 100	Week 84	92.5 percentage of participants

Secondary

Percentage of Participants Who Achieved a DAS28 (CRP) Response Through Week 24

DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. DAS 28 (CRP) response criteria was defined as follows: Good response: \<=3.2 at visit and \>1.2 improvement; Moderate response: \>3.2 at visit and \>1.2 improvement or \<=5.1 at visit and \>0.6-1.2 improvement; No response: \<=0.6 improvement, or \>5.1 at visit and \<=1.2 improvement. The values are 0=best to 10=worst. A DAS28 (CRP) responder is defined as achieving a good or moderate DAS28 response at a specific visit.

Time frame: Weeks 2, 4, 8, 12, 16, 20 and 24

Population: Analysis population is FAS1. Participants who achieved a DAS28 (CRP) response at a specific time point and did not meet any TF criteria before, were considered as responders at that time point. Participants who met 1 or more TF criteria before or with missing data at that time point were considered as non-responders.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Response Through Week 24	Week 24	52.4 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Response Through Week 24	Week 2	21.5 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Response Through Week 24	Week 12	51.2 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Response Through Week 24	Week 20	50.4 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Response Through Week 24	Week 8	38.6 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Response Through Week 24	Week 16	51.2 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Response Through Week 24	Week 4	32.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DAS28 (CRP) Response Through Week 24	Week 16	69.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DAS28 (CRP) Response Through Week 24	Week 20	75.0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DAS28 (CRP) Response Through Week 24	Week 4	38.7 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DAS28 (CRP) Response Through Week 24	Week 24	75.4 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DAS28 (CRP) Response Through Week 24	Week 8	56.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DAS28 (CRP) Response Through Week 24	Week 12	67.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DAS28 (CRP) Response Through Week 24	Week 2	23.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Response Through Week 24	Week 24	80.0 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Response Through Week 24	Week 4	40.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Response Through Week 24	Week 8	54.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Response Through Week 24	Week 12	65.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Response Through Week 24	Week 16	72.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Response Through Week 24	Week 20	76.3 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DAS28 (CRP) Response Through Week 24	Week 2	24.5 percentage of participants

Secondary

Percentage of Participants Who Achieved a DLQI Score of 0 or 1 at Weeks 24 and 52 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. A DLQI score of 0 or 1 indicates psoriasis had no effect at all on patient's life.

Time frame: Weeks 24 and 52

Population: Analysis population is FAS2 among the participants with DLQI Score \>1, with \>=3% BSA psoriatic involvement and an IGA score of \>=2 (mild) at baseline. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DLQI Score of 0 or 1 at Weeks 24 and 52 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	12.1 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DLQI Score of 0 or 1 at Weeks 24 and 52 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	56.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DLQI Score of 0 or 1 at Weeks 24 and 52 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	65.6 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DLQI Score of 0 or 1 at Weeks 24 and 52 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	68.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DLQI Score of 0 or 1 at Weeks 24 and 52 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	61.4 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DLQI Score of 0 or 1 at Weeks 24 and 52 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	68.7 percentage of participants

Secondary

Percentage of Participants Who Achieved a DLQI Score of 0 or 1 at Weeks 52, 76 and 100 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. A DLQI score of 0 or 1 indicates psoriasis had no effect at all on patient's life.

Time frame: Weeks 52, 76 and 100

Population: Analysis population is FAS3 among the participants with DLQI Score \>1, with \>=3% BSA psoriatic involvement and an IGA score of \>=2 (mild) at baseline. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DLQI Score of 0 or 1 at Weeks 52, 76 and 100 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 76	66.9 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DLQI Score of 0 or 1 at Weeks 52, 76 and 100 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	56.5 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DLQI Score of 0 or 1 at Weeks 52, 76 and 100 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 100	74.7 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DLQI Score of 0 or 1 at Weeks 52, 76 and 100 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 76	66.7 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DLQI Score of 0 or 1 at Weeks 52, 76 and 100 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	68.4 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DLQI Score of 0 or 1 at Weeks 52, 76 and 100 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 100	69.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DLQI Score of 0 or 1 at Weeks 52, 76 and 100 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	68.5 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DLQI Score of 0 or 1 at Weeks 52, 76 and 100 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 100	64.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DLQI Score of 0 or 1 at Weeks 52, 76 and 100 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 76	68.9 percentage of participants

Secondary

Percentage of Participants Who Achieved a DLQI Score of 0 or 1 Through Week 24 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

Dermatology Life Quality Index (DLQI) is a 10-item instrument questionnaire used to assess the patient's perspective of the impact of psoriasis on daily living. Each item was scored on a 4-point scale (0 =not at all /not relevant; 1 =a little; 2 =a lot; 3 =very much), and the total score (0-30) is the sum of the 10 items. The higher the score, the more quality of life is impaired. A DLQI score of 0 or 1 indicates psoriasis had no effect at all on patient's life.

Time frame: Weeks 8, 16, 24

Population: FAS1 among participants with DLQI \>1, \>=3% BSA of psoriasis and IGA score \>=2 (mild) at baseline. Participants with DLQI score of 0/1 at specific time point and did not meet TF criteria before, considered responders at that time point. Participants who met 1/more TF criteria before or with missing data at that time point considered non-responders.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DLQI Score of 0 or 1 Through Week 24 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 16	10.0 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DLQI Score of 0 or 1 Through Week 24 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 8	7.6 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DLQI Score of 0 or 1 Through Week 24 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	11.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DLQI Score of 0 or 1 Through Week 24 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 16	51.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DLQI Score of 0 or 1 Through Week 24 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 8	33.5 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a DLQI Score of 0 or 1 Through Week 24 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	63.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DLQI Score of 0 or 1 Through Week 24 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 8	26.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DLQI Score of 0 or 1 Through Week 24 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	59.0 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a DLQI Score of 0 or 1 Through Week 24 Among the Participants With DLQI Score >1, With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 16	45.1 percentage of participants

Secondary

Percentage of Participants Who Achieved an ACR 50 Response at Week 24

ACR 50 response was defined as greater than or equal to (\>=)50 percent (%) improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and C-Reactive Protein (CRP).

Time frame: Week 24

Population: Analysis population is FAS1. Participants who achieved ACR 50 response at Week 24 and did not meet any TF criteria before Week 24 were considered as responders. Participants who met 1 or more TF criteria or with missing data were considered as non-responders.

Arm	Measure	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved an ACR 50 Response at Week 24	14.2 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved an ACR 50 Response at Week 24	31.5 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved an ACR 50 Response at Week 24	33.1 percentage of participants

p-value: <0.00195% CI: [10, 24.4]Cochran-Mantel-Haenszel

p-value: <0.00195% CI: [11.5, 26.1]Cochran-Mantel-Haenszel

Secondary

Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 16

ACR 20 response was defined as \>= 20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.

Time frame: Week 16

Population: Analysis population is FAS1. Participants who achieved ACR 20 response at Week 16 and did not meet any TF criteria before Week 16 were considered as responders. Participants who met 1 or more TF criteria before Week 16 or with missing data were considered as non-responders.

Arm	Measure	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 16	33.7 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 16	55.2 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 16	55.9 percentage of participants

p-value: <0.00195% CI: [13.1, 30]Cochran-Mantel-Haenszel

p-value: <0.00195% CI: [13.7, 30.7]Cochran-Mantel-Haenszel

Secondary

Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 50 Response at Week 16

ACR 50 response was defined as \>= 50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.

Time frame: Week 16

Population: Analysis population is FAS1. Participants who achieved ACR 50 response at Week 16 and did not meet any TF criteria before Week 16 were considered as responders. Participants who met 1 or more TF criteria or with missing data were considered as non-responders.

Arm	Measure	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 50 Response at Week 16	9.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 50 Response at Week 16	28.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 50 Response at Week 16	20.8 percentage of participants

p-value: <0.00195% CI: [12.6, 25.9]Cochran-Mantel-Haenszel

p-value: <0.00195% CI: [5.2, 17.7]Cochran-Mantel-Haenszel

Secondary

Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 70 Response at Week 24

ACR 70 response was defined as \>= 70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.

Time frame: Week 24

Population: Analysis population is FAS1. Participants who achieved ACR 70 response at Week 24 and did not meet any TF criteria before Week 24 were considered as responders. Participants who met 1 or more TF criteria or with missing data were considered as non-responders.

Arm	Measure	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 70 Response at Week 24	4.1 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 70 Response at Week 24	18.5 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 70 Response at Week 24	13.1 percentage of participants

p-value: <0.00195% CI: [9.1, 19.9]Cochran-Mantel-Haenszel

p-value: <0.00195% CI: [4.1, 13.8]Cochran-Mantel-Haenszel

Secondary

Percentage of Participants Who Achieved an IGA Response at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>= 2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Time frame: Weeks 24 and 52

Population: Analysis population is FAS2 among the participants who had \>=3% BSA of psoriatic involvement and an IGA score \>=2 (mild) at baseline.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved an IGA Response at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	19.9 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved an IGA Response at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	84.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved an IGA Response at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	72.1 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved an IGA Response at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	77.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved an IGA Response at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	71.0 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved an IGA Response at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	84.4 percentage of participants

Secondary

Percentage of Participants Who Achieved an IGA Score of 0 (Cleared) at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

Time frame: Weeks 24 and 52

Population: Analysis population is FAS2 among the participants who had \>=3% BSA of psoriatic involvement and an IGA score \>=2 (mild) at baseline.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved an IGA Score of 0 (Cleared) at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	8.0 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved an IGA Score of 0 (Cleared) at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	66.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved an IGA Score of 0 (Cleared) at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	51.2 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved an IGA Score of 0 (Cleared) at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	60.0 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved an IGA Score of 0 (Cleared) at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	52.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved an IGA Score of 0 (Cleared) at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	66.5 percentage of participants

Secondary

Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 24, 28, 36, 44 and 52

The modified PsARC response was defined as improvement in at least 2 of the four criteria: \>=30% decrease in swollen joint count, \>=30% decrease in tender joint count, \>=20% improvement in patient's Global Assessment of Disease Activity (arthritis) on a VAS (0-100 mm, 0=excellent and 100= poor), \>=20% improvement in physician's Global Assessment of Disease Activity using VAS (VAS: 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), and at least one of the 2 joint criteria with no deterioration in the other criteria.

Time frame: Weeks 24, 28, 36, 44 and 52

Population: Analysis population is FAS2. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 24, 28, 36, 44 and 52	Week 44	77.6 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 24, 28, 36, 44 and 52	Week 36	78.7 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 24, 28, 36, 44 and 52	Week 24	46.6 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 24, 28, 36, 44 and 52	Week 28	64.6 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 24, 28, 36, 44 and 52	Week 52	81.2 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 24, 28, 36, 44 and 52	Week 36	82.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 24, 28, 36, 44 and 52	Week 24	76.4 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 24, 28, 36, 44 and 52	Week 28	79.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 24, 28, 36, 44 and 52	Week 44	83.7 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 24, 28, 36, 44 and 52	Week 52	86.3 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 24, 28, 36, 44 and 52	Week 52	82.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 24, 28, 36, 44 and 52	Week 44	82.2 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 24, 28, 36, 44 and 52	Week 24	72.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 24, 28, 36, 44 and 52	Week 36	84.3 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 24, 28, 36, 44 and 52	Week 28	83.1 percentage of participants

Secondary

Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 52, 68, 76, 84 and 100

Time frame: Weeks 52, 68, 76, 84 and 100

Population: Analysis population is FAS3 which included all participants still on treatment at Week 52. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 52, 68, 76, 84 and 100	Week 100	86.3 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 52, 68, 76, 84 and 100	Week 68	84.3 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 52, 68, 76, 84 and 100	Week 52	81.4 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 52, 68, 76, 84 and 100	Week 76	84.6 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 52, 68, 76, 84 and 100	Week 84	87.4 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 52, 68, 76, 84 and 100	Week 76	88.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 52, 68, 76, 84 and 100	Week 100	89.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 52, 68, 76, 84 and 100	Week 84	87.7 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 52, 68, 76, 84 and 100	Week 68	89.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 52, 68, 76, 84 and 100	Week 52	86.2 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 52, 68, 76, 84 and 100	Week 100	88.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 52, 68, 76, 84 and 100	Week 68	87.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 52, 68, 76, 84 and 100	Week 76	90.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 52, 68, 76, 84 and 100	Week 84	87.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 52, 68, 76, 84 and 100	Week 52	83.6 percentage of participants

Secondary

Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) Through Week 24

Time frame: Weeks 2, 4, 8, 12, 16, 20 and 24

Population: Analysis population is FAS1. Participants who achieved a modified PsARC response at a specific time point and did not meet any TF criteria before, were considered as responders at that time point. Participants who met 1 or more TF criteria before or with missing data at that time point were considered as non-responders.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) Through Week 24	Week 4	27.2 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) Through Week 24	Week 16	44.7 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) Through Week 24	Week 12	40.7 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) Through Week 24	Week 2	13.0 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) Through Week 24	Week 24	44.7 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) Through Week 24	Week 20	46.7 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) Through Week 24	Week 8	35.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) Through Week 24	Week 12	60.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) Through Week 24	Week 2	22.2 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) Through Week 24	Week 4	32.7 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) Through Week 24	Week 8	48.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) Through Week 24	Week 16	66.5 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) Through Week 24	Week 20	72.2 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) Through Week 24	Week 24	72.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) Through Week 24	Week 16	66.5 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) Through Week 24	Week 4	29.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) Through Week 24	Week 24	68.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) Through Week 24	Week 20	69.0 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) Through Week 24	Week 12	60.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) Through Week 24	Week 8	50.2 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) Through Week 24	Week 2	18.0 percentage of participants

Secondary

Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

In PASI, each area (head, trunk, upper and lower extremities) was assessed for % of area involved and translated to numeric score from 0 (no involvement) to 6 (90-100% involvement) and for erythema, induration, and scaling, each rated on scale of 0 to 4. PASI produces numeric score from 0 to 72. Higher scores=more severe disease. PASI 75: \>=75% improvement in PASI score from baseline. ACR 20: \>=20% improvement in SJC (66 joints)+TJC (68 joints) and \>=20% improvement in 3 of 5: patient's assessment of pain (VAS; 0-100 mm, 0=no pain to 100=worst possible pain), PtGA of disease activity (VAS; 0-100 mm, 0=excellent to 100=poor), PGA of disease activity (VAS; 0-100 mm, 0=no arthritis to 100=extremely active arthritis), patient's assessment of physical function (HAQ-DI -20-question instrument; range- 0=no difficulty to 3=inability to perform task) and CRP.

Time frame: Weeks 24 and 52

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	11.4 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	59.6 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	58.1 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	73.5 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	59.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	69.9 percentage of participants

Secondary

Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

In PASI, each area (head, trunk, upper and lower extremities) was assessed for % of area involved and translated to numeric score from 0 (no involvement) to 6 (90-100% involvement) and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI produces numeric score from 0 to 72. Higher scores=more severe disease. PASI 75: \>=75% improvement in PASI score from baseline. ACR 20: \>=20% improvement in swollen joint count (SJC) (66 joints) + tender joint count (TJC) (68 joints) and \>=20% improvement in 3 of 5: patient's assessment of pain (VAS; 0-100 mm, 0=no pain to 100=worst possible pain), PtGA of disease activity (VAS; 0-100 mm, 0=excellent to 100=poor), PGA of disease activity (VAS; 0-100 mm, 0=no arthritis to 100=extremely active arthritis), patient's assessment of physical function (HAQ-DI -20-question instrument; range- 0=no difficulty to 3=inability to perform task) and CRP.

Time frame: Weeks 52, 76 and 100

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 76	71.1 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	59.4 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 100	73.0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 76	75.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	73.4 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 100	76.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	70.5 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 100	77.5 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 76	76.7 percentage of participants

Secondary

Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

In PASI, each area (head, trunk, upper and lower extremities) was assessed for % of area involved and translated to numeric score from 0 (no involvement) to 6 (90-100% involvement) and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI produces numeric score from 0 to 72. Higher scores=more severe disease. PASI 75: \>=75% improvement in PASI score from baseline. ACR 20: \>=20% improvement in swollen joint count (SJC) (66 joints) + tender joint count (TJC) (68 joints) and \>=20% improvement in 3 of 5: patient's assessment of pain (VAS; 0-100 mm, 0=no pain to 100=worst possible pain), PtGA of disease activity (VAS; 0-100 mm, 0=excellent to 100=poor), PGA of disease activity (VAS; 0-100 mm, 0=no arthritis to 100=extremely active arthritis), patient's assessment of physical function (HAQ-DI -20-question instrument; range- 0=no difficulty to 3=inability to perform task) and CRP.

Time frame: Weeks 16 and 24

Population: FAS1 participants with \>=3% BSA psoriatic involvement and IGA score \>=2 at baseline. Participants with both PASI75 and ACR20 responses at specific timepoint and did not meet TF criteria before, considered responders at that time point. Participants who met 1/more TF criteria before or with missing data at that time point considered non-responders.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 16	10.4 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	11.5 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 16	48.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	56.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 16	48.4 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	57.1 percentage of participants

Secondary

Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

In PASI, each area (head, trunk, upper and lower extremities) was assessed separately for % of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90-100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4. PASI produces numeric score range from 0 to 72. Higher scores=more severe disease. PASI75 response: \>=75% improvement in PASI score from baseline. Modified PsARC response: improvement in at least 2 of 4 criteria: \>=30% decrease in SJC and TJC, \>=20% improvement in PtGA of Disease Activity (arthritis) on VAS (0-100 mm, 0=excellent and 100=poor), \>=20% improvement in PGA of Disease Activity on VAS (VAS: 0-100 mm, 0=no arthritis and 100=extremely active arthritis), and at least 1 of 2 joint criteria with no deterioration in other criteria.

Time frame: Weeks 24 and 52

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	15.3 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	70.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	66.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	79.4 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	63.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	76.3 percentage of participants

Secondary

Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response at Weeks 52, 76, and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

In PASI, each area (head, trunk, upper and lower extremities) was assessed separately for % of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90-100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI produces numeric score range from 0 to 72. Higher scores=more severe disease. PASI 75 response: \>=75% improvement in PASI score from baseline. Modified PsARC response: improvement in at least 2 of 4 criteria: \>=30% decrease in SJC and TJC, \>=20% improvement in PtGA of Disease Activity (arthritis) on VAS (0-100 mm, 0=excellent and 100=poor), \>=20% improvement in PGA of Disease Activity on VAS (VAS: 0-100 mm, 0=no arthritis and 100=extremely active arthritis), and at least 1 of 2 joint criteria with no deterioration in other criteria.

Time frame: Weeks 52, 76 and 100

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response at Weeks 52, 76, and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 76	78.3 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response at Weeks 52, 76, and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	70.8 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response at Weeks 52, 76, and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 100	78.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response at Weeks 52, 76, and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 76	79.4 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response at Weeks 52, 76, and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	79.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response at Weeks 52, 76, and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 100	81.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response at Weeks 52, 76, and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	76.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response at Weeks 52, 76, and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 100	78.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response at Weeks 52, 76, and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 76	82.6 percentage of participants

Secondary

Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

In PASI, each area (head, trunk, upper and lower extremities) was assessed separately for % of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90-100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI produces numeric score range from 0 to 72. Higher scores=more severe disease. PASI 75 response: \>=75% improvement in PASI score from baseline. Modified PsARC response: improvement in at least 2 of 4 criteria: \>=30% decrease in SJC and TJC, \>=20% improvement in PtGA of Disease Activity (arthritis) on VAS (0-100 mm, 0=excellent and 100=poor), \>=20% improvement in PGA of Disease Activity on VAS (VAS: 0-100 mm, 0=no arthritis and 100=extremely active arthritis), and at least 1 of 2 joint criteria with no deterioration in other criteria.

Time frame: Weeks 16 and 24

Population: FAS1 with \>=3% BSA psoriatic involvement and IGA score \>=2 at baseline. Participants with both PASI 75 and modified PsARC responses at specific timepoint and did not meet TF criteria before, considered responders at that time point. Participants who met 1/more TF criteria before or with missing data at that time point considered non-responders.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 16	13.1 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	15.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 16	56.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	65.3 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 16	54.3 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	60.9 percentage of participants

Secondary

Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 24 and 52

MDA is a measure that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved the PsA MDA at a visit if the participant has fulfilled at least 5 of the following 7 criteria at that visit: Tender joint count (68 joints)\<=1, Swollen joint count (66 joints) \<=1, Psoriasis activity and severity index \<=1, Patient's Assessment of Pain \<=15 on a 100-unit VAS, Patient's Global Assessment of Disease Activity (arthritis and psoriasis) \<=20 on a 100-unit VAS, HAQ-DI score \<=0.5, and Tender entheseal points \<= 1 (LEI index score \<= 1).

Time frame: Weeks 24 and 52

Population: Analysis population is FAS2. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 24 and 52	Week 24	6.3 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 24 and 52	Week 52	31.6 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 24 and 52	Week 24	26.5 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 24 and 52	Week 52	32.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 24 and 52	Week 24	19.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 24 and 52	Week 52	36.8 percentage of participants

Secondary

Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 52, 76 and 100

Time frame: Weeks 52, 76 and 100

Population: Analysis population is FAS3 which included all participants still on treatment at Week 52. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 52, 76 and 100	Week 76	34.7 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 52, 76 and 100	Week 52	32.0 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 52, 76 and 100	Week 100	42.5 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 52, 76 and 100	Week 76	40.0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 52, 76 and 100	Week 52	32.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 52, 76 and 100	Week 100	44.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 52, 76 and 100	Week 52	37.2 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 52, 76 and 100	Week 100	42.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 52, 76 and 100	Week 76	39.0 percentage of participants

Secondary

Percentage of Participants Who Achieved Minimal Disease Activity (MDA) Criteria Through Week 24

Time frame: Weeks 16 and 24

Population: Analysis population is FAS1. Participants who achieved MDA at a specific time point and did not meet any TF criteria before, were considered as responders at that time point. Participants who met 1 or more TF criteria before or with missing data at that time point were considered as non-responders.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Minimal Disease Activity (MDA) Criteria Through Week 24	Week 16	3.3 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Minimal Disease Activity (MDA) Criteria Through Week 24	Week 24	6.1 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved Minimal Disease Activity (MDA) Criteria Through Week 24	Week 16	16.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved Minimal Disease Activity (MDA) Criteria Through Week 24	Week 24	25.0 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Minimal Disease Activity (MDA) Criteria Through Week 24	Week 16	13.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Minimal Disease Activity (MDA) Criteria Through Week 24	Week 24	18.8 percentage of participants

Secondary

Percentage of Participants Who Achieved PASI 100 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 100 response: 100% improvement in PASI score from baseline.

Time frame: Weeks 24 and 52

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 100 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	2.8 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 100 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	55.2 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved PASI 100 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	46.5 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved PASI 100 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	54.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 100 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	46.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 100 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	61.3 percentage of participants

Secondary

Percentage of Participants Who Achieved PASI 100 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 100 response: 100% improvement in PASI score from baseline.

Time frame: Weeks 52, 76 and 100

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 100 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 76	65.1 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 100 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	55.0 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 100 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 100	69.4 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved PASI 100 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 76	59.4 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved PASI 100 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	54.4 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved PASI 100 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 100	57.3 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 100 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	60.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 100 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 100	64.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 100 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 76	68.0 percentage of participants

Secondary

Percentage of Participants Who Achieved PASI 100 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline

PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 100 response: 100% improvement in PASI score from baseline.

Time frame: Weeks 16 and 24

Population: FAS1 among participants with \>=3% BSA of psoriasis and IGA score \>=2 at baseline. Participants with PASI 100 response at specific time point and did not meet any TF criteria before, were considered responders at that time point. Participants who met 1/more TF criteria before or with missing data at that time point were considered non-responders.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 100 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline	Week 16	3.8 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 100 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline	Week 24	2.7 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved PASI 100 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline	Week 16	27.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved PASI 100 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline	Week 24	45.5 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 100 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline	Week 16	33.2 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 100 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline	Week 24	44.6 percentage of participants

Secondary

Percentage of Participants Who Achieved PASI 50 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 50 response: \>=50% improvement in PASI score from baseline.

Time frame: Weeks 24 and 52

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 50 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	95.9 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 50 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	39.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved PASI 50 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	94.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved PASI 50 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	97.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 50 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	93.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 50 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	98.3 percentage of participants

Secondary

Percentage of Participants Who Achieved PASI 50 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 50 response: \>=50% improvement in PASI score from baseline.

Time frame: Weeks 52, 76 and 100

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 50 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 76	97.6 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 50 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	95.9 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 50 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 100	95.6 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved PASI 50 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 76	96.4 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved PASI 50 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	97.0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved PASI 50 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 100	97.0 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 50 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	98.3 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 50 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 100	98.2 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 50 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 76	97.1 percentage of participants

Secondary

Percentage of Participants Who Achieved PASI 75 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 75 response: \>=75% improvement in PASI score from baseline.

Time frame: Weeks 24 and 52

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 75 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	23.3 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 75 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	88.4 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved PASI 75 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	80.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved PASI 75 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	88.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 75 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	81.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 75 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	91.9 percentage of participants

Secondary

Percentage of Participants Who Achieved PASI 75 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 75 response: \>=75% improvement in PASI score from baseline.

Time frame: Weeks 52, 76 and 100

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 75 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 76	92.8 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 75 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	88.3 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 75 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 100	91.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved PASI 75 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 76	87.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved PASI 75 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	88.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved PASI 75 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 100	87.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 75 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	91.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 75 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 100	89.4 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 75 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 76	93.0 percentage of participants

Secondary

Percentage of Participants Who Achieved PASI 75 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 75 response: \>=75% improvement in PASI score from baseline.

Time frame: Weeks 16 and 24

Population: FAS1 among participants with \>=3% BSA of psoriasis and IGA score \>=2 at baseline. Participants with PASI 75 response at specific time point and did not meet any TF criteria before, were considered responders at that time point. Participants who met 1/more TF criteria before or with missing data at that time point were considered non-responders.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 75 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 16	18.6 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 75 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	23.0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved PASI 75 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 16	73.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved PASI 75 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	79.0 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 75 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 16	73.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 75 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	78.3 percentage of participants

Secondary

Percentage of Participants Who Achieved PASI 90 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 90 response: \>=90% improvement in PASI score from baseline.

Time frame: Weeks 24 and 52

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 90 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	10.2 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 90 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	76.7 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved PASI 90 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	70.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved PASI 90 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	77.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 90 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	63.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 90 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	81.5 percentage of participants

Secondary

Percentage of Participants Who Achieved PASI 90 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 90 response: \>=90% improvement in PASI score from baseline.

Time frame: Weeks 52, 76 and 100

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 90 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 76	85.5 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 90 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	76.6 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 90 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 100	87.5 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved PASI 90 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 76	75.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved PASI 90 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	76.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved PASI 90 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 100	75.0 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 90 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	81.5 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 90 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 100	80.0 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 90 Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 76	80.2 percentage of participants

Secondary

Percentage of Participants Who Achieved PASI 90 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 90 response: \>=90% improvement in PASI score from baseline.

Time frame: Weeks 16 and 24

Population: FAS1 among participants with \>=3% BSA of psoriasis and IGA score \>=2 at baseline. Participants with PASI 90 response at specific time point and did not meet any TF criteria before, were considered responders at that time point. Participants who met 1 or more TF criteria before or with missing data at that time point were considered non-responders.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 90 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 16	8.2 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 90 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	9.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved PASI 90 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 16	55.1 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved PASI 90 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	68.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 90 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 16	53.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved PASI 90 Response Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	60.9 percentage of participants

Secondary

Percentage of Participants Who Achieved Psoriasis Response With IGA Score of 0 (Cleared) or 1 (Minimal) and >=2 Grade Reduction From Baseline at Week 24 Among Participants With >=3% BSA Psoriatic Involvement and IGA Score of >=2 (Mild) at Baseline

A psoriasis Investigator's Global Assessment (IGA) response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>=2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Time frame: Week 24

Population: FAS1 among participants with \>=3% BSA psoriatic involvement and an IGA score \>=2 (mild) at baseline. Participants who achieved psoriasis IGA response at Week 24 and did not meet any TF criteria before Week 24 were considered as responders. Participants who met 1 or more TF criteria or with missing data were considered as non-responders.

Arm	Measure	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Psoriasis Response With IGA Score of 0 (Cleared) or 1 (Minimal) and >=2 Grade Reduction From Baseline at Week 24 Among Participants With >=3% BSA Psoriatic Involvement and IGA Score of >=2 (Mild) at Baseline	19.1 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Achieved Psoriasis Response With IGA Score of 0 (Cleared) or 1 (Minimal) and >=2 Grade Reduction From Baseline at Week 24 Among Participants With >=3% BSA Psoriatic Involvement and IGA Score of >=2 (Mild) at Baseline	70.5 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Achieved Psoriasis Response With IGA Score of 0 (Cleared) or 1 (Minimal) and >=2 Grade Reduction From Baseline at Week 24 Among Participants With >=3% BSA Psoriatic Involvement and IGA Score of >=2 (Mild) at Baseline	68.5 percentage of participants

p-value: <0.00195% CI: [42.2, 59.7]Cochran-Mantel-Haenszel

p-value: <0.00195% CI: [41.2, 58.4]Cochran-Mantel-Haenszel

Secondary

Percentage of Participants Who Maintained a HAQ-DI Response (>=0.35 Improvement From Baseline in HAQ-DI Score) at Week 100 Among Participants Who Achieved a HAQ-DI Response at Week 52

HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3, where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.

Time frame: Week 100

Population: Analysis population is FAS3 among participants with HAQ-DI Score \>=0.35 at Baseline and who achieved a HAQ-DI response at Week 52. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure.

Arm	Measure	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Maintained a HAQ-DI Response (>=0.35 Improvement From Baseline in HAQ-DI Score) at Week 100 Among Participants Who Achieved a HAQ-DI Response at Week 52	91.6 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Maintained a HAQ-DI Response (>=0.35 Improvement From Baseline in HAQ-DI Score) at Week 100 Among Participants Who Achieved a HAQ-DI Response at Week 52	90.4 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Maintained a HAQ-DI Response (>=0.35 Improvement From Baseline in HAQ-DI Score) at Week 100 Among Participants Who Achieved a HAQ-DI Response at Week 52	88.5 percentage of participants

Secondary

Percentage of Participants Who Maintained a HAQ-DI Response (>=0.35 Improvement From Baseline in HAQ-DI Score) at Week 52 Among Participants Who Achieved a HAQ-DI Response at Week 24

HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.

Time frame: Week 52

Population: Analysis population is FAS2 among participants who achieved a HAQ-DI response at Week 24. The OM was planned to assess the maintenance of guselkumab effect only through Week 52, hence the data in this outcome measure is reported for guselkumab 100 mg q8w and guselkumab 100 mg q4w arms only and not for placebo arm.

Arm	Measure	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Maintained a HAQ-DI Response (>=0.35 Improvement From Baseline in HAQ-DI Score) at Week 52 Among Participants Who Achieved a HAQ-DI Response at Week 24	92.0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Maintained a HAQ-DI Response (>=0.35 Improvement From Baseline in HAQ-DI Score) at Week 52 Among Participants Who Achieved a HAQ-DI Response at Week 24	88.6 percentage of participants

Secondary

Percentage of Participants Who Maintained an ACR 20 Response at Week 100 Among Participants Who Achieved an ACR 20 Response at Week 52

Time frame: Week 100

Population: FAS3 among participants who achieved ACR20 response at Week 52.

Arm	Measure	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Maintained an ACR 20 Response at Week 100 Among Participants Who Achieved an ACR 20 Response at Week 52	94.6 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Maintained an ACR 20 Response at Week 100 Among Participants Who Achieved an ACR 20 Response at Week 52	90.4 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Maintained an ACR 20 Response at Week 100 Among Participants Who Achieved an ACR 20 Response at Week 52	93.0 percentage of participants

Secondary

Percentage of Participants Who Maintained an ACR 20 Response at Week 52 Among Participants Who Achieved an ACR 20 Response at Week 24

Time frame: Week 52

Population: FAS2 among participants achieved ACR20 response at Week 24. Here, N (number of participants analyzed) signifies number of participants analyzed for this OM. OM was planned to assess maintenance of guselkumab effect only through Week 52, hence data is reported for guselkumab 100mg q8w and guselkumab 100mg q4w arms only and not for placebo arm.

Arm	Measure	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Maintained an ACR 20 Response at Week 52 Among Participants Who Achieved an ACR 20 Response at Week 24	91.7 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Maintained an ACR 20 Response at Week 52 Among Participants Who Achieved an ACR 20 Response at Week 24	86.8 percentage of participants

Secondary

Percentage of Participants Who Maintained an ACR 50 Response at Week 100 Among Participants Who Achieved an ACR 50 Response at Week 52

Time frame: Week 100

Population: FAS3 among participants who achieved ACR50 response at Week 52.

Arm	Measure	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Maintained an ACR 50 Response at Week 100 Among Participants Who Achieved an ACR 50 Response at Week 52	81.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Maintained an ACR 50 Response at Week 100 Among Participants Who Achieved an ACR 50 Response at Week 52	81.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Maintained an ACR 50 Response at Week 100 Among Participants Who Achieved an ACR 50 Response at Week 52	83.8 percentage of participants

Secondary

Percentage of Participants Who Maintained an ACR 50 Response at Week 52 Among Participants Who Achieved an ACR 50 Response at Week 24

Time frame: Week 52

Population: FAS2 among participants achieved ACR50 response at Week 24. Here, N (number of participants analyzed) signifies number of participants analyzed for this OM. The OM was planned to assess maintenance of guselkumab effect only through Week 52, hence data is reported for guselkumab 100 mg q8w and guselkumab 100 mg q4w arms only and not for placebo arm.

Arm	Measure	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Maintained an ACR 50 Response at Week 52 Among Participants Who Achieved an ACR 50 Response at Week 24	87.2 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Maintained an ACR 50 Response at Week 52 Among Participants Who Achieved an ACR 50 Response at Week 24	79.2 percentage of participants

Secondary

Percentage of Participants Who Maintained an ACR 70 Response at Week 100 Among Participants Who Achieved an ACR 70 Response at Week 52

ACR 70 response was defined as \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 millimeters \[mm\], 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

Time frame: Week 100

Population: FAS3 among participants who achieved ACR70 response at Week 52.

Arm	Measure	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Maintained an ACR 70 Response at Week 100 Among Participants Who Achieved an ACR 70 Response at Week 52	65.1 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Maintained an ACR 70 Response at Week 100 Among Participants Who Achieved an ACR 70 Response at Week 52	80.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Who Maintained an ACR 70 Response at Week 100 Among Participants Who Achieved an ACR 70 Response at Week 52	71.9 percentage of participants

Secondary

Percentage of Participants Who Maintained an ACR 70 Response at Week 52 Among Participants Who Achieved an ACR 70 Response at Week 24

ACR 70 response was defined as \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 millimeters \[mm\], 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.

Time frame: Week 52

Population: Analysis population is FAS2 among participants who achieved ACR 70 response at Week 24. The outcome measure was planned to assess the maintenance of guselkumab effect only through Week 52, hence the data in this outcome measure is reported for guselkumab 100 mg q8w and guselkumab 100 mg q4w arms only and not for placebo arm.

Arm	Measure	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Who Maintained an ACR 70 Response at Week 52 Among Participants Who Achieved an ACR 70 Response at Week 24	82.6 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Who Maintained an ACR 70 Response at Week 52 Among Participants Who Achieved an ACR 70 Response at Week 24	75.0 percentage of participants

Secondary

Percentage of Participants With a Change of <=0 From Baseline and <=0.5 From Baseline in Modified vdH-S Erosion Score at Week 24

Time frame: Week 24

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With a Change of <=0 From Baseline and <=0.5 From Baseline in Modified vdH-S Erosion Score at Week 24	Change of <=0 from Baseline	66.8 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With a Change of <=0 From Baseline and <=0.5 From Baseline in Modified vdH-S Erosion Score at Week 24	Change of <=0.5 from Baseline	72.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With a Change of <=0 From Baseline and <=0.5 From Baseline in Modified vdH-S Erosion Score at Week 24	Change of <=0 from Baseline	66.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With a Change of <=0 From Baseline and <=0.5 From Baseline in Modified vdH-S Erosion Score at Week 24	Change of <=0.5 from Baseline	76.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With a Change of <=0 From Baseline and <=0.5 From Baseline in Modified vdH-S Erosion Score at Week 24	Change of <=0 from Baseline	71.4 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With a Change of <=0 From Baseline and <=0.5 From Baseline in Modified vdH-S Erosion Score at Week 24	Change of <=0.5 from Baseline	80.2 percentage of participants

Secondary

Percentage of Participants With a Change of <=0 From Baseline and <=0.5 From Baseline in Modified vdH-S JSN Score at Week 24

The modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). The JSN score is the sum of JSN score in 40 joints of the two hands and 12 joints of the 2 feet. Each joint is scored from 0 - 4 with 0 indicating no JSN, and 4 indicating a complete loss of joint space, bony ankylosis, or complete luxation, for a maximum JSN score of 208. Higher score indicates more severe joint space narrowing. Change from baseline in the modified vdH-S JSN score \<=0 (assessed by both readers) or \<=0.5 (assessed by at least one reader) was considered as no progression of JSN.

Time frame: Week 24

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With a Change of <=0 From Baseline and <=0.5 From Baseline in Modified vdH-S JSN Score at Week 24	Change of <=0 from Baseline	78.6 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With a Change of <=0 From Baseline and <=0.5 From Baseline in Modified vdH-S JSN Score at Week 24	Change of <=0.5 from Baseline	85.5 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With a Change of <=0 From Baseline and <=0.5 From Baseline in Modified vdH-S JSN Score at Week 24	Change of <=0 from Baseline	78.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With a Change of <=0 From Baseline and <=0.5 From Baseline in Modified vdH-S JSN Score at Week 24	Change of <=0.5 from Baseline	88.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With a Change of <=0 From Baseline and <=0.5 From Baseline in Modified vdH-S JSN Score at Week 24	Change of <=0 from Baseline	80.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With a Change of <=0 From Baseline and <=0.5 From Baseline in Modified vdH-S JSN Score at Week 24	Change of <=0.5 from Baseline	88.3 percentage of participants

Secondary

Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Erosion Score at Week 52

Time frame: Week 52

Population: FAS2 for structural damage (FAS2-SD) among all randomized participants who were continuing study treatment at Week 24. Here, n (number analyzed) signifies the number of participants analyzed at specified category.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Erosion Score at Week 52	Change of <=0 from Baseline	58.3 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Erosion Score at Week 52	Change of <=0.5 from Baseline	70.4 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Erosion Score at Week 52	Change of <=0 from Baseline	59.6 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Erosion Score at Week 52	Change of <=0.5 from Baseline	71.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Erosion Score at Week 52	Change of <=0 from Baseline	60.3 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Erosion Score at Week 52	Change of <=0.5 from Baseline	72.1 percentage of participants

Secondary

Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S JSN Score at Week 52

Time frame: Week 52

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S JSN Score at Week 52	Change of <=0 from Baseline	78.7 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S JSN Score at Week 52	Change of <=0.5 from Baseline	88.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S JSN Score at Week 52	Change of <=0 from Baseline	75.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S JSN Score at Week 52	Change of <=0.5 from Baseline	86.0 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S JSN Score at Week 52	Change of <=0 from Baseline	79.5 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S JSN Score at Week 52	Change of <=0.5 from Baseline	86.5 percentage of participants

Secondary

Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Score at Week 24

Time frame: Week 24

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Score at Week 24	Change of <=0 from Baseline	64.7 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Score at Week 24	Change of <=0.5 from Baseline	72.1 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Score at Week 24	Change of <=0 from Baseline	63.5 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Score at Week 24	Change of <=0.5 from Baseline	74.4 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Score at Week 24	Change of <=0 from Baseline	67.3 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Score at Week 24	Change of <=0.5 from Baseline	78.0 percentage of participants

Secondary

Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Score at Week 52

Time frame: Week 52

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Score at Week 52	Change of <=0 from Baseline	57.4 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Score at Week 52	Change of <=0.5 from Baseline	67.4 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Score at Week 52	Change of <=0 from Baseline	55.7 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Score at Week 52	Change of <=0.5 from Baseline	67.2 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Score at Week 52	Change of <=0 from Baseline	56.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline in Modified vdH-S Score at Week 52	Change of <=0.5 from Baseline	72.1 percentage of participants

Secondary

Percentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S Erosion Score

Time frame: Baseline to Week 100

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S Erosion Score	Change of <=0 from Baseline	64.2 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S Erosion Score	Change of <=0.5 from Baseline	75.0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S Erosion Score	Change of <=0 from Baseline	61.1 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S Erosion Score	Change of <=0.5 from Baseline	73.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S Erosion Score	Change of <=0 from Baseline	65.4 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S Erosion Score	Change of <=0.5 from Baseline	75.4 percentage of participants

Secondary

Percentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S JSN Score

Time frame: Baseline to Week 100

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S JSN Score	Change of <=0 from Baseline	77.5 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S JSN Score	Change of <=0.5 from Baseline	84.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S JSN Score	Change of <=0 from Baseline	68.5 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S JSN Score	Change of <=0.5 from Baseline	79.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S JSN Score	Change of <=0 from Baseline	73.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S JSN Score	Change of <=0.5 from Baseline	81.0 percentage of participants

Secondary

Percentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S Score

Time frame: Baseline to Week 100

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S Score	Change of <=0 from Baseline	60.8 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S Score	Change of <=0.5 from Baseline	72.1 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S Score	Change of <=0 from Baseline	55.6 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S Score	Change of <=0.5 from Baseline	63.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S Score	Change of <=0 from Baseline	62.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With a Change of <=0 or <=0.5 From Baseline to Week 100 in Modified vdH-S Score	Change of <=0.5 from Baseline	72.5 percentage of participants

Secondary

Percentage of Participants With an IGA Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

Time frame: Weeks 52, 76 and 100

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With an IGA Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 76	85.5 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With an IGA Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	84.2 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With an IGA Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 100	88.1 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With an IGA Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 76	77.6 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With an IGA Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	76.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With an IGA Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 100	76.4 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With an IGA Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	84.4 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With an IGA Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 100	82.4 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With an IGA Response at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 76	86.0 percentage of participants

Secondary

Percentage of Participants With an IGA Score of 0 (Cleared) at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

Time frame: Weeks 52, 76 and 100

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With an IGA Score of 0 (Cleared) at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 76	72.9 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With an IGA Score of 0 (Cleared) at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	66.7 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With an IGA Score of 0 (Cleared) at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 100	76.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With an IGA Score of 0 (Cleared) at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 76	64.2 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With an IGA Score of 0 (Cleared) at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	59.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With an IGA Score of 0 (Cleared) at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 100	58.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With an IGA Score of 0 (Cleared) at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 52	65.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With an IGA Score of 0 (Cleared) at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 100	67.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With an IGA Score of 0 (Cleared) at Weeks 52, 76 and 100 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 76	72.1 percentage of participants

Secondary

Percentage of Participants With an IGA Score of 0 (Cleared) Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>=2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Time frame: Weeks 16 and 24

Population: FAS1 among participants with \>=3% BSA of psoriasis and IGA score \>=2 at baseline. Participants with IGA score of 0(cleared) at specific time point and did not meet TF criteria before, were considered responders at that time point. Participants who met 1/more TF criteria before or with missing data at that time point were considered non-responders.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With an IGA Score of 0 (Cleared) Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 16	6.0 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With an IGA Score of 0 (Cleared) Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	7.7 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With an IGA Score of 0 (Cleared) Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 16	38.6 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With an IGA Score of 0 (Cleared) Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	50.0 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With an IGA Score of 0 (Cleared) Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 16	40.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With an IGA Score of 0 (Cleared) Through Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline	Week 24	51.5 percentage of participants

Secondary

Percentage of Participants With Low Disease Activity Based on Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 24 and 52

GRACE index is a composite PsA disease activity score converted from Arithmetic Mean of Desirability Function (AMDF), derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), PtGA of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100=poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), PtGA of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL=25.355 + \[2.367\*HAQ-DI\]-\[0.234\*SF-PCS\]-\[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score range= 0-100, higher scores= better quality of life) and SF-MCS (score range=0-100, higher scores= better quality of life). Total score is 0-10, lower score=better response. Higher score= more active disease activity. Negative change from baseline indicates improvement of PsA disease activity. GRACE low disease activity is GRACE score \<=2.3 at the analysis visit.

Time frame: Weeks 24 and 52

Population: Analysis population is FAS2. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity Based on Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 24 and 52	Week 24	7.6 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity Based on Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 24 and 52	Week 52	34.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Low Disease Activity Based on Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 24 and 52	Week 24	29.5 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Low Disease Activity Based on Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 24 and 52	Week 52	43.2 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity Based on Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 24 and 52	Week 24	27.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity Based on Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 24 and 52	Week 52	43.0 percentage of participants

Secondary

Percentage of Participants With Low Disease Activity Based on Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 52, 76 and 100

Time frame: Weeks 52, 76 and 100

Population: Analysis population is FAS3 which included all participants still on treatment at Week 52. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity Based on Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 52, 76 and 100	Week 76	45.7 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity Based on Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 52, 76 and 100	Week 52	35.4 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity Based on Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 52, 76 and 100	Week 100	48.1 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Low Disease Activity Based on Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 52, 76 and 100	Week 76	48.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Low Disease Activity Based on Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 52, 76 and 100	Week 52	42.7 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Low Disease Activity Based on Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 52, 76 and 100	Week 100	51.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity Based on Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 52, 76 and 100	Week 52	43.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity Based on Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 52, 76 and 100	Week 100	54.5 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity Based on Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 52, 76 and 100	Week 76	49.8 percentage of participants

Secondary

Percentage of Participants With Low Disease Activity Based on mCPDAI at Weeks 52, 76 and 100

Time frame: Weeks 52, 76 and 100

Population: Analysis population is FAS3 which included all participants still on treatment at Week 52. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity Based on mCPDAI at Weeks 52, 76 and 100	Week 100	67.5 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity Based on mCPDAI at Weeks 52, 76 and 100	Week 52	56.6 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity Based on mCPDAI at Weeks 52, 76 and 100	Week 76	64.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Low Disease Activity Based on mCPDAI at Weeks 52, 76 and 100	Week 76	63.7 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Low Disease Activity Based on mCPDAI at Weeks 52, 76 and 100	Week 100	71.7 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Low Disease Activity Based on mCPDAI at Weeks 52, 76 and 100	Week 52	61.2 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity Based on mCPDAI at Weeks 52, 76 and 100	Week 52	60.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity Based on mCPDAI at Weeks 52, 76 and 100	Week 100	68.0 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity Based on mCPDAI at Weeks 52, 76 and 100	Week 76	68.6 percentage of participants

Secondary

Percentage of Participants With Low Disease Activity Based on Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Weeks 24 and 52

Time frame: Weeks 24 and 52

Population: Analysis population is FAS2. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity Based on Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Weeks 24 and 52	Week 24	15.1 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity Based on Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Weeks 24 and 52	Week 52	56.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Low Disease Activity Based on Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Weeks 24 and 52	Week 24	48.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Low Disease Activity Based on Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Weeks 24 and 52	Week 52	61.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity Based on Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Weeks 24 and 52	Week 24	43.5 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity Based on Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Weeks 24 and 52	Week 52	60.1 percentage of participants

Secondary

Percentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100

DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL), patient assessment of pain (0-10 cm VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10 cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. The assessment does not have a score range with an upper or lower bound. Low: DAPSA\<=14; Remission: DAPSA\<=4.

Time frame: Weeks 52, 68, 76, 84 and 100

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100	Week 68: Remission	15.6 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100	Week 52: Low Disease Activity	50.7 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100	Week 52: Remission	10.2 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100	Week 68: Low Disease Activity	54.1 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100	Week 76: Low Disease Activity	58.2 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100	Week 76: Remission	16.4 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100	Week 84: Low Disease Activity	60.6 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100	Week 84: Remission	17.8 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100	Week 100: Low Disease Activity	61.9 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100	Week 100: Remission	18.6 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100	Week 100: Low Disease Activity	65.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100	Week 76: Remission	26.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100	Week 52: Low Disease Activity	55.2 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100	Week 76: Low Disease Activity	61.2 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100	Week 84: Remission	28.0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100	Week 52: Remission	19.4 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100	Week 100: Remission	26.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100	Week 84: Low Disease Activity	66.5 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100	Week 68: Low Disease Activity	64.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100	Week 68: Remission	23.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100	Week 68: Low Disease Activity	63.3 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100	Week 68: Remission	23.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100	Week 76: Low Disease Activity	61.4 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100	Week 76: Remission	19.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100	Week 100: Low Disease Activity	68.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100	Week 84: Low Disease Activity	64.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100	Week 100: Remission	23.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100	Week 52: Low Disease Activity	55.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100	Week 52: Remission	17.3 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Low Disease Activity or Remission Based on DAPSA at Weeks 52, 68, 76, 84 and 100	Week 84: Remission	23.6 percentage of participants

Secondary

Percentage of Participants With Low or Very Low Disease Activity Based on PASDAS at Weeks 52, 76 and 100

PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a composite score of overall disease activity combining PtGA of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), PGA of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0= 0 sites with tenderness to 6= worst possible score; 6 sites with tenderness), tender dactylitis count (scoring each digit from 0-3 \[where 0= no tenderness and 3= extreme tenderness\] and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score with score range 0-100 (higher score-better quality of life) of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity. Low: PASDAS \<= 3.2; Very low: PASDAS \<= 1.9.

Time frame: Weeks 52, 76 and 100

Population: Analysis population is FAS3. Here, n (number analyzed) signifies the number of participants analyzed for specified categories at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Low or Very Low Disease Activity Based on PASDAS at Weeks 52, 76 and 100	Week 52: Low	39.0 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Low or Very Low Disease Activity Based on PASDAS at Weeks 52, 76 and 100	Week 76: Low	52.1 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Low or Very Low Disease Activity Based on PASDAS at Weeks 52, 76 and 100	Week 100: Very Low	19.9 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Low or Very Low Disease Activity Based on PASDAS at Weeks 52, 76 and 100	Week 100: Low	55.3 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Low or Very Low Disease Activity Based on PASDAS at Weeks 52, 76 and 100	Week 76: Very Low	18.3 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Low or Very Low Disease Activity Based on PASDAS at Weeks 52, 76 and 100	Week 52: Very Low	13.0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Low or Very Low Disease Activity Based on PASDAS at Weeks 52, 76 and 100	Week 76: Very Low	23.4 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Low or Very Low Disease Activity Based on PASDAS at Weeks 52, 76 and 100	Week 52: Very Low	22.0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Low or Very Low Disease Activity Based on PASDAS at Weeks 52, 76 and 100	Week 100: Very Low	26.0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Low or Very Low Disease Activity Based on PASDAS at Weeks 52, 76 and 100	Week 76: Low	50.0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Low or Very Low Disease Activity Based on PASDAS at Weeks 52, 76 and 100	Week 52: Low	44.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Low or Very Low Disease Activity Based on PASDAS at Weeks 52, 76 and 100	Week 100: Low	54.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Low or Very Low Disease Activity Based on PASDAS at Weeks 52, 76 and 100	Week 100: Very Low	23.4 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Low or Very Low Disease Activity Based on PASDAS at Weeks 52, 76 and 100	Week 52: Low	46.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Low or Very Low Disease Activity Based on PASDAS at Weeks 52, 76 and 100	Week 52: Very Low	16.0 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Low or Very Low Disease Activity Based on PASDAS at Weeks 52, 76 and 100	Week 76: Low	49.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Low or Very Low Disease Activity Based on PASDAS at Weeks 52, 76 and 100	Week 76: Very Low	22.0 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Low or Very Low Disease Activity Based on PASDAS at Weeks 52, 76 and 100	Week 100: Low	57.8 percentage of participants

Secondary

Percentage of Participants With Low or Very Low Disease Activity Based on Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 24 and 52

Time frame: Weeks 24 and 52

Population: Analysis population is FAS2. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Low or Very Low Disease Activity Based on Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 24 and 52	Week 24	8.1 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Low or Very Low Disease Activity Based on Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 24 and 52	Week 52	38.5 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Low or Very Low Disease Activity Based on Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 24 and 52	Week 24	31.6 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Low or Very Low Disease Activity Based on Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 24 and 52	Week 52	45.3 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Low or Very Low Disease Activity Based on Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 24 and 52	Week 24	24.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Low or Very Low Disease Activity Based on Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 24 and 52	Week 52	46.3 percentage of participants

Secondary

Percentage of Participants Without Radiographic Erosion Progression (Based on SDC) From Baseline to Week 100

Modified vdH-S score is sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is summary of erosion severity in 40 joints of hand scored according to surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic erosion progression was defined as change from baseline in the modified vdH-S erosion score \<=SDC of 2.66.

Time frame: Baseline to Week 100

Arm	Measure	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Without Radiographic Erosion Progression (Based on SDC) From Baseline to Week 100	86.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Without Radiographic Erosion Progression (Based on SDC) From Baseline to Week 100	87.0 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Without Radiographic Erosion Progression (Based on SDC) From Baseline to Week 100	88.6 percentage of participants

Secondary

Percentage of Participants Without Radiographic Joint Erosion Progression (Based on SDC) From Baseline at Week 24

Modified vdH-S score is sum of erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC defined as the cut-off above which changes can be detected beyond measurement error. Without radiographic joint erosion progression was defined as change from baseline in modified vdH-S erosion score \<=SDC of 1.83.

Time frame: Week 24

Arm	Measure	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Without Radiographic Joint Erosion Progression (Based on SDC) From Baseline at Week 24	84.0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Without Radiographic Joint Erosion Progression (Based on SDC) From Baseline at Week 24	89.0 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Without Radiographic Joint Erosion Progression (Based on SDC) From Baseline at Week 24	89.9 percentage of participants

Secondary

Percentage of Participants Without Radiographic Joint Erosion Progression Based on (SDC) From Baseline at Week 52

Modified vdH-S score is sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is summary of erosion severity in 40 joints of hand scored according to surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is total JSN score in same 52 joints as above, each joint scored according to subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic joint erosion progression was defined as change from baseline in modified vdH-S erosion score \<=SDC of 2.22.

Time frame: Week 52

Arm	Measure	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Without Radiographic Joint Erosion Progression Based on (SDC) From Baseline at Week 52	82.2 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Without Radiographic Joint Erosion Progression Based on (SDC) From Baseline at Week 52	84.3 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Without Radiographic Joint Erosion Progression Based on (SDC) From Baseline at Week 52	87.3 percentage of participants

Secondary

Percentage of Participants Without Radiographic JSN Progression Based on (SDC) From Baseline at Week 52

Modified vdH-S score is sum of erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is summary of erosion severity in 40 joints of hand scored according to surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is total JSN score in same 52 joints as above, each joint scored according to subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as cut-off above which changes can be detected beyond measurement error. Without radiographic JSN progression was defined as change from baseline in modified vdH-S JSN score \<=SDC of 1.02.

Time frame: Week 52

Arm	Measure	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Without Radiographic JSN Progression Based on (SDC) From Baseline at Week 52	91.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Without Radiographic JSN Progression Based on (SDC) From Baseline at Week 52	91.5 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Without Radiographic JSN Progression Based on (SDC) From Baseline at Week 52	90.4 percentage of participants

Secondary

Percentage of Participants Without Radiographic JSN Progression (Based on SDC) From Baseline to Week 100

Modified vdH-S score is sum of erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is summary of erosion severity in 40 joints of hand scored according to surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic JSN progression was defined as change from baseline in the modified vdH-S JSN score \<=SDC of 1.66.

Time frame: Baseline to Week 100

Arm	Measure	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Without Radiographic JSN Progression (Based on SDC) From Baseline to Week 100	90.7 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Without Radiographic JSN Progression (Based on SDC) From Baseline to Week 100	89.4 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Without Radiographic JSN Progression (Based on SDC) From Baseline to Week 100	88.2 percentage of participants

Secondary

Percentage of Participants Without Radiographic JSN Progression (Based on the SDC) From Baseline at Week 24

The modified vdH-S score is the sum of the erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). The JSN score is the sum of JSN score in 40 joints of the two hands and 12 joints of the 2 feet. Each joint is scored from 0 - 4 with 0 indicating no JSN, and 4 indicating a complete loss of joint space, bony ankylosis, or complete luxation, for a maximum JSN score of 208. Higher score indicates more severe joint space narrowing. The smallest detectable change (SDC) was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic JSN progression was defined as change from baseline in the modified vdH-S JSN score \<=SDC of 1.11.

Time frame: Week 24

Arm	Measure	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Without Radiographic JSN Progression (Based on the SDC) From Baseline at Week 24	91.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Without Radiographic JSN Progression (Based on the SDC) From Baseline at Week 24	93.5 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Without Radiographic JSN Progression (Based on the SDC) From Baseline at Week 24	91.7 percentage of participants

Secondary

Percentage of Participants Without Radiographic Modified vdH-S Progression Based on (SDC) From Baseline to Week 100

Modified vdH-S score is the sum of the erosion score (hand, feet) and JSN score (hand, feet). Joint erosion score is the summary of erosion severity in 40 joints of hand scored according to the surface area, from 0 (no erosion) to 5 (complete collapse of bone) and 12 joints of 2 feet (each side of foot joint is graded on same 0-5 scale, thus maximum erosion score for a foot joint is 10), for a maximum erosion score of 320. JSN score is the total JSN score in same 52 joints as above, each joint scored according to the subluxation from 0 (normal) to 4 (bony ankylosis or complete luxation), for a maximum JSN score of 208. Total score ranges from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score indicates more joint damage. SDC was defined as the cut-off above which the changes can be detected beyond measurement error. Without radiographic progression was defined as change from baseline in the modified vdH-S score \<=SDC of 3.46.

Time frame: Baseline to Week 100

Arm	Measure	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Without Radiographic Modified vdH-S Progression Based on (SDC) From Baseline to Week 100	86.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Without Radiographic Modified vdH-S Progression Based on (SDC) From Baseline to Week 100	84.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Without Radiographic Modified vdH-S Progression Based on (SDC) From Baseline to Week 100	87.2 percentage of participants

Secondary

Percentage of Participants Without Radiographic Progression Based on the (SDC) From Baseline at Week 52

Time frame: Week 52

Arm	Measure	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Without Radiographic Progression Based on the (SDC) From Baseline at Week 52	80.4 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Without Radiographic Progression Based on the (SDC) From Baseline at Week 52	82.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Without Radiographic Progression Based on the (SDC) From Baseline at Week 52	85.2 percentage of participants

Secondary

Percentage of Participants Without Radiographic Progression (Based on the Smallest Detectable Change [SDC]) From Baseline at Week 24

Time frame: Week 24

Arm	Measure	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants Without Radiographic Progression (Based on the Smallest Detectable Change [SDC]) From Baseline at Week 24	86.4 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants Without Radiographic Progression (Based on the Smallest Detectable Change [SDC]) From Baseline at Week 24	87.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants Without Radiographic Progression (Based on the Smallest Detectable Change [SDC]) From Baseline at Week 24	89.3 percentage of participants

Secondary

Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline and Week 24

Pencil in Cup or Gross Osteolytis Deformities are radiographic features specific for psoriatic arthritis.

Time frame: Baseline and Week 24

Population: Analysis population is FAS1-SD. Observed data were summarized regardless if 1 or more TF criteria were met.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline and Week 24	Baseline	4.5 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline and Week 24	Week 24	4.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline and Week 24	Baseline	3.6 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline and Week 24	Week 24	3.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline and Week 24	Baseline	3.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline and Week 24	Week 24	3.8 percentage of participants

Secondary

Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline and Week 52

Percentage of Participants with Pencil in cup or Gross Osteolysis Deformities were reported. Pencil in Cup or Gross Osteolytis Deformities are radiographic features specific for psoriatic arthritis.

Time frame: Baseline and Week 52

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline and Week 52	Baseline	6.9 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline and Week 52	Week 52	7.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline and Week 52	Week 52	5.1 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline and Week 52	Baseline	4.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline and Week 52	Baseline	6.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline and Week 52	Week 52	7.0 percentage of participants

Secondary

Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline, Weeks 24, 52, and 100

Pencil in Cup or Gross Osteolytis Deformities are radiographic features specific for psoriatic arthritis.

Time frame: Baseline, Weeks 24, 52, and 100

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline, Weeks 24, 52, and 100	Week 52	4.2 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline, Weeks 24, 52, and 100	Baseline	3.7 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline, Weeks 24, 52, and 100	Week 100	4.9 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline, Weeks 24, 52, and 100	Week 24	3.7 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline, Weeks 24, 52, and 100	Week 52	4.4 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline, Weeks 24, 52, and 100	Week 24	3.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline, Weeks 24, 52, and 100	Week 100	4.6 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline, Weeks 24, 52, and 100	Baseline	3.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline, Weeks 24, 52, and 100	Week 100	3.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline, Weeks 24, 52, and 100	Baseline	3.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline, Weeks 24, 52, and 100	Week 24	4.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Pencil in Cup or Gross Osteolysis Deformities at Baseline, Weeks 24, 52, and 100	Week 52	3.6 percentage of participants

Secondary

Percentage of Participants With Resolution of Dactylitis at Week 24 Among the Participants With Dactylitis at Baseline

The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \>0. The outcome measure was planned to be reported for pooled population from CNTO1959PSA3001 and CNTO1959PSA3002 studies.

Time frame: Week 24

Population: FAS1 among participants with dactylitis at baseline pooled from CNTO1959PSA3001 (NCT03162796) and CNTO1959PSA3002 (NCT03158285) studies. Participants with dactylitis resolution at Week 24 and did not meet any TF criteria before Week 24 considered responders. Participants who met 1/more TF criteria or with missing data considered non-responders.

Arm	Measure	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Dactylitis at Week 24 Among the Participants With Dactylitis at Baseline	42.2 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Resolution of Dactylitis at Week 24 Among the Participants With Dactylitis at Baseline	59.4 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Dactylitis at Week 24 Among the Participants With Dactylitis at Baseline	63.5 percentage of participants

p-value: 0.0395% CI: [7.4, 28.6]Cochran-Mantel-Haenszel

p-value: 0.01195% CI: [10.5, 32]Cochran-Mantel-Haenszel

Secondary

Percentage of Participants With Resolution of Dactylitis at Weeks 24 and 52 Among Participants With Dactylitis at Baseline

The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \>0.

Time frame: Weeks 24 and 52

Population: Analysis population is FAS2 among the participants with dactylitis at baseline. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Dactylitis at Weeks 24 and 52 Among Participants With Dactylitis at Baseline	Week 24	41.1 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Dactylitis at Weeks 24 and 52 Among Participants With Dactylitis at Baseline	Week 52	78.5 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Resolution of Dactylitis at Weeks 24 and 52 Among Participants With Dactylitis at Baseline	Week 24	60.7 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Resolution of Dactylitis at Weeks 24 and 52 Among Participants With Dactylitis at Baseline	Week 52	81.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Dactylitis at Weeks 24 and 52 Among Participants With Dactylitis at Baseline	Week 24	68.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Dactylitis at Weeks 24 and 52 Among Participants With Dactylitis at Baseline	Week 52	81.1 percentage of participants

Secondary

Percentage of Participants With Resolution of Dactylitis at Weeks 52, 76 and 100 Among Participants With Dactylitis at Baseline

The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \>0.

Time frame: Weeks 52, 76 and 100

Population: Analysis population is FAS3 among participants with dactylitis at baseline. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Dactylitis at Weeks 52, 76 and 100 Among Participants With Dactylitis at Baseline	Week 100	83.7 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Dactylitis at Weeks 52, 76 and 100 Among Participants With Dactylitis at Baseline	Week 52	78.3 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Dactylitis at Weeks 52, 76 and 100 Among Participants With Dactylitis at Baseline	Week 76	80.2 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Resolution of Dactylitis at Weeks 52, 76 and 100 Among Participants With Dactylitis at Baseline	Week 76	84.0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Resolution of Dactylitis at Weeks 52, 76 and 100 Among Participants With Dactylitis at Baseline	Week 52	81.7 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Resolution of Dactylitis at Weeks 52, 76 and 100 Among Participants With Dactylitis at Baseline	Week 100	91.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Dactylitis at Weeks 52, 76 and 100 Among Participants With Dactylitis at Baseline	Week 52	80.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Dactylitis at Weeks 52, 76 and 100 Among Participants With Dactylitis at Baseline	Week 100	82.9 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Dactylitis at Weeks 52, 76 and 100 Among Participants With Dactylitis at Baseline	Week 76	82.4 percentage of participants

Secondary

Percentage of Participants With Resolution of Dactylitis Through Week 24 Among the Participants With Dactylitis at Baseline

The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \>0.

Time frame: Weeks 2, 4, 8, 16 and 24

Population: FAS1 among participants with dactylitis at baseline. Participants who achieved dactylitis resolution at specific time point and did not meet any TF criteria before, were considered as responders at that time point. Participants who met 1 or more TF criteria before or with missing data at that time point were considered as non-responders.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Dactylitis Through Week 24 Among the Participants With Dactylitis at Baseline	Week 24	38.4 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Dactylitis Through Week 24 Among the Participants With Dactylitis at Baseline	Week 2	12.1 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Dactylitis Through Week 24 Among the Participants With Dactylitis at Baseline	Week 4	18.2 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Dactylitis Through Week 24 Among the Participants With Dactylitis at Baseline	Week 8	29.3 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Dactylitis Through Week 24 Among the Participants With Dactylitis at Baseline	Week 16	36.4 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Resolution of Dactylitis Through Week 24 Among the Participants With Dactylitis at Baseline	Week 8	30.6 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Resolution of Dactylitis Through Week 24 Among the Participants With Dactylitis at Baseline	Week 16	45.0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Resolution of Dactylitis Through Week 24 Among the Participants With Dactylitis at Baseline	Week 2	13.5 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Resolution of Dactylitis Through Week 24 Among the Participants With Dactylitis at Baseline	Week 24	56.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Resolution of Dactylitis Through Week 24 Among the Participants With Dactylitis at Baseline	Week 4	19.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Dactylitis Through Week 24 Among the Participants With Dactylitis at Baseline	Week 16	52.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Dactylitis Through Week 24 Among the Participants With Dactylitis at Baseline	Week 4	20.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Dactylitis Through Week 24 Among the Participants With Dactylitis at Baseline	Week 8	31.4 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Dactylitis Through Week 24 Among the Participants With Dactylitis at Baseline	Week 24	63.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Dactylitis Through Week 24 Among the Participants With Dactylitis at Baseline	Week 2	13.2 percentage of participants

Secondary

Percentage of Participants With Resolution of Enthesitis at Week 24 Among the Participants With Enthesitis at Baseline

Enthesitis was assessed using the Leeds Enthesitis Index (LEI), a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI\>0. The outcome measure was planned to be reported for pooled population from CNTO1959PSA3001 and CNTO1959PSA3002 studies.

Time frame: Week 24

Population: FAS1 among participants with enthesitis at baseline pooled from CNTO1959PSA3001 (NCT03162796) and CNTO1959PSA3002 (NCT03158285) studies. Participants with enthesitis resolution at Week 24 and did not meet any TF criteria before Week 24 considered responders. Participants who met 1/more TF criteria or with missing data considered non-responders.

Arm	Measure	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Enthesitis at Week 24 Among the Participants With Enthesitis at Baseline	29.4 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Resolution of Enthesitis at Week 24 Among the Participants With Enthesitis at Baseline	49.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Enthesitis at Week 24 Among the Participants With Enthesitis at Baseline	44.9 percentage of participants

p-value: 0.0395% CI: [11.8, 28.5]Cochran-Mantel-Haenszel

p-value: 0.0395% CI: [6.4, 22.7]Cochran-Mantel-Haenszel

Secondary

Percentage of Participants With Resolution of Enthesitis at Weeks 24 and 52 Among the Participants With Enthesitis at Baseline

Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI\>0.

Time frame: Weeks 24 and 52

Population: Analysis population is FAS2 among the participants with enthesitis (LEI) at baseline. Here, n (number analyzed) signifies the number of participants evaluable for enthesitis resolution at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Enthesitis at Weeks 24 and 52 Among the Participants With Enthesitis at Baseline	Week 24	32.6 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Enthesitis at Weeks 24 and 52 Among the Participants With Enthesitis at Baseline	Week 52	67.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Resolution of Enthesitis at Weeks 24 and 52 Among the Participants With Enthesitis at Baseline	Week 24	57.6 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Resolution of Enthesitis at Weeks 24 and 52 Among the Participants With Enthesitis at Baseline	Week 52	65.5 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Enthesitis at Weeks 24 and 52 Among the Participants With Enthesitis at Baseline	Week 24	45.5 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Enthesitis at Weeks 24 and 52 Among the Participants With Enthesitis at Baseline	Week 52	60.0 percentage of participants

Secondary

Percentage of Participants With Resolution of Enthesitis (LEI) at Weeks 52, 76 and 100 Among the Participants With Enthesitis (LEI) at Baseline

Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI\>0.

Time frame: Weeks 52, 76, and 100

Population: Analysis population is FAS3 among the participants with enthesitis (LEI) at baseline. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Enthesitis (LEI) at Weeks 52, 76 and 100 Among the Participants With Enthesitis (LEI) at Baseline	Week 100	75.2 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Enthesitis (LEI) at Weeks 52, 76 and 100 Among the Participants With Enthesitis (LEI) at Baseline	Week 52	67.3 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Enthesitis (LEI) at Weeks 52, 76 and 100 Among the Participants With Enthesitis (LEI) at Baseline	Week 76	72.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Resolution of Enthesitis (LEI) at Weeks 52, 76 and 100 Among the Participants With Enthesitis (LEI) at Baseline	Week 76	71.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Resolution of Enthesitis (LEI) at Weeks 52, 76 and 100 Among the Participants With Enthesitis (LEI) at Baseline	Week 100	77.5 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Resolution of Enthesitis (LEI) at Weeks 52, 76 and 100 Among the Participants With Enthesitis (LEI) at Baseline	Week 52	66.0 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Enthesitis (LEI) at Weeks 52, 76 and 100 Among the Participants With Enthesitis (LEI) at Baseline	Week 52	61.0 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Enthesitis (LEI) at Weeks 52, 76 and 100 Among the Participants With Enthesitis (LEI) at Baseline	Week 100	67.7 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Enthesitis (LEI) at Weeks 52, 76 and 100 Among the Participants With Enthesitis (LEI) at Baseline	Week 76	67.5 percentage of participants

Secondary

Percentage of Participants With Resolution of Enthesitis Through Week 24 Among the Participants With Enthesitis at Baseline

Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI\>0.

Time frame: Weeks 2, 4, 8, 16 and 24

Population: FAS1 among participants with enthesitis at baseline. Participants with enthesitis resolution at specific time point and did not meet any TF criteria before, were considered as responders at that time point. Participants who met 1 or more TF criteria before or with missing data at that time point were considered as non-responders.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Enthesitis Through Week 24 Among the Participants With Enthesitis at Baseline	Week 16	30.9 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Enthesitis Through Week 24 Among the Participants With Enthesitis at Baseline	Week 8	24.7 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Enthesitis Through Week 24 Among the Participants With Enthesitis at Baseline	Week 2	16.3 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Enthesitis Through Week 24 Among the Participants With Enthesitis at Baseline	Week 4	18.0 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Enthesitis Through Week 24 Among the Participants With Enthesitis at Baseline	Week 24	30.3 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Resolution of Enthesitis Through Week 24 Among the Participants With Enthesitis at Baseline	Week 8	31.0 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Resolution of Enthesitis Through Week 24 Among the Participants With Enthesitis at Baseline	Week 2	17.7 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Resolution of Enthesitis Through Week 24 Among the Participants With Enthesitis at Baseline	Week 4	21.5 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Resolution of Enthesitis Through Week 24 Among the Participants With Enthesitis at Baseline	Week 16	47.5 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Resolution of Enthesitis Through Week 24 Among the Participants With Enthesitis at Baseline	Week 24	53.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Enthesitis Through Week 24 Among the Participants With Enthesitis at Baseline	Week 24	43.5 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Enthesitis Through Week 24 Among the Participants With Enthesitis at Baseline	Week 16	40.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Enthesitis Through Week 24 Among the Participants With Enthesitis at Baseline	Week 2	17.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Enthesitis Through Week 24 Among the Participants With Enthesitis at Baseline	Week 8	27.6 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Resolution of Enthesitis Through Week 24 Among the Participants With Enthesitis at Baseline	Week 4	25.3 percentage of participants

Secondary

Percentage of Participants With Very Low Disease Activity (VLDA) at Weeks 24 and 52

A measurement that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved VLDA at a visit if the participant fulfilled all 7 criteria (tender joint count \<=1; swollen joint count \<=1; PASI \<=1; patient pain VAS score of \<=15; patient global disease activity VAS \[arthritis and psoriasis\] score of \<=20; Health Assessment Questionnaire (HAQ) score \<=0.5; and tender entheseal points \<=1) at that visit.

Time frame: Weeks 24 and 52

Population: Analysis population is FAS2. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Very Low Disease Activity (VLDA) at Weeks 24 and 52	Week 24	1.3 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With Very Low Disease Activity (VLDA) at Weeks 24 and 52	Week 52	6.9 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Very Low Disease Activity (VLDA) at Weeks 24 and 52	Week 24	4.6 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With Very Low Disease Activity (VLDA) at Weeks 24 and 52	Week 52	17.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Very Low Disease Activity (VLDA) at Weeks 24 and 52	Week 24	5.1 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With Very Low Disease Activity (VLDA) at Weeks 24 and 52	Week 52	12.2 percentage of participants

Secondary

Percentage of Participants With VLDA at Weeks 52, 76 and 100

Time frame: Weeks 52, 76 and 100

Population: Analysis population is FAS3 which included all participants still on treatment at Week 52. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (NUMBER)
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With VLDA at Weeks 52, 76 and 100	Week 52	7.0 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With VLDA at Weeks 52, 76 and 100	Week 76	12.2 percentage of participants
Placebo to Guselkumab 100 mg q4w	Percentage of Participants With VLDA at Weeks 52, 76 and 100	Week 100	14.6 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With VLDA at Weeks 52, 76 and 100	Week 100	18.8 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With VLDA at Weeks 52, 76 and 100	Week 76	19.6 percentage of participants
Guselkumab 100 mg q8w	Percentage of Participants With VLDA at Weeks 52, 76 and 100	Week 52	16.8 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With VLDA at Weeks 52, 76 and 100	Week 52	12.4 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With VLDA at Weeks 52, 76 and 100	Week 100	15.0 percentage of participants
Guselkumab 100 mg q4w	Percentage of Participants With VLDA at Weeks 52, 76 and 100	Week 76	14.8 percentage of participants

Secondary

Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52

Time frame: Baseline, Weeks 24, 28, 36, 44 and 52

Population: Analysis population is FAS2. Here, n (number analyzed) signifies the number of participants analyzed at specified timepoints.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: PGA of Disease Activity	-71.05 percent change	Standard Deviation 25.056
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: Patient's Assessment of Pain	-35.65 percent change	Standard Deviation 43.207
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: Swollen Joint Count	-81.85 percent change	Standard Deviation 26.328
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: PGA of Disease Activity	-68.32 percent change	Standard Deviation 25.56
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: Patient's Assessment of Pain	-37.45 percent change	Standard Deviation 43.534
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: Tender Joint Count	-62.21 percent change	Standard Deviation 34.292
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: PGA of Disease Activity	-64.57 percent change	Standard Deviation 25.695
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: Patient's Assessment of Pain	-38.23 percent change	Standard Deviation 47.43
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: CRP	-0.25 percent change	Standard Deviation 208.267
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: PGA of Disease Activity	-49.72 percent change	Standard Deviation 30.129
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: PtGA of Disease Activity	-13.78 percent change	Standard Deviation 45.943
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: CRP	19.81 percent change	Standard Deviation 150.274
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: PGA of Disease Activity	-36.13 percent change	Standard Deviation 33.383
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: PtGA of Disease Activity	-23.78 percent change	Standard Deviation 40.895
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: Swollen Joint Count	-82.34 percent change	Standard Deviation 30.494
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: PtGA of Disease Activity	-39.34 percent change	Standard Deviation 44.933
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: PtGA of Disease Activity	-38.82 percent change	Standard Deviation 37.114
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: CRP	-8.33 percent change	Standard Deviation 143.843
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: PtGA of Disease Activity	-38.45 percent change	Standard Deviation 43.993
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: HAQ-DI score	-26.83 percent change	Standard Deviation 54.38
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: Tender Joint Count	-32.53 percent change	Standard Deviation 44.85
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: Swollen Joint Count	-66.15 percent change	Standard Deviation 37.305
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: Swollen Joint Count	-53.44 percent change	Standard Deviation 45.655
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: HAQ-DI score	-27.01 percent change	Standard Deviation 49.683
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: Tender Joint Count	-65.88 percent change	Standard Deviation 33.344
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: CRP	-6.70 percent change	Standard Deviation 183.299
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: HAQ-DI score	-23.34 percent change	Standard Deviation 46.393
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: Tender Joint Count	-67.29 percent change	Standard Deviation 35.583
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: Swollen Joint Count	-80.38 percent change	Standard Deviation 28.144
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: HAQ-DI score	-15.66 percent change	Standard Deviation 49.522
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: Patient's Assessment of Pain	-11.52 percent change	Standard Deviation 48.647
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: Tender Joint Count	-45.52 percent change	Standard Deviation 41.132
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: HAQ-DI score	-6.86 percent change	Standard Deviation 54.753
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: Patient's Assessment of Pain	-22.20 percent change	Standard Deviation 42.404
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: CRP	-0.80 percent change	Standard Deviation 155.637
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: CRP	-26.90 percent change	Standard Deviation 110.466
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: Tender Joint Count	-62.48 percent change	Standard Deviation 32.82
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: Swollen Joint Count	-72.06 percent change	Standard Deviation 33.971
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: Swollen Joint Count	-78.02 percent change	Standard Deviation 30.197
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: Swollen Joint Count	-82.82 percent change	Standard Deviation 26.054
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: Swollen Joint Count	-82.10 percent change	Standard Deviation 27.742
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: Swollen Joint Count	-83.18 percent change	Standard Deviation 30.121
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: Tender Joint Count	-54.81 percent change	Standard Deviation 37.134
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: Tender Joint Count	-66.12 percent change	Standard Deviation 32.829
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: Tender Joint Count	-70.90 percent change	Standard Deviation 29.688
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: Tender Joint Count	-70.29 percent change	Standard Deviation 31.985
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: Patient's Assessment of Pain	-38.44 percent change	Standard Deviation 40.734
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: Patient's Assessment of Pain	-42.17 percent change	Standard Deviation 41.66
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: Patient's Assessment of Pain	-45.89 percent change	Standard Deviation 40.125
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: Patient's Assessment of Pain	-46.48 percent change	Standard Deviation 41.725
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: Patient's Assessment of Pain	-49.00 percent change	Standard Deviation 39.082
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: PtGA of Disease Activity	-37.18 percent change	Standard Deviation 38.628
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: PtGA of Disease Activity	-39.92 percent change	Standard Deviation 40.228
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: PtGA of Disease Activity	-44.21 percent change	Standard Deviation 36.982
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: PtGA of Disease Activity	-46.64 percent change	Standard Deviation 38.228
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: PtGA of Disease Activity	-48.73 percent change	Standard Deviation 38.925
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: PGA of Disease Activity	-57.60 percent change	Standard Deviation 32.634
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: PGA of Disease Activity	-62.89 percent change	Standard Deviation 28.027
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: PGA of Disease Activity	-67.98 percent change	Standard Deviation 25.989
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: PGA of Disease Activity	-69.79 percent change	Standard Deviation 26.949
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: PGA of Disease Activity	-73.09 percent change	Standard Deviation 24.133
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: HAQ-DI score	-25.47 percent change	Standard Deviation 63.639
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: HAQ-DI score	-28.82 percent change	Standard Deviation 73.93
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: HAQ-DI score	-31.95 percent change	Standard Deviation 78.348
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: HAQ-DI score	-33.84 percent change	Standard Deviation 60.164
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: HAQ-DI score	-33.49 percent change	Standard Deviation 63.823
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: CRP	-21.09 percent change	Standard Deviation 144.287
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: CRP	-25.47 percent change	Standard Deviation 157.839
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: CRP	-37.54 percent change	Standard Deviation 76.302
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: CRP	-23.15 percent change	Standard Deviation 104.461
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: CRP	-17.44 percent change	Standard Deviation 127.594
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: PGA of Disease Activity	-70.27 percent change	Standard Deviation 24.516
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: Patient's Assessment of Pain	-41.02 percent change	Standard Deviation 39.624
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: CRP	15.69 percent change	Standard Deviation 468.613
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: PGA of Disease Activity	-72.46 percent change	Standard Deviation 24.485
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: Patient's Assessment of Pain	-36.64 percent change	Standard Deviation 38.086
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: Swollen Joint Count	-78.85 percent change	Standard Deviation 28.109
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: HAQ-DI score	-33.72 percent change	Standard Deviation 51.766
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: Tender Joint Count	-69.82 percent change	Standard Deviation 32.122
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: Swollen Joint Count	-73.17 percent change	Standard Deviation 30.614
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: HAQ-DI score	-33.91 percent change	Standard Deviation 59.31
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: Tender Joint Count	-72.10 percent change	Standard Deviation 27.67
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: CRP	-23.97 percent change	Standard Deviation 104.641
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: HAQ-DI score	-37.74 percent change	Standard Deviation 56.329
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: Tender Joint Count	-68.50 percent change	Standard Deviation 30
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: Tender Joint Count	-64.31 percent change	Standard Deviation 31.767
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: HAQ-DI score	-32.45 percent change	Standard Deviation 72.337
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: Swollen Joint Count	-84.07 percent change	Standard Deviation 24.07
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: CRP	-0.99 percent change	Standard Deviation 193.429
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: PtGA of Disease Activity	-45.52 percent change	Standard Deviation 38.659
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: HAQ-DI score	-35.02 percent change	Standard Deviation 65.765
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: PtGA of Disease Activity	-42.45 percent change	Standard Deviation 39.243
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: PtGA of Disease Activity	-40.70 percent change	Standard Deviation 36.587
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: Swollen Joint Count	-83.32 percent change	Standard Deviation 24.289
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: PtGA of Disease Activity	-45.50 percent change	Standard Deviation 40.653
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: PtGA of Disease Activity	-33.90 percent change	Standard Deviation 51.672
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: Tender Joint Count	-57.11 percent change	Standard Deviation 35.073
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: PGA of Disease Activity	-59.06 percent change	Standard Deviation 28.137
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 52: Patient's Assessment of Pain	-43.51 percent change	Standard Deviation 45.742
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 24: CRP	-28.35 percent change	Standard Deviation 88.038
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 28: PGA of Disease Activity	-64.14 percent change	Standard Deviation 25.784
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 44: Patient's Assessment of Pain	-43.60 percent change	Standard Deviation 42.56
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: Swollen Joint Count	-81.49 percent change	Standard Deviation 27.338
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: PGA of Disease Activity	-67.74 percent change	Standard Deviation 28.029
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52	Week 36: Patient's Assessment of Pain	-43.29 percent change	Standard Deviation 44.442

Secondary

Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24

ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-10 cm, 0=no pain and 10=worst possible pain), patient's global assessment (PtGA) of disease activity (arthritis, VAS; 0-10 cm, 0=excellent and 10= poor), physician's global assessment (PGA) of disease activity (VAS; 0-10 cm, 0=no arthritis activity and 10=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP (milligram/deciliter \[mg/dL\]).

Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24

Population: Analysis population is FAS1. Here 'n' (number analyzed) signifies number of participants with observed data regardless meeting TF criteria at specified categories.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 16: PGA of Disease Activity	-31.11 percent change	Standard Deviation 32.023
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 8: Patient's Assessment of Pain	-6.76 percent change	Standard Deviation 34.213
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 20: Swollen Joint Count	-54.2 percent change	Standard Deviation 41.7
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 12: PGA of Disease Activity	-27.63 percent change	Standard Deviation 32.379
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 12: Patient's Assessment of Pain	-9.01 percent change	Standard Deviation 36.061
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 20: CRP	42.282 percent change	Standard Deviation 284.133
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 8: PGA of Disease Activity	-23.29 percent change	Standard Deviation 28.416
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 16: Patient's Assessment of Pain(0-10cm)	-9.70 percent change	Standard Deviation 41.673
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 4: CRP	28.042 percent change	Standard Deviation 208.6385
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 4: PGA of Disease Activity	-16.63 percent change	Standard Deviation 27.573
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 20: Patient's Assessment of Pain	-10.85 percent change	Standard Deviation 46.497
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 24: Swollen Joint Count	-53.9 percent change	Standard Deviation 45.54
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 2: PGA of Disease Activity	-9.79 percent change	Standard Deviation 25.687
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 24: Patient's Assessment of Pain	-11.84 percent change	Standard Deviation 48.324
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 8: Swollen Joint Count	-37.4 percent change	Standard Deviation 39.03
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 24: PtGA of Disease Activity	-13.87 percent change	Standard Deviation 45.65
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 2: PtGA of Disease Activity	-1.12 percent change	Standard Deviation 35.882
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 2: CRP	86.677 percent change	Standard Deviation 645.0281
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 20: PtGA of Disease Activity	-12.52 percent change	Standard Deviation 42.498
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 4: PtGA of Disease Activity	-2.27 percent change	Standard Deviation 34.291
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 2: Tender Joint Count	-9.4 percent change	Standard Deviation 25.99
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 16: PtGA of Disease Activity	-12.34 percent change	Standard Deviation 39.207
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 8: PtGA of Disease Activity	-6.51 percent change	Standard Deviation 35.908
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 24: CRP	19.263 percent change	Standard Deviation 149.512
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 12: PtGA of Disease Activity	-9.30 percent change	Standard Deviation 37.185
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 24: HAQ-DI Score	-6.7995 percent change	Standard Deviation 54.78602
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 4: Tender Joint Count	-14.1 percent change	Standard Deviation 36.04
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 16: CRP	28.595 percent change	Standard Deviation 237.666
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 20: HAQ-DI Score	-10.4296 percent change	Standard Deviation 50.87958
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 8: Tender Joint Count	-21.9 percent change	Standard Deviation 37.83
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 12: Swollen Joint Count	-46.1 percent change	Standard Deviation 41.2
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 16: HAQ-DI Score	-7.1776 percent change	Standard Deviation 48.33253
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 12: Tender Joint Count	-30.4 percent change	Standard Deviation 37.57
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 4: Swollen Joint Count	-27.1 percent change	Standard Deviation 37.29
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 12: HAQ-DI Score	-8.0811 percent change	Standard Deviation 46.90093
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 16: Tender Joint Count	-30.6 percent change	Standard Deviation 41.87
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 8: HAQ-DI Score	-5.0965 percent change	Standard Deviation 39.89566
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 4: HAQ-DI Score	-2.8744 percent change	Standard Deviation 46.90795
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 20: Tender Joint Count	-33.9 percent change	Standard Deviation 44.22
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 12: CRP	47.034 percent change	Standard Deviation 313.9875
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 2: HAQ-DI Score	-0.3191 percent change	Standard Deviation 36.62364
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 24: Tender Joint Count	-33.3 percent change	Standard Deviation 44.87
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 16: Swollen Joint Count	-48.6 percent change	Standard Deviation 43.01
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 24: PGA of Disease Activity	-36.59 percent change	Standard Deviation 33.74
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 2: Patient's Assessment of Pain	0.05 percent change	Standard Deviation 35.794
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 2: Swollen Joint Count	-18.9 percent change	Standard Deviation 32.16
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 20: PGA of Disease Activity	-34.13 percent change	Standard Deviation 36.576
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 4: Patient's Assessment of Pain	-0.64 percent change	Standard Deviation 35.849
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 8: CRP	45.451 percent change	Standard Deviation 322.4433
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 16: Tender Joint Count	-47.0 percent change	Standard Deviation 40.96
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 20: CRP	-13.551 percent change	Standard Deviation 193.3814
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 2: Swollen Joint Count	-18.8 percent change	Standard Deviation 39.68
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 4: Swollen Joint Count	-30.5 percent change	Standard Deviation 36.92
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 8: Swollen Joint Count	-46.8 percent change	Standard Deviation 40.68
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 12: Swollen Joint Count	-57.6 percent change	Standard Deviation 39.22
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 16: Swollen Joint Count	-64.1 percent change	Standard Deviation 35.46
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 20: Swollen Joint Count	-69.3 percent change	Standard Deviation 33.63
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 24: Swollen Joint Count	-71.3 percent change	Standard Deviation 34.06
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 2: Tender Joint Count	-10.4 percent change	Standard Deviation 40.31
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 4: Tender Joint Count	-15.0 percent change	Standard Deviation 41.57
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 8: Tender Joint Count	-31.0 percent change	Standard Deviation 42.36
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 12: Tender Joint Count	-40.9 percent change	Standard Deviation 42.73
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 20: Tender Joint Count	-53.9 percent change	Standard Deviation 37.83
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 24: Tender Joint Count	-54.2 percent change	Standard Deviation 37.15
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 2: Patient's Assessment of Pain	-8.92 percent change	Standard Deviation 32.374
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 4: Patient's Assessment of Pain	-12.58 percent change	Standard Deviation 33.065
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 8: Patient's Assessment of Pain	-21.61 percent change	Standard Deviation 36.705
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 12: Patient's Assessment of Pain	-26.26 percent change	Standard Deviation 40.223
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 16: Patient's Assessment of Pain(0-10cm)	-31.94 percent change	Standard Deviation 42.882
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 20: Patient's Assessment of Pain	-35.16 percent change	Standard Deviation 39.471
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 24: Patient's Assessment of Pain	-38.06 percent change	Standard Deviation 40.565
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 2: PtGA of Disease Activity	-10.15 percent change	Standard Deviation 31.06
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 4: PtGA of Disease Activity	-12.71 percent change	Standard Deviation 34.44
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 8: PtGA of Disease Activity	-21.58 percent change	Standard Deviation 33.697
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 12: PtGA of Disease Activity	-27.86 percent change	Standard Deviation 38.9
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 16: PtGA of Disease Activity	-32.25 percent change	Standard Deviation 40.056
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 20: PtGA of Disease Activity	-35.31 percent change	Standard Deviation 36.205
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 24: PtGA of Disease Activity	-37.05 percent change	Standard Deviation 38.372
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 2: PGA of Disease Activity	-15.06 percent change	Standard Deviation 27.15
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 4: PGA of Disease Activity	-23.72 percent change	Standard Deviation 27.658
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 8: PGA of Disease Activity	-36.54 percent change	Standard Deviation 31.224
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 12: PGA of Disease Activity	-46.54 percent change	Standard Deviation 30.489
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 16: PGA of Disease Activity	-52.02 percent change	Standard Deviation 31.915
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 20: PGA of Disease Activity	-54.32 percent change	Standard Deviation 30.941
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 24: PGA of Disease Activity	-57.22 percent change	Standard Deviation 32.48
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 2: HAQ-DI Score	-6.3577 percent change	Standard Deviation 50.8198
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 4: HAQ-DI Score	-9.1272 percent change	Standard Deviation 53.41051
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 8: HAQ-DI Score	-12.7684 percent change	Standard Deviation 67.23239
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 12: HAQ-DI Score	-18.0336 percent change	Standard Deviation 66.96524
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 16: HAQ-DI Score	-19.3627 percent change	Standard Deviation 70.83578
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 20: HAQ-DI Score	-24.9496 percent change	Standard Deviation 64.8682
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 24: HAQ-DI Score	-25.2578 percent change	Standard Deviation 63.1545
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 2: CRP	0.935 percent change	Standard Deviation 91.3783
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 4: CRP	-16.885 percent change	Standard Deviation 79.3501
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 8: CRP	-11.214 percent change	Standard Deviation 150.1689
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 12: CRP	-25.620 percent change	Standard Deviation 97.1384
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 16: CRP	-19.874 percent change	Standard Deviation 134.521
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 24: CRP	-27.470 percent change	Standard Deviation 109.5239
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 4: Patient's Assessment of Pain	-7.96 percent change	Standard Deviation 37.958
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 20: Swollen Joint Count	-71.4 percent change	Standard Deviation 30.42
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 16: PGA of Disease Activity	-49.18 percent change	Standard Deviation 31.383
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 2: Patient's Assessment of Pain	-4.66 percent change	Standard Deviation 32.229
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 4: Swollen Joint Count	-33.6 percent change	Standard Deviation 37.57
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 20: PGA of Disease Activity	-54.59 percent change	Standard Deviation 29.336
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 24: Tender Joint Count	-57.3 percent change	Standard Deviation 34.98
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 4: CRP	1.128 percent change	Standard Deviation 168.9301
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 24: PGA of Disease Activity	-58.70 percent change	Standard Deviation 28.255
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 20: Tender Joint Count	-54.2 percent change	Standard Deviation 35.43
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 16: Swollen Joint Count	-63.7 percent change	Standard Deviation 34.42
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 2: HAQ-DI Score	-0.2385 percent change	Standard Deviation 57.44896
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 16: Tender Joint Count	-48.1 percent change	Standard Deviation 37.01
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 20: CRP	-28.701 percent change	Standard Deviation 83.0912
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 4: HAQ-DI Score	-5.1209 percent change	Standard Deviation 85.16625
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 8: CRP	-17.474 percent change	Standard Deviation 112.3803
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 12: Swollen Joint Count	-58.3 percent change	Standard Deviation 35.42
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 8: HAQ-DI Score	-9.8081 percent change	Standard Deviation 86.78973
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 12: Tender Joint Count	-43.0 percent change	Standard Deviation 35.9
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 2: Swollen Joint Count	-18.5 percent change	Standard Deviation 38.38
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 12: HAQ-DI Score	-17.7758 percent change	Standard Deviation 67.44643
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 8: Tender Joint Count	-33.8 percent change	Standard Deviation 37.58
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 12: CRP	-22.277 percent change	Standard Deviation 122.3489
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 16: HAQ-DI Score	-26.6732 percent change	Standard Deviation 53.14973
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 4: Tender Joint Count	-22.6 percent change	Standard Deviation 32.91
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 8: PtGA of Disease Activity	-19.13 percent change	Standard Deviation 40.545
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 8: Swollen Joint Count	-46.7 percent change	Standard Deviation 37.69
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 12: PtGA of Disease Activity	-28.33 percent change	Standard Deviation 34.058
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 4: PtGA of Disease Activity	-11.02 percent change	Standard Deviation 33.605
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 20: HAQ-DI Score	-28.9317 percent change	Standard Deviation 60.67279
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 16: PtGA of Disease Activity	-28.60 percent change	Standard Deviation 39.759
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 2: PtGA of Disease Activity	-5.25 percent change	Standard Deviation 32.658
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 2: Tender Joint Count	-14.8 percent change	Standard Deviation 28.31
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 20: PtGA of Disease Activity	-35.11 percent change	Standard Deviation 37.791
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 24: Patient's Assessment of Pain	-36.52 percent change	Standard Deviation 38.423
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 24: CRP	-28.125 percent change	Standard Deviation 87.7229
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 24: PtGA of Disease Activity	-34.13 percent change	Standard Deviation 51.445
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 20: Patient's Assessment of Pain	-35.35 percent change	Standard Deviation 39.016
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 24: HAQ-DI Score	-33.8837 percent change	Standard Deviation 51.59441
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 2: PGA of Disease Activity	-13.85 percent change	Standard Deviation 23.307
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 16: Patient's Assessment of Pain(0-10cm)	-27.85 percent change	Standard Deviation 38.913
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 24: Swollen Joint Count	-73.1 percent change	Standard Deviation 30.67
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 4: PGA of Disease Activity	-22.32 percent change	Standard Deviation 28.183
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 12: Patient's Assessment of Pain	-25.91 percent change	Standard Deviation 37.862
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 16: CRP	-26.592 percent change	Standard Deviation 86.8465
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 8: PGA of Disease Activity	-37.99 percent change	Standard Deviation 29.97
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 8: Patient's Assessment of Pain	-17.05 percent change	Standard Deviation 44.783
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 2: CRP	10.664 percent change	Standard Deviation 132.5947
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 2, 4, 8, 12, 16, 20 and 24	Week 12: PGA of Disease Activity	-42.84 percent change	Standard Deviation 31.305

Secondary

Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100

Time frame: Baseline, Weeks 52, 68, 76, 84 and 100

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: Patient's Assessment of Pain	-44.91 percent change	Standard Deviation 44.371
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: Swollen Joint Count	-87.72 percent change	Standard Deviation 22.243
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: PGA of Disease Activity	-77.68 percent change	Standard Deviation 23.015
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: Patient's Assessment of Pain	-46.02 percent change	Standard Deviation 44.989
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: CRP	-4.33 percent change	Standard Deviation 196.246
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: PGA of Disease Activity	-74.76 percent change	Standard Deviation 23.29
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: Patient's Assessment of Pain	-49.64 percent change	Standard Deviation 40.991
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: Swollen Joint Count	-87.61 percent change	Standard Deviation 21.214
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: PGA of Disease Activity	-71.24 percent change	Standard Deviation 24.771
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: Patient's Assessment of Pain	-50.82 percent change	Standard Deviation 42.97
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: CRP	-10.76 percent change	Standard Deviation 226.332
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: PtGA of Disease Activity	-48.17 percent change	Standard Deviation 44.804
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: PtGA of Disease Activity	-39.70 percent change	Standard Deviation 44.981
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: HAQ-DI score	-40.36 percent change	Standard Deviation 44.407
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: PtGA of Disease Activity	-49.38 percent change	Standard Deviation 42.315
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: PtGA of Disease Activity	-42.93 percent change	Standard Deviation 44.22
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: Tender Joint Count	-67.29 percent change	Standard Deviation 35.725
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: PtGA of Disease Activity	-46.42 percent change	Standard Deviation 45.106
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: Swollen Joint Count	-87.41 percent change	Standard Deviation 24.049
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: HAQ-DI score	-36.73 percent change	Standard Deviation 47.541
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: Tender Joint Count	-74.28 percent change	Standard Deviation 29.764
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: CRP	-0.72 percent change	Standard Deviation 387.986
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: HAQ-DI score	-34.38 percent change	Standard Deviation 47.311
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: Tender Joint Count	-75.71 percent change	Standard Deviation 27.653
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: CRP	-1.68 percent change	Standard Deviation 330.574
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: HAQ-DI score	-33.34 percent change	Standard Deviation 49.027
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: Tender Joint Count	-77.21 percent change	Standard Deviation 27.045
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: Swollen Joint Count	-87.98 percent change	Standard Deviation 20.617
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: HAQ-DI score	-27.27 percent change	Standard Deviation 54.587
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: Tender Joint Count	-77.04 percent change	Standard Deviation 27.51
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: Swollen Joint Count	-82.64 percent change	Standard Deviation 30.161
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: PGA of Disease Activity	-78.11 percent change	Standard Deviation 24.049
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: Patient's Assessment of Pain	-39.52 percent change	Standard Deviation 44.939
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: CRP	-2.67 percent change	Standard Deviation 205.761
Placebo to Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: PGA of Disease Activity	-75.77 percent change	Standard Deviation 23.674
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: HAQ-DI score	-33.28 percent change	Standard Deviation 64.067
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: Swollen Joint Count	-83.03 percent change	Standard Deviation 30.21
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: Swollen Joint Count	-86.08 percent change	Standard Deviation 29.764
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: Swollen Joint Count	-86.05 percent change	Standard Deviation 21.096
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: Swollen Joint Count	-87.68 percent change	Standard Deviation 23.304
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: Swollen Joint Count	-86.19 percent change	Standard Deviation 40.865
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: Tender Joint Count	-70.18 percent change	Standard Deviation 32.062
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: Tender Joint Count	-75.63 percent change	Standard Deviation 29.437
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: Tender Joint Count	-74.71 percent change	Standard Deviation 29.728
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: Tender Joint Count	-78.01 percent change	Standard Deviation 26.112
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: Tender Joint Count	-75.96 percent change	Standard Deviation 32.6
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: Patient's Assessment of Pain	-48.81 percent change	Standard Deviation 39.191
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: Patient's Assessment of Pain	-55.77 percent change	Standard Deviation 38.78
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: Patient's Assessment of Pain	-54.38 percent change	Standard Deviation 39.135
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: Patient's Assessment of Pain	-55.28 percent change	Standard Deviation 40.388
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: Patient's Assessment of Pain	-56.36 percent change	Standard Deviation 41.31
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: PtGA of Disease Activity	-48.48 percent change	Standard Deviation 38.982
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: PtGA of Disease Activity	-53.84 percent change	Standard Deviation 35.096
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: PtGA of Disease Activity	-54.41 percent change	Standard Deviation 35.276
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: PtGA of Disease Activity	-54.17 percent change	Standard Deviation 37.132
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: PtGA of Disease Activity	-55.08 percent change	Standard Deviation 37.052
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: PGA of Disease Activity	-72.95 percent change	Standard Deviation 24.168
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: PGA of Disease Activity	-76.00 percent change	Standard Deviation 22.55
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: PGA of Disease Activity	-74.42 percent change	Standard Deviation 25.014
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: PGA of Disease Activity	-76.77 percent change	Standard Deviation 24.433
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: PGA of Disease Activity	-77.15 percent change	Standard Deviation 23.217
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: HAQ-DI score	-37.47 percent change	Standard Deviation 57.37
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: HAQ-DI score	-40.08 percent change	Standard Deviation 58.932
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: HAQ-DI score	-40.10 percent change	Standard Deviation 58.703
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: HAQ-DI score	-42.84 percent change	Standard Deviation 54.187
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: CRP	-23.41 percent change	Standard Deviation 104.622
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: CRP	-28.38 percent change	Standard Deviation 138.159
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: CRP	7.85 percent change	Standard Deviation 502.17
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: CRP	-26.87 percent change	Standard Deviation 114.471
Guselkumab 100 mg q8w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: CRP	-23.99 percent change	Standard Deviation 150.816
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: PGA of Disease Activity	-75.56 percent change	Standard Deviation 23.613
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: Patient's Assessment of Pain	-43.86 percent change	Standard Deviation 45.891
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: CRP	-1.34 percent change	Standard Deviation 194.673
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: PGA of Disease Activity	-76.49 percent change	Standard Deviation 24.355
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: Tender Joint Count	-76.21 percent change	Standard Deviation 27.345
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: Swollen Joint Count	-86.41 percent change	Standard Deviation 22.642
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: PGA of Disease Activity	-77.82 percent change	Standard Deviation 22.733
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: Tender Joint Count	-75.45 percent change	Standard Deviation 32.489
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: Swollen Joint Count	-87.16 percent change	Standard Deviation 24.888
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: HAQ-DI score	-35.17 percent change	Standard Deviation 66.105
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: Tender Joint Count	-75.11 percent change	Standard Deviation 28.559
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: CRP	-13.91 percent change	Standard Deviation 174.522
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: HAQ-DI score	-44.33 percent change	Standard Deviation 44.064
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: Tender Joint Count	-74.40 percent change	Standard Deviation 29.76
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: Swollen Joint Count	-84.27 percent change	Standard Deviation 23.698
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: HAQ-DI score	-41.84 percent change	Standard Deviation 47.877
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: Tender Joint Count	-70.54 percent change	Standard Deviation 31.311
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: CRP	-19.89 percent change	Standard Deviation 131.695
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: PtGA of Disease Activity	-52.47 percent change	Standard Deviation 38.155
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: HAQ-DI score	-43.18 percent change	Standard Deviation 52.116
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: PtGA of Disease Activity	-50.66 percent change	Standard Deviation 40.992
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: PtGA of Disease Activity	-46.07 percent change	Standard Deviation 40.614
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: Swollen Joint Count	-86.31 percent change	Standard Deviation 24.106
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: PtGA of Disease Activity	-51.86 percent change	Standard Deviation 44.532
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: Patient's Assessment of Pain	-54.27 percent change	Standard Deviation 40.819
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: CRP	-24.22 percent change	Standard Deviation 110.486
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: PtGA of Disease Activity	-57.09 percent change	Standard Deviation 34.97
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 84: Patient's Assessment of Pain	-52.59 percent change	Standard Deviation 43.131
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: HAQ-DI score	-47.54 percent change	Standard Deviation 47.265
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 52: PGA of Disease Activity	-72.58 percent change	Standard Deviation 24.579
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: Patient's Assessment of Pain	-51.34 percent change	Standard Deviation 41.903
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 76: Swollen Joint Count	-85.82 percent change	Standard Deviation 22.291
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: PGA of Disease Activity	-74.48 percent change	Standard Deviation 26.28
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 68: Patient's Assessment of Pain	-52.43 percent change	Standard Deviation 41.186
Guselkumab 100 mg q4w	Percent Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100	Week 100: CRP	-14.35 percent change	Standard Deviation 171.666

Source: ClinicalTrials.gov · Data processed: Aug 3, 2026

A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis

Conditions

Brief summary

Detailed description

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Contacts

Participant flow

Pre-assignment details

Participants by arm

Baseline characteristics

Adverse events

Outcome results

Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24

ACR Components at Weeks 24, 28, 36, 44 and 52

ACR Components at Weeks 52, 68, 76, 84 and 100

Change From Baseline in 36-Item Short Form Health Survey (SF-36) Mental Component Summary (MCS) at Week 24

Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24

Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52

Change From Baseline in ACR Components at Weeks 52, 68, 76, 84 and 100

Change From Baseline in BASDAI Score at Weeks 52, 76 and 100 Among Participants With Spondylitis and Peripheral Arthritis and BASDAI Score>0 at Baseline

Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score at Weeks 24 and 52 Among Participants With Spondylitis and Peripheral Arthritis at Baseline

Change From Baseline in Dactylitis Score at Weeks 24 and 52 Among the Participants With Dactylitis at Baseline

Change From Baseline in Dactylitis Scores at Week 24 Among the Participants With Dactylitis at Baseline

Change From Baseline in Dactylitis Scores at Weeks 2, 4, 8, 16 and 24 Among the Participants With Dactylitis at Baseline

Change From Baseline in Dactylitis Scores at Weeks 52, 76 and 100 Among the Participants With Dactylitis at Baseline

Change From Baseline in DAPSA at Weeks 52, 68, 76, 84 and 100

Change From Baseline in DAS28 (CRP) at Weeks 2, 4, 8, 12, 16, 20 and 24

Change From Baseline in DAS28 (CRP) Score at Weeks 24, 28, 36, 44 and 52

Change From Baseline in DAS28 (CRP) Score at Weeks 52, 68, 76, 84 and 100

Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Weeks 2, 4, 8, 12, 16, 20 and 24

Change From Baseline in Disease Activity Score (DAS28) (C-reactive Protein [CRP]) Score at Week 24

Change From Baseline in DLQI Score at Weeks 24 and 52 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

Change From Baseline in DLQI Score at Weeks 52, 76 and 100 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

Change From Baseline in DLQI Score at Weeks 8, 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

Change From Baseline in Enthesitis Score (Based on LEI) at Week 24 Among the Participants With Enthesitis at Baseline

Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 2, 4, 8, 16, and 24 Among the Participants With Enthesitis at Baseline

Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 24 and 52 Among the Participants With Enthesitis at Baseline

Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 52, 76 and 100 Among the Participants With Enthesitis at Baseline

Change From Baseline in EQ-5D-5L at Weeks 16 and 24: EQ-5D Index

Change From Baseline in EQ-5D-5L at Weeks 24 and 52: EQ-5D Index

Change From Baseline in EQ-5D-5L at Weeks 24 and 52: EQ-VAS

Change From Baseline in EQ-5D-5L at Weeks 52, 76 and 100: EQ-5D Index

Change From Baseline in EQ-5D-5L at Weeks 52, 76 and 100: EQ-VAS

Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) at Weeks 16 and 24: EQ-VAS

Change From Baseline in FACIT-Fatigue Score at Weeks 24 and 52

Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 52, 76 and 100

Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 8, 16, and 24

Change From Baseline in GRAPPA Composite Score (GRACE) at Weeks 52, 76 and 100

Change From Baseline in Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Composite Score (GRACE) at Weeks 16 and 24

Change From Baseline in Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 24 and 52

Change From Baseline in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52

Change From Baseline in HAQ-DI Score at Weeks 2, 4, 8, 12, 16, 20 and 24

Change From Baseline in HAQ-DI Score at Weeks 52, 68, 76, 84 and 100

Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24

Change From Baseline in mCPDAI Score at Weeks 52, 76 and 100

Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Week 16 and 24

Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Weeks 24 and 52

Change From Baseline in Modified Van Der Heijde-Sharp (vdH-S) Score at Week 24

Change From Baseline in Modified vdH-S Erosion Score at Week 24

Change From Baseline in Modified vdH-S Erosion Score at Week 52

Change From Baseline in Modified vdH-S Joint Space Narrowing (JSN) Score at Week 24

Change From Baseline in Modified vdH-S JSN Score at Week 52

Change From Baseline in Modified vdH-S Score at Week 52

Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 24

Change From Baseline in Modified vdH-S Score by Region and Type of Damage (ie, Hand Erosion, Hand JSN, Foot Erosion, Foot JSN Subscores) at Week 52

Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 24 and 52

Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 52, 76 and 100

Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24

Change From Baseline in PASDAS Score at Weeks 52, 76 and 100

Change From Baseline in PASI Score at Weeks 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline